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Abstract 
Type 2 Diabetes Mellitus (T2DM) and obesity are widespread and associated metabolic 
diseases with worldwide rising prevalence [1]. The gut hormone Oxyntomodulin induces 
satiety and normalizes hyperglycaemia without risk of hypoglycaemic excursions [2]. 
However, native incretin hormones are quickly degraded by peptidases and renally excreted, 
which has so far impaired pharmaceutical exploitation of anorectic and glucose-homeostatic 
activities [3]. It is known that many – if not all – peptides can be converted to self-assembled 
nanostructures [4]. Amyloid fibrils are characterized by enhanced chemical, biological and 
mechanic stability compared to soluble peptides, and allow a controlled release by 
dissociation of monomers from the fibril termini [5]. Here I propose self-assembled peptides 
as a prolonged-activity, self-mediated drug delivery system for subcutaneous injection of 
pharmaceutically active drugs. Oxyntomodulin is used as a model peptide due to previously 
futile attempts at finding long-acting analogues, and Oxyntomodulin’s so far unreported self-
assembly behaviour. This thesis shows a method to reproducibly form subcutaneously 
injectable Oxyntomodulin fibrils with high conversion yield and low polydispersity, as well 
as methods to characterize morphology, kinetics and thermodynamics of Oxyntomodulin self-
assembly. Oxyntomodulin fibrils display amyloid-like characteristics and release soluble 
peptide in a peptide-deprived environment. Association and dissociation kinetics and 
thermodynamics are sensitively dependent on salts and temperature, with an association 
temperature optimum at room temperature that is unique in amyloid-type self-assembly. An 
alternative fibril type forms under different conditions and displays altered fibrillation kinetics 
and thermodynamics. The specificity of fibrillation to the peptide sequence is shown in 
presence of Oxyntomodulin’s sister peptide glucagon and the analogue Aib-2-
Oxyntomodulin. Extended release of active peptide from a subcutaneous Oxyntomodulin 
fibril depot has been proved in rodent studies at MedImmune [6]. As amyloid-like self-
assembly is a generic feature of the peptide chain, the strategies and methods described in this 
project can be applied to other pharmaceutically active peptides and proteins.   
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V 
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TEM  transmission electron microscopy 
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1 Introduction 
1.1 Application of gut hormones in treatment of Type 2 Diabetes 
Mellitus  
1.1.1 The pathophysiology and current treatment of T2DM  
Diabetes is one of the most common diseases worldwide. In 2017, the prevalence of diabetes 
was estimated 8.8 % of adults worldwide, or 425 million people. Due to population growth, 
ageing and lifestyle changes especially in the developing countries, an increase to 693 million 
is expected by 2045 [7]. T2DM makes up about 90 % of diabetes diseases. Major risk factors 
for T2DM include a family history of T2DM, obesity, sedentary lifestyle, dyslipidaemia, 
hypertension and low birth weight [8].  
In a healthy individual, glucose plasma concentration is mainly regulated by the release of 
glucagon from pancreatic α cells, or insulin from pancreatic β cells. Glucagon induces 
gluconeogenesis and glycogenolysis in liver and muscle cells, which causes an increase in 
blood glucose levels. Insulin inhibits glucagon-mediated pathways, promotes glucose uptake 
from the bloodstream, and induces glycogen formation in liver and tissue cells [9]. Insulin-
sensitive cells in central and peripheral tissues ingest plasma glucose, amino acids and fatty 
acids in response to insulin concentration, and feed back their need for insulin to β cells [10]. 
Prediabetes and T2DM are initiated by the decrease of insulin sensitivity (insulin resistance) 
in peripheral cells. Isolated insulin resistance is usually asymptomatic, because the relative 
insulin deficiency is counteracted by increased insulin secretion from β cells. If β cells are not 
capable of supplying sufficient amounts of insulin, blood glucose levels rise [10]. The 
resulting state of impaired glucose tolerance is often referred to as prediabetes [11]. Chronic 
glucose challenging and toxic metabolic side products associated to hyperglycaemia lead to 
an irreversible destruction of pancreatic β cells. Concurrently, dysfunctions in α cells increase 
fasting glucagon levels, which further enhances hyperglycaemia [10].  
Permanently high plasma glucose levels induce peripheral vascular disease, which is the 
pathophysiologic hallmark of T2DM. Structural changes of endothelial cells in capillaries and 
arterioles can manifest as microaneurysms, rhetinopathy, neuropathy and chronic kidney 
disease. Hyperglycaemic impact on macrovasculare dramatically increases the risk for 
atherosclerosis and cardiovascular disease [11]. A life-time treatment is implicated for T2DM 
patients [8].  
T2DM drugs aim at restoring glucose homeostasis by increasing insulin levels, delimiting 
nutrient uptake in the gut, altering hepatic gluconeogenesis, or enhancing renal glucose 
excretion.  It has been shown that a change in lifestyle towards weight loss and enhanced 
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physical activity increases chances to achieve a partial or complete remission of (pre)diabetes 
[12].  However, most antidiabetics cause weight gain, which itself is strongly associated with 
the progression of T2DM, the occurrence of concomitant diseases, and patient 
incompliance [13]. Inhibition of the renal sodium-glucose-co-transporter 2 (SGLT-2) is the 
only pharmaceutical T2DM treatment that effectively favours weight loss. However, the 
enhanced glucose excretion in urine is associated with infections of the lower urinary tract 
and cardiovascular complications. As discussed in chapter 1.1.2, some analogues of the 
human gastrointestinal hormone glucagon-like peptide 1 (GLP-1) induce moderate weight 
loss while effectively normalizing blood glucose levels [14].  
Advanced hyperglycaemia usually requires pharmaceutically increased insulin levels. 
Remaining β cell function can be enhanced by administration of sulfonylureas. If this is not 
sufficient, recombinant human insulin (or analogues thereof) has to be administered 
subcutaneously [10]. The at least daily syringe application causes patient discomfort and high 
costs for health systems. Complications caused by noncompliance are the biggest factor in 
diabetes health care costs. Especially in late-stage T2DM, patients’ ability to self-deliver 
drugs at a daily basis can be complicated by impaired vision and decreased mobility [7]. 
Moreover, intensive plasma glucose lowering by insulin or sulfonylureas induces weight gain, 
poses patients at risk of hypoglycaemic excursions, and does not reduce the risk for 
cardiovascular complications [15][16].  
The most successful treatment of concurrent T2DM and obesity is bariatric surgery, 
especially Roux-en-Y gastric bypass (RYGB). While surgery is not a rational first line 
treatment, the observed changes in gut hormone levels following RYGB have given rise to the 
development of incretin based drugs for the treatment of obesity and T2DM [13]. 
1.1.2 The potential of gut hormone drug formulations in T2DM  
Following food intake, a number of peptide hormones are released from the gut. The function 
of these hormones is to reduce food intake, inhibit gastric exocrine secretion, delay gastric 
emptying, and facilitate nutrient uptake into peripheral cells. Appetite is reduced via 
endocrine and vagus nerve signaling to the brain [17]. Delayed gastric emptying facilitates 
glucose homeostasis and mediates a sensation of fullness, which further inhibits food intake. 
Some peptide hormones exhibit a regulatory function on pancreatic glucagon and insulin 
secretion, named incretin effect [18]. After RYGB surgery, patients with T2DM and/or 
obesity show permanently increased levels of peptide YY (PYY), gastric inhibitory peptide 
(GIP), Glucagon-like peptide (GLP-1) and Oxyntomodulin (Oxm) [13]. The antidiabetic 
effect of gastric binding is achieved before significant weight reduction takes place [9]. These 
findings led to the assumption that the benefits of RYGB could be achieved by a 
pharmaceutically induced increase in plasma levels of gut hormones.  
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While all of these peptides cause appetite suppression after parenteral application, the 
influence on glucose homeostasis is diverging (see Table 1-1) [2][17]. PYY has no reported 
effect on glucose, insulin or glucagon levels. GIP enhances insulin release from pancreatic β 
cells but worsens glucose tolerance in T2DM patients. GLP-1 and Oxyntomodulin act as 
insulin secretagogues and glucagon release inhibitors [9]. Oxyntomodulin additionally 
increases energy expenditure and ketogenesis, making it a potentially more effective 
candidate for treating overweight [19][20]. 
Table 1-1: Metabolic characteristics of postprandially secreted peptide hormones 
Green/black/red arrows: potentially positive/neutral/negative action in T2DM patients. For 
references, see main text.  
peptide secretion proteolysis metabolic activity 
GLP-1 
• Postprandial 
• intestinal L cells 
• Increased secretion 
after RYGB surgery 
• DPP-4  
• Neprilysin 
• Insulin secretion ↑ 
• Glucagon secretion ↓ 
• Glucose tolerance in T2DM 
patients ↑ 
• Delayed gastric emptying 
• Appetite ↓ 
• Energy expentiture ↓ 
Oxynto-
modulin 
• Postprandial 
• intestinal L cells 
• Increased secretion 
after RYGB surgery 
• DPP-4  
• Neprilysin 
• Insulin secretion ↑ 
• Glucagon secretion ↓ 
• Glucose tolerance in T2DM 
patients ↑ 
• Appetite ↓ 
• Energy expentiture ↑ 
PYY 
• Postprandial 
• intestinal L cells 
• Increased secretion 
after RYGB surgery 
• DPP-4  
• Insulin → 
• Glucagon → 
• Appetite ↓ 
GIP 
• Postprandial 
• intestinal K cells 
• Increased secretion 
after RYGB surgery 
• DPP-4 (activation) 
• Insulin ↑ 
• Appetite ↓ 
• Glucose tolerance in T2DM 
patients ↓ 
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Figure 1-1: Tissue-specific cleavage of Proglucagon 
Posttranslational modification of Proglucagon by prohormone convertase 2 yields glucagon as 
the main active gene product. The region containing GLP-1 and GLP-2 is partially secreted as 
the inactive major proglucagon fragment (MPGF). Metabolic functions of glicentin related 
pancreatic peptide (GRPP) and GLP-2 are widely unknown. In brain and gut, proteolytic 
processing by prohormone convertase 1/3 results in formation of GLP-1, GLP-2 and 
Oxyntomodulin (figure adapted from [21]). 
In a healthy individual, GLP-1 and Oxyntomodulin are secreted from L cells of the small and 
large intestine. The magnitude of secretion is proportional to calorie intake [13]. GLP-1 and 
Oxyntomodulin are transcribed in the same gene as glucagon, whose precursor enzyme 
Proglucagon is enzymatically processed in a tissue-specific way (see Figure 1-1). In the 
pancreas, Prohormone convertase 2 produces glucagon as the predominant gene product. 
Alternative cleavage by Prohormone convertase 1 and 3 in the gut brings about GLP-1 and 
Oxyntomodulin as the major active substances [21]. The most abundant active form of GLP-1 
is the amidated 78-107 fragment of Proglucagon [18]. Wild-type Oxyntomodulin is the 33-69 
cleavage product of Proglucagon and contains the whole sequence of Glucagon with a C-
terminal octapeptide extension (hence also called Glucagon-37) [21]. Due to its sequence 
homology to GLP-1 and Glucagon (see Figure 2-2), Oxyntomodulin combines the 
characteristics of GLP-1 and Glucagon [9]. GLP-1 and Oxyntomodulin activate local 
receptors on gastrointestinal cells, induce vagus nerve signalling, and reach the bloodstream 
by paracrine transport. Both hormones cross the blood-brain barrier [17].  
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GLP-1 exerts its activity via a single known receptor (GLP-1R), which is expressed in 
pancreatic islets, brain, heart, kidney, and the gastrointestinal tract [18]. GLP-1R activation in 
the gastrointestinal tract mediates a potentiating effect on α and β cells, which assists in 
postprandial glucose level normalization by decrease of glucagon secretion and increase of 
insulin secretion. Importantly, GLP-1R induced insulin secretion is glucose dependent, 
precluding the possibility of GLP-1 induced hypoglycaemia [2]. Moreover, GLP-1R 
activation was reported to cause β cell proliferation and reduced β cell apoptosis in rodents 
[22][23]. GLP-1 delays gastric emptying, which further regulates blood sugar levels and 
transmits a feeling of fullness that reduces food ingestion. However, beneficial effects of 
delayed gastric emptying may be negligible in chronic treatment with GLP-1 analogues due to 
rapid tachyphylaxis [24]. GLP-1R activation in the hypothalamus causes appetite suppression 
by stimulating reward centres and anorexigenic neurons, as well as inhibiting orexigenic 
neuron signalling [25][26]. Clinical trials showed cardio- and vasculature-protective 
characteristics of GLP-1 analogues [27], with the drawback of reduced energy expenditure 
[13].  
Oxyntomodulin activates both GLP-1R and the glucagon receptor (GCGR), although with 
reduced affinity in comparison to the single agonists. The levels of activated second 
messengers differ from activation by glucagon and/or GLP-1 [17][28]. The dual receptor 
agonism of Oxyntomodulin brings about an antidiabetic function similar to GLP-1 
accompanied by cardioprotective functions and superior weight loss in comparison to single 
GLP-1R targeting [29][19]. The latter can be explained by the additional satiety induction by 
targeting glucagon pathways, as well as the increased energy expenditure mediated by GCGR 
activation [30][31]. Thus, the synergistic effect of dual GCGR- and GLP-1R-agonism is 
potentially more effective in treatment of T2DM and obesity than GLP-1 or glucagon 
[19][21].  
Gut hormones are evolutionarily selected for their short action in the human body. After the 
desired effect is achieved, circulating hormones are mainly inactivated by enzymatic 
   1......... 11........ 21........ 31..... 
Glucagon:   HSQGTFTSDY SKYLDSRRAQ DFVQWLMNT. ....... 
Oxyntomodulin:  HSQGTFTSDY SKYLDSRRAQ DFVQWLMNTK RNRNNIA 
GLP-1(7-37):     HDEFERHAEG TFTSDVSSYL EGQAAKEFIA WLVKGRG 
 
Figure 1-2: Sequence homology of Glucagon, GLP-1 and Oxyntomodulin 
Oxyntomodulin, GLP-1 and GIP have different degrees of sequence homology (green) with 
Glucagon. Physiologically active GLP-1 is predominantly cleaved after positions 6 and/or 36 
(red). Source: http://www.uniprot.org/uniprot/P01275 (20/09/2018). 
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degradation, glomerular filtration, and hepatic degradation. GLP-1 and Oxyntomodulin are 
predominantly cleaved by the ubiquitous enzyme Dipeptidyl Peptidase 4 (DPP-4) after 
position A8 (GLP-1) and S2 (Oxyntomodulin) (3).  Neutral Endopeptidase 24.11 (Neprilysin, 
NEP) has six cleavage positions in both peptides, but plays a minor role in incretin 
degradation [14]. Human plasma half-lives are 2 and 12 min for GLP-1 and Oxyntomodulin, 
respectively, which renders the exploitation of native peptide solutions inefficient for the 
continuous treatment of T2DM and/or obesity [32][18].  
Inhibition of DPP-4 enhances intrinsic levels of GLP-1 and Oxyntomodulin. The 
consequently increased insulin secretion and inhibited glucagon release normalizes glucose 
levels. The DPP-4 inhibitors Sitagliptin and Vildagliptin have achieved pharmaceutical 
approval for the treatment of T2DM in combination with other antidiabetic drugs. However, 
the regulatory effect of DPP-4 on other peptides – especially the activation of the anorectic 
hormone PYY – prevents a positive overall effect on weight reduction [9].  
Long-acting GLP-1R agonists have been the subject of intense pharmaceutical research for 
the past decades, culminating in several blockbuster antidiabetic drugs and the first incretin 
hormone analogue approved for weight management. Currently, there are nine approved 
GLP-1R agonist formulations, of which two are combination drugs containing insulin. 
Strategies to prevent DPP-4 degradation comprise steric hindrance by acylation (Liraglutide), 
and substitution of Ala7 for Glycin (Exenatide, Lixisenatide, Albiglutide, Dulaglutide) or the 
nonproteinogenic amino acid Amino-isobutyric acid (Aib) (Semaglutide). Acylation-driven 
albumin binding (Liraglutide, Semaglutide), albumin fusion (Albiglutide) or IgG4 Fc fusion 
(Dulaglutide) further enhance half-life by reduction of glomerular filtration and hepatic 
degradation. Dosing frequencies range from twice daily to once weekly, with tendentially 
better glycaemic control achieved by the longer-acting drugs [14]. Moderate weight reduction 
by GLP-1R agonists was shown in healthy and obese subjects as well as in T2DM patients 
[33][34]. The weight-lowering effect achieved through satiety induction is dampened by the 
reduction of energy expenditure mediated by GLP-1R activation in cardiac tissue [13]. 
Delayed gastric emptying does not seem to have a long-term beneficial effect due to 
habituation [24]. Nausea, vomiting and diarrhoea are frequent adverse side effects of all 
marketed GLP-1R agonists [9][13][14].  
Although far less investigated than GLP-1, native Oxyntomodulin seems to have beneficial 
actions in vivo and in clinical studies. Oxyntomodulin improves glucose tolerance in healthy 
and diet-induced insulin-resistant mice [35][36]. Glucose-regulatory effects are mainly 
mediated via GLP-1R activation, overacting the hyperglycaemic effects of GCGR activation 
[35][37][38][20]. Very recently, it was shown that i.v. infused Oxyntomodulin regulates 
glycaemic excursions in healthy obese persons as well as obese T2DM patients to comparable 
extent as the currently market-dominating GLP-1 analogue Liraglutide [39][14]. Promising 
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effects of Oxyntomodulin were also shown in a mouse model of Type I Diabetes Mellitus 
[29]. Further functions of Oxyntomodulin comprise decreased gastric acid and exocrine 
secretion, inhibition of gastric emptying, cardio- and neuroprotective effects [32][40]. 
Oxyntomodulin has superior weight-reducing potential in comparison to single GLP-1R 
agonists. GCGR activation enhances appetite suppression and induces thermogenesis, 
lipolysis, fatty acid oxidation, and ketogenesis [21][37]. In rodents, Oxyntomodulin reduces 
food intake both upon peritoneal and hypothalamic administration [31]. After repeated 
injection, more weight loss is achieved than in an isocaloric (pair fed) control group, proving 
that Oxyntomodulin significantly increases energy expenditure [41]. In normal-weight 
humans, a single preprandial i.v. injection of Oxyntomodulin reduces caloric intake by 20 % 
[42]. Randomized, placebo-controlled studies showed that energy expenditure is increased in 
overweight or obese humans receiving s.c. Oxyntomodulin, and a 2.4 ± 0.4 % body weight 
decrease was reached after injecting Oxyntomodulin 30 min s.c. before a meal over 4 weeks 
[2][43]. Neither of the studies reported occurrence of nausea, vomiting or affection of food 
palatability.  
Despite these findings, there is currently no approved compound based on Oxyntomodulin, 
and no Oxyntomodulin analogue has reached phase III of clinical studies. Oxyntomodulin 
analogues suitable as drug candidates need to address the problem of short plasma half-life as 
well as maintain activity at both GLP-1R and GCGR. It is increasingly acknowledged that the 
balance of receptor activation needs to be similar to the wild type to maintain 
Oxyntomodulin’s beneficial effects on glucose regulation, food intake, and energy 
expenditure [44]. Furthermore, the native Oxyntomodulin sequence needs to adopt a helical 
conformation to activate its receptors [45][46][47]. It was suggested that the glucagon-identic 
N-terminal fraction is α-helical and followed by a short 310 helix [48]. Residues 1, 4, 6, 7 and 
11 and the C-terminal octapeptide seem to be crucial for GLP-1R activation, while the 
midsection alters GLP-1R activation levels [49]. The C-terminal octapeptide regulates gastric 
acid secretion [50]. GCGR activation requires Glutamine at the degradation prone position 3 
[37][44].  
Consequently, rational design of long-acting Oxyntomodulin analogues is a complex task. 
Reported modification techniques comprise amino acid substitutions, C-and N- terminal 
elongation, acylation, PEGylation, cholesterylation, and Fc fusion [51][52][53][40][29]. 
While enhanced plasma half-life is often achieved, most of the analogues upset the balance of 
receptor activation or lose activity at one receptor entirely. For example, N-terminal capping 
or substitution of the DPP4-sensitive Serine (Ser) in position 2 with any canonical amino acid 
is detrimental to receptor affinity [49]. Considerable is the substitution of Ser2 with the non-
coding amino acids D-Serine or Aminoisobutyric acid (Aib). Although D-Serine-2-
Oxyntomodulin has lowered receptor affinities and Aib-2-Oxyntomodulin is a GLP-1R biased 
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agonist, both substances showed better glucose tolerance and similar appetite suppression in 
mice as Oxyntomodulin [53]. Interestingly, a GCGR biased Oxyntomodulin analogue in fact 
increased food consumption in mice, but still lowered body weight by GCGR-mediated 
energy expenditure, emphasizing the complexity of chimeric agonism [54].  
In 2017, we reported a novel strategy to increase the plasma half-life of Oxyntomodulin while 
maintaining its natural structure. Reversibly self-assembled Oxyntomodulin was administered 
s.c. to mice and rats, from where it continually diffused into the bloodstream over 5 d. The 
self-assembled state did not activate receptors, but receptor activation by Oxyntomodulin 
released from the peptide assemblies was indistinguishable from freshly dissolved human 
Oxyntomodulin. In rats, Oxyntomodulin released from the s.c. depot reduced basal glucose 
and improved glucose tolerance after a glucose bolus [6]. 
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1.2 Self-assembled peptide as a long-acting drug formulation 
1.2.1 Protein and peptide self-assembly in disease, physiology, and 
engineering  
The flexibility of the peptide backbone and side chain orientations allows single peptides and 
proteins to adopt a three-dimensional structure. Native proteins are evolutionarily selected to 
be able to rapidly fold into a structure that equals a single minimum of the free energy 
landscape in their respective natural environment [55]. The driving force of protein folding1 is 
the enthalpically favourable exclusion of hydrophobic residues from the aquatic cellular 
environment. Attractive interactions between side chains stabilize the conformation. During 
folding, unspecific protein interactions are prevented by chaperone-mediated shielding of 
hydrophobic patches, degradation of misfolded structures, reversible end-capping, and spatial 
seclusion of similar sequences in a heterogeneous mixture of molecules. Consequently, 
intramolecular interactions are kinetically favoured under native conditions, enabling the 
protein to collapse into the least-hydrophobic surface structure [56][57]. Burial of 
aggregation-prone patches and presence of chaperones allows the coexistence of proteins 
without aggregation even at supersaturated conditions [58][59]. 
Under certain conditions, an alternative energetic minimum can be adopted by homotypic 
interactions of equal parts of associating monomers. This process is termed self-assembly in 
following. As the structures resulting from packing of equivalent molecules differ from 
folding of heterogeneous patches within a polypeptide chain, the function of the resulting 
aggregate is altered or impaired [60]. Peptides and proteins can adopt various self-assembled 
states including fibrils, tubes, helices and globular structures [61][62][63]. Molecules within 
supramolecular structures may or not have structural similarity to the native fold [64].  
Peptides and proteins undergoing self-assembly have long been associated with protein 
misfolding diseases [4][64]. Pathological effects of misfolding and aggregation include 
depletion of a relevant protein, formation of toxic metabolites, or aggregate deposition. Most 
protein misfolding diseases are caused by the formation of amyloid fibrils. Amyloid plaques 
in the brain are related to neuropathic diseases like Alzheimer’s, Parkinson’s and 
Huntingdon’s disease. Nonneuropathic amyloidosis can be localized (e.g. amylin amyloidosis 
in T2DM) or systemic (e.g. lysozyme amyloidosis). However, recent findings imply that toxic 
effects of protein misfolding are primarily caused by the transient formation of toxic 
oligomers and not by the bulk of deposited aggregate [65]. A possible explanation for this 
 
1 In this thesis, the term folding is used for the specific adoption of intramolecular interactions and 
intermolecular interactions leading to a functional protein structure. Self-assembly is used for homotypic 
intermolecular interactions between multiple amino acid chains.  
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phenomenon is the unphysiological exposure of amino acid patches that would be buried in 
folded or assembled states [4]. 
Over the last two decades, more and more proteins have been found to accomplish a 
physiologic purpose in self-assembled state. Bacteria like Escherichia coli use extracellular 
amyloid fibrils for surface interactions and cell-cell contacts [5]. Chorion protein aggregates 
fulfil structural and protective functions in insects and fish eggs [66]. Yeast and fungi use 
self-assembled structures as epigenetic elements, and prion proteins are involved in long-term 
learning of the marine snail Aplysia [67][68]. Fibrils of the mammalian amyloid Pmel17 
direct melanosome actions and sequester toxic melanin precursors [69]. More complex states 
of self-assembly are crucial for structural (collagen, microtubules) and motoric (myosin) 
purposes [70].  
Peptides are generally too short to adopt a folded structure, and are thus more prone to 
undergo self-assembly. A striking example of functional self-assembled peptide is the storage 
of pituitary peptide hormones in secretory granules. The microenvironment inside the 
granules drives peptides into an amyloid state, allowing storage in a dense, pure, and 
physicochemically stable form. Upon hypothalamic signalling, secretory granules melt with 
the cell membrane and release their payload into the extracellular environment, where altered 
solution conditions favor the disaggregated, active state of the hormone [71]. This finding 
supports the rationale that self-assembled peptides or proteins could be used as a long-acting 
drug formulation [5][61].  
Fibrillated gonadotropin releasing hormone (GnRH) analogues were shown to release 
functional monomer from the fibril ends, and exert prolonged in vivo activity by ongoing 
monomer release from the depot [5]. The peptide analogue Lanreotide, an approved long-
acting drug for the treatment of acromegaly, is applied subcutaneously as a self-assembled 
hydrogel [72]. The long-acting insulin analogue insulin glargine forms reversible precipitate 
at the injection site, which allow sustained peptide release from a depot [73].  
Beyond the use of self-assembled drugs, hydrogels consisting of self-assembled peptides can 
be used to physically entrap and stabilize other active molecules. Reversible attachment of 
drugs to peptide side chains offers a possibility for prodrug delivery with enhanced stability 
[74][75]. Peptides can be produced in high purity by solid phase synthesis, enabling tuneable 
characteristics and cheap production compared to e.g. cell culture-derived collagen. 
Hydrogels formed of human proteins and peptides are thus promising scaffolds for catalysis, 
tissue engineering and biomineralization, due to their biocompatibility, biodegradability, and 
mechanical properties [76][77].  
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1.2.2 The hierarchical structure of amyloid proteins and peptides 
The term “amyloid” (starch-like) was populated by Rudolph Virchow in 1854 following the 
observation of a positive iodine staining reaction in abnormal tissue deposits. Five years later, 
Virchow’s classification as starch- or cellulose deposits was corrected by Nicolaus Friedreich 
and August Kekule, who proved the proteinaceous nature of amyloid patches [78]. In 1935, 
William Astbury and Silvia Dickinson proposed a cross-beta arrangement from the X-Ray 
diffraction pattern of stretched poached egg, and indeed proposed the structure to be a 
ubiquitous motif in denatured protein [79]. However, only in the past few decades has it 
become accepted that amyloid formation is a generic feature of the polypeptide backbone, 
which – given the right conditions – can be adopted by all proteins and peptides [80].  
Amyloid-type self-assembly is dictated by the intrinsic propensity of the peptide2 backbone to 
form homotypic beta-sheet interactions in a cross-beta motif (see Figure 2-3). The amyloid 
core is formed by an almost infinitely repeating intermolecular beta sheet motif that can 
elongate by recruiting peptides to the fibril ends [70]. Individual strands align approximately 
parallel to each other with the peptide backbone direction approximately perpendicular to the 
sheet normal and fibril axis. Amino acid side chains lie on either side of the beta sheet, 
protruding away from the fibril [57].  
In general, beta sheets in amyloid structures do not exist as singles but are paired with an 
opposing sheet, a structure often called protofilament [70]. The opposing sheets can be 
formed by distinct molecules, or by amyloid-like stacking of single peptides in a turn 
conformation [4][81]. Protofilaments may align laterally or stack with the side chains facing 
each other, forming a filament3. The spacial alignment of (proto)filaments represents the 
fibril. Mature fibrils have translational symmetry by definition, but often display one or more 
rotational symmetry elements by helical or screw twist of (proto)fibrils [82]. Most amyloid 
fibrils are composed of 2-8 sheets with the peptides lying parallel within a sheet and 
antiparallel to the opposite sheet, however more complex arrangements are known [83]. 
Typical amyloid fibrils are 6-20 nm wide and up to several micrometers long [70]. 
Amyloid fibrils are stabilized by a network of noncovalent interactions. Every sheet 
comprises a multitude of H bonds formed between the carbonyl oxygen atoms and the amine 
group hydrogen atoms of the peptide backbone. Backbone-backbone H bonds are in the sheet 
plane. Sheets are further stabilized by arrays of homotypic side chain interactions, especially 
by aromatic residue stacking (π-π-interactions), hydrophobic interactions and salt bridges 
between charged side chains [84].  
 
2 For easier reading, the term peptide shall be used interchangeably with protein for the current chapter.  
3 The term protofibril is sometimes interchangeably used for a fibrillar subclass (59). Here, I will use protofibril 
as a term for a general intermediate state with unknown structure.  
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Figure 1-3: Hierarchical structure of an exemplary amyloid fibril 
A-C: Atomic-resolution structure of the decapeptide TTR(105-115), determined by MAS-
NMR. A, individual peptides align perpendicular to the fibril axis. The H bonds (dotted 
orange lines) run within the beta sheet. Amino acid residues protrude away from the fibril and 
stack in-register with analogous side chains of the neighbouring peptides within the sheet. B, 
two sheets align in parallel to form a protofilament. Peptides of opposing sheets are aligned in 
an antiparallel and staggered way. Side chains of sheets interdigitate. C, several 
protofilaments can align side by side with a head-to-tail peptide alignment. The resulting 
(proto)fibril is stabilized by the interaction of terminal peptide side chains. D, scanning 
transmission electron imaging (left) reveals the regular twist of amyloid fibrils (scale bar, 
50 nm; false colour). The shown fibril is composed of three protofibrils consisting of two 
parallel aligned protofilaments each (model magnifications middle and right). Figures adapted 
from [87].  
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Adjacent sheets can interact by interdigitation of side chains, a motif widely known as steric 
zipper. Close side chain contacts in the dry interface of the protofibril are thermodynamically 
favorable because of van der Waals interactions, hydrogen bonding in a water-free 
environment, and the entropic gain of water exclusion (see also chapter 1.2.3). Optimal 
alignment may require a slight offset of sheets resulting in alternating growth competence of 
sheets [85]. Sidechain packing restrictions, electrostatic effects and the intrinsic chirality of 
peptides can also induce twisting of individual peptides and the fibril. The degree of twisting 
or coiling is – among others – dependent on the sequence, the number and arrangement of 
associated sheets, and the solvent conditions [86][87][88][89].  
The amyloid structure provides a protected environment for individual peptides. Amyloid 
peptide fibrils are stable in a wide range of temperature, pH, and chaotropic substances [61]. 
Peptide sequences in the amyloid core are protected from enzymatic degradation [90]. 
Amyloid fibrils show remarkable mechanic stability, comprising tensile strengths in the range 
of steel, and stiffness (E modulus) comparable to wood or dragline silk [91].  
The morphology of fibrils does not usually change along the length of a fibril. Persistence 
lengths of several micrometers are often observed, meaning that the structures are self-
propagating over thousands of molecules with remarkably few errors [92]. Conversely, the 
sequence does not determine the amyloid structure, and one sequence may give rise to a 
multitude of polymorphic fibrils [93]. Polymorphism can occur on all structural levels from 
the conformation of single peptides to the bundling and interweaving of mature fibrils.  
Segmental polymorphism comprises different possibilities how one peptide can form beta-
sheets within a fibril (see Figure 2-5) [82]. The amyloid core can span the whole amino acid 
chain or only a fraction of it [4][94]. Beta strands are generally formed by a single peptide; 
however one molecule may contribute to several strands [95]. In fact, the number of residues 
per strand rarely exceeds 10-12. Other parts of the peptide may be unstructured, helical, or 
form a separate strand within the fibril. A common structural motif is the beta-arch, in which 
one molecule is part of two or more beta-strands in separate beta-sheets within the fibril [92]. 
Individual beta-strands do not need to be in extended conformation within an amyloid fibril. 
The resulting paired sheets are often approximately parallel and connected by an array of 
turns. Less frequently observed is a beta-hairpin motif, in which a peptide forms two or more 
antiparallel strands within the same sheet of a fibril, connected by β-turns [96]. More complex 
fibril core architectures such as the beta-solenoid structure of HET-s have been found [95].   
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Packing polymorphism stems from the different possibilities to align strands respectively to 
their neighboring strands. As shown in Figure 2-4, strands may be in-or out-of-register; 
parallel or antiparallel within a sheet [70]. In-register, parallel alignment is the predominant 
type in reported fibril structures, presumably due to the saturation of homotypic side chain 
interactions. However, other alignments may be favorable for example for short, hydrophobic 
strands, where the repulsion of charged termini can be a destabilizing factor in perfectly 
aligned, parallel sheets [93][97][98]. Opposing sheets can be oriented in the same direction or 
upside-down, with strands parallel or antiparallel to the paired sheet, and in- or out-of-register 
sheet alignment [70][98][85].  
Figure 1-5: Segmental polymorphism 
A, the whole sequence, or B, only a part of the sequence is part of the β-sheet. C, monomers in β-arch 
conformation spanning connecting two sheets; D, monomers in β-turn conformation connecting two 
strands. 
 
A C B D 
Figure 1-4: Packing polymorphism 
A, parallel and B, antiparallel strand arrangement. C, D, G, H, sheet arrangements at example of 
parallel, in-register strands. C, G, parallel sheets, D, H antiparallel sheets. C, D, upside up, G, H, 
upside down sheets, represented by the shadow location. E, out-of-register alignment within a sheet; F, 
out-of-register alignment of opposing sheets.  
A B C D 
G H E F 
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Assembly polymorphism results from the number and alignment of protofilaments in a fibril. 
Examples are shown in Figure 2-6. Protofilaments may align laterally with N-, or C-termini 
facing each other, or in a “head-to-tail” alignment where sheets are facing the same direction. 
The latter polymorph is stabilized by the opposing charges at N- and C-terminus. 
Protofilaments may also stack with either of their flat sides facing each other, or form tubes 
by angular interactions [92][99]. For example, Aβ1-40 may have an approximately rectangular 
or a hollow triangular cross-section, depending on the alignment of two or three 
protofilaments per fibril [100][101][102]. 
Side-chain polymorphism describes polymorphism based on the different orientation of side 
chains. Although relatively discrete, side-chain polymorphism may influence all hierarchical 
elements of amyloid assembly by steric hindrance [93].  
By combination, even a small peptide could theoretically adopt dozens to hundreds of 
polymorphic states. However, for a given set of external conditions, only few conformations 
are kinetically and thermodynamically accessible [70]. Spontaneous structural rearrangement 
to more stable classes within a fibril is not usually possible, but class switching is possible by 
dissolution of less stable polymorphs and rearrangement in more stable fibrils (see also 
chapter 1.2.3) [92][103]. On a mesoscopic scale, mechanically strained twisted ribbons can 
reorganize to helical ribbons or closed nanotubes with water-filled cores [104]. Fibril splitting 
and thinning is rarely observed [83], but can lead to altered appearance despite little changes 
A B 
C D 
Figure 1-6: Assembly polymorphism 
Protofilaments can align A, N-to C-terminus (head to tail), or B, with the same termini facing each 
other (head to head). Lamination occurs when protofibrils assemble with the sheets facing each other, 
either C, in an alternative way, or D, with a distinct inner and outer sheet. 
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at structural level [104]. Concentrated dispersions of amyloid fibrils can cause hydrogel 
formation [105][89][61][106].  
Amyloid fibril morphology can be sensitive to peptide concentration, incubation time, pH, 
ionic strength, and the presence of pre-formed seeds [107][104][94][108][103]. Seeding with 
fibrils of a certain morphology often leads to inheritance of the fibril morphology, even in 
conditions where unseeded fibrillation leads to another fibril type [94][107][109]. For 
example, glucagon fibrillation has been shown to depend on peptide concentration, presence 
of sulphate and chloride anions, pH, and agitation [110]. At low peptide concentrations, the 
fibrils have a predominantly twisted morphology with a beta-turn-rich peptide arrangement. 
Increasing peptide concentration leads to predominant or exclusive occurrence of a straight 
fibril species. In seeding experiments, the twisted morphology is only inherited in low 
concentrations, while cross-seeding into low or high glucagon concentrations leads to straight 
morphology independent of the seed type [94][111]. Charge screening by salt addition 
enables formation of polymorphs that are not thermodynamically accessible in water [112]. 
pH and temperature affect the stability and morphology of glucagon fibrils [113]. Agitation is 
believed to give a selective advantage for a less mechanically stable fibril type, because the 
generation of growth-competent fibril ends is multiplied by stress-induced breakage [110]. 
Moreover, initial oligomeric and fibril types have been shown to convert into different types 
over time [103].  
Despite their highly ordered nature, high-resolution structural determination of amyloid fibrils 
is a challenging task [82]. With few examples of short peptide sequences, amyloid structures 
do not crystallize [84][98][97]. X-Ray diffraction of aligned fibrils can however reveal the 
inter-strand distances [79][114][115][111][116]. Similarly, diffraction data can be derived 
from digitized electron micrographs, especially from Cryo EM images 
[117][99][111][85][118]. Cross-beta structures are generally characterized by a meridional 
~4.7 Å diffraction, which corresponds to the distance of peptide strands within a sheet, and a 
weaker equatorial reflection at ~8-12 Å that represents the spacing of paired sheets [114][70]. 
Closely interdigitating, “dry” steric zippers diffract at 8-9 Å, while less dense packing is 
characterized by larger reflections [85][96]. A few high-resolution amyloid structures have 
been determined by helical reconstitution of Cryo-EM images, or by solid-phase NMR 
[117][119][85][118][95][102]. 
At lower resolution, imaging techniques like atomic force microscopy (AFM) or electron 
microscopy (EM) can differentiate polymorphic fibrils based on their dimensions and twist 
[83][88][104][111][94][88]. For example, the number of laterally interacting protofilaments is 
proportional to maximum width (by EM) or height (by AFM), allowing implicit 
determination of the number and dimensions of protofilaments even without resolving 
individual protofilaments. 
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Similarly, the cross-over pitch of twisted sheets decreases with the increasing number of 
aligned protofilaments due to mechanical strain, making pitch distances a measure for sheet 
dimensions (see Figure 2-7) [83][107][104][88][111][94]. Imaging also provides information 
about oligomeric precursors, amorphic aggregates, and higher-order assemblies [103][104].  
Besides cross-beta specific arrangement and fibrillar morphology, the contemporary 
definition of amyloid structure includes binding of an amyloid reporter-dye. Thioflavin T 
(ThT) is the most widely used amyloid reporter dye for in vitro samples [120]. Due to its low 
interference with the fibrillation process, easy handling and – within similar samples – 
quantitative fluorescence yield, it is often used to study fibrillation kinetics [121][122][123]. 
ThT predominantly binds to the grooves adjacent to stacked aromatic side-chains along a 
fibril. Immobilization restricts the conformation of the otherwise freely rotating dye molecule, 
and preserves its excited state [124]. However, ThT often has reduced specificity to 
protofibrillar species and may show false-positive fluorescence in presence of non-fibrillar 
hydrophobic structures and DNA [123]. If present, intrinsic Tryptophan (Trp) residue 
fluorescence can be a useful indicator of fibrillation and structure. The Tryptophan 
fluorescence maximum is blue-shifted from ~300 nm to ~330-355 nm in hydrophobic 
environments, and signal broadening indicates sample heterogeneity [125]. 
Spectroscopic methods like circular dichroism (CD) and Fourier-transform infrared 
spectroscopy (FTIR) are sensitive to secondary structure elements. Both methods can give 
estimates of the percentage of α-helices, β-sheet, turn and unordered structure. FTIR can also 
distinguish parallel and antiparallel alignment [126][127]. 
Figure 1-7: The number of protofilaments correlates with height and periodicity of 
amyloid fibrils 
Amyloid structures of β-lactoglobulin contain different numbers of aligned protofilaments. 
The maximum heights of twisted fibrils are integer multiples of the thinnest observed filament. 
The periodicity increases with increasing height. Top: model representations of multi-stranded 
fibrils; bottom: AFM images with the number of filaments ranging between 1 and 5. Figure 
adapted from [83]. 
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1.2.3 The interplay of kinetics and thermodynamics in amyloid-type 
self-assembly 
Amyloid structure provides an alternative minimum of the free energy landscape that is 
accessible to every at least partially unfolded peptide sequence. In contrast to the single 
thermodynamic optimum in protein folding, the free energy landscape of amyloid-type self-
assembly is multidimensional (see Figure 2-8, adapted from [57]). Sequence and solution 
conditions determine which minimum of the landscape is adopted, resulting in a multitude of 
possible polymorphic states [57]. Which equilibrium state is reached depends both on the 
thermodynamic stability of polymorphs, their nucleation and polymerization kinetics, and the 
energetic barriers of conversion into more stable species. The state at infinite time may not 
correspond to the global thermodynamic minimum, because the conversion of polymorphic 
states generally requires crossing of an energetic barrier (activation energy) [128][129][92]. 
Off-pathway aggregates can be kinetically trapped in alternative or transition states, while 
residual free peptide may be below the critical concentration for spontaneous nucleation 
[130][92].  
Similarly, conversion of partially or fully folded proteins or peptides into amyloid requires an 
activation energy [131]. An aggregation-prone state can be reached by agitation-induced 
unfolding, cavitation in ultrasonic devices, the presence of chaotropic substances, or thermal 
stress. Thermal unfolding is a frequently reported inducer of protein fibrillation [132][133].  
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Figure 1-8: Free energy landscape of folding and self-assembly 
The energy landscape of protein folding in vivo (blue) generally has a single global free 
energy minimum that corresponds to the natively folded state. Less stable optima correspond 
to folding intermediates on the way to full folding. In self-assembly (red), a single molecule 
can adopt various stable states (minima) depending on the solution conditions. Conversion 
between polymorphs and off-pathway intermediates can be hindered by high transition state 
energies (maxima).  
 Introduction  19 
 
Temperature elevation may also increase the aggregation tendency of peptide aggregation by 
destabilization of helices and stabilization of β-sheets in peptides [134][135][136][137]. 
Amyloid structures are formed by elongation of nuclei (see Figure 2-9 ). A nucleus is defined 
as the minimal structure that can give rise to amyloid type elongation [64]. Starting from 
solution, oligomers are formed by random intermolecular interactions of aggregation-prone 
sequences. Early stage structures are not necessarily fibrillar, but can be composed of 
unstructured, ring-shaped or spherical aggregates [103]. Primary nucleation is independent of 
the presence of fibrils; secondary nuclei are formed by surface catalysis or fibril 
fragmentation. Growth-competent nuclei then elongate until an equilibrium between 
monomer incorporation and monomer release is reached [138][139].  
If self-assembly is followed in presence of an amyloid specific reporter dye, a sigmoidal 
curve of fluorescence reflects the kinetics of amyloid formation (see Figure 2-10). The initial 
phase of low signal intensity is referred to as the lag phase, which is the time needed to form a 
critical amount of nuclei and fibrils to be detected by the measurement. In the following 
growth phase, the exponential signal increase correlates with the incorporation of peptides 
into the cross-beta structure. The signal increase is arrested by monomer depletion, resulting 
in a post-transition baseline [122]. Primary and surface-catalysed nucleation, fragmentation 
and elongation can occur at all stages of the self-assembly process. The conversion can 
alternatively be followed by circular dichroism, Fourier-transform infrared spectroscopy 
(FTIR), decrease of monomer concentration, time-dependent high resolution imaging of 
aliquots, or biosensing techniques such as quartz crystal microbalance (QCM) [83][138][140]. 
The conversion is often described by fitting a logistic function to the experimental data [138].  
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Figure 1-9: Processes involved in amyloid formation 
Amyloid fibrils adopt an equilibrium with free peptide (left) by attachment and detachment of 
monomers. New fibrils can be created by fragmentation (middle left), primary (middle right) 
and surface-catalysed secondary nucleation (right). For illustration purposes, only one 
protofibril with in-register β-arch conformation is shown. 
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The formation of nuclei can be accelerated by agitation, pH alteration, enhanced peptide 
concentration, temperature increase, provision with a surface or air-water-interface, or 
seeding with pre-formed nuclei [108][122][141].  
In conditions where polymorphism can be excluded, amyloid formation can be expressed by a 
mean-field master equation [139]. The concentration f(t,j) of an aggregate of the size j at time 
t is expressed as a differential rate law taking into account primary and secondary nucleation, 
elongation and fragmentation: 
 
𝜕𝑓(𝑡, 𝑗)
𝜕𝑡
= 2𝑘+𝑚(𝑡)𝑓(𝑡, 𝑗 − 1) − 2𝑘+𝑚(𝑡)𝑓(𝑡, 𝑗) + 
+2𝑘− ∑ 𝑓(𝑡, 𝑖)
∞
𝑖=𝑗+1
− 𝑘−(𝑗 − 1)𝑓(𝑡, 𝑗) + 
+𝑘𝑛1𝑚(𝑡)
𝑛𝑐𝛿𝑗,𝑛𝑐 + 𝑘𝑛2𝑚(𝑡)
𝑛2 ∑ 𝑖𝑓(𝑡, 𝑖)𝛿𝑗,𝑛2
∞
𝑖=𝑛𝑐
 ( 1-2 ) 
Figure 1-10: Sigmoidal curve of amyloid formation kinetics  
The sigmoidal course of self-assembly reflects the conversion of monomer into amyloid 
structures. The lag phase is characterised by the time needed for formation of nuclei. In the 
growth phase, the bulk of peptide is converted to the self-assembled state, resulting in a signal 
saturation by monomer depletion. The course of amyloid formation can often be fitted with a 
logistic function.  
y(t), signal dependent on amyloid presence, e.g. ThT fluorescence intensity; y0, pre-transition 
baseline signal; yend, post-transition baseline signal; t, time; t1/2, time for reaching a half 
maximum signal; k, apparent growth rate [138]. 
 
( 1-1 ) 
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where first term accounts for the rate of formation of an aggregate sized j from monomer at 
concentration m(t) and fibrils at length j-1. Analogously, the second term describes the loss of 
fibrils at length j by addition of another monomer. k+ is the elongation rate constant, doubled 
for two ends per fibril4. The third term stands for fibrils of length j formed by fragmentation 
from longer fibrils at fragmentation rate k-, while fibril loss by breaking is included in the 
fourth term. The fourth term defines formation of nuclei of size nc by primary nucleation with 
the nucleation rate kn1. The Kronecker symbol δ is 1 for i=j and 0 otherwise. The last term 
describes surface-catalysed formation of secondary nuclei of size j at rate kn2. Monomer 
concentration change is then related to the formation of fibrils of either length, and equals the 
opposite of total fibril mass concentration change M(t) [142]: 
 
𝑑𝑚(𝑡)
𝑑𝑡
= − ∑ 𝑗
𝜕𝑓(𝑡, 𝑗)
𝑑𝑡
= −
𝑑𝑀(𝑡)
𝑑𝑡
∞
𝑗=𝑛𝑐
 ( 1-3 ) 
Models have been developed to globally fit kinetic data to integrated rate laws of amyloid 
formation, which has helped understanding of nucleation, fragmentation and elongation 
processes in some systems [143][144][145][146][142]. However, these methods are beyond 
the scope of this thesis. Because of the relevance to this thesis, the following paragraphs will 
discuss kinetics and thermodynamics of elongation and dissociation at constant fibril number 
and morphology.  
While amyloid-type aggregation is generally kinetically controlled, thermodynamic control 
analogous to protein folding is achieved in conditions that exclusively allow transition over a 
single free energy border [129]. This borderline condition is satisfied for a sufficiently seeded 
system where nucleation or formation of off-pathway conformers are negligible. The 
exclusive elongation of fibrils can be described analogously to a polymerization chain 
reaction [147]. In ( 1-4 ), F denotes the fibrillar state, S the soluble state, kon the observable 
association rate constant and koff the observable dissociation rate constant, j-1 the fibril length 
at the start of the reaction, and m the fibril length in equilibrium. The reaction constants are a 
function of external conditions, e.g. pH, pI, and temperature.  
 
 
4 It was recently shown that some amyloid fibrils have different elongation rates at both ends, but this is not 
easily accessible in kinetic experiments [189]. Apparent, i.e. observable rates are used in following. 
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( 1-4 ) 
As the association or dissociation process is independent of fibril length and the number of 
fibrils is constant, the reaction constants as well as the apparent reaction constant kapp are 
solely dependent on the soluble peptide concentration at a specific time. kapp incorporates the 
concentration of growth competent fibril ends, which is maximally twice the total fibril 
number N [92]. 
 𝑘𝑎𝑝𝑝(𝑚(𝑡)) = 𝑘𝑜𝑛(𝑚(𝑡)) + 𝑘𝑜𝑓𝑓(𝑚(𝑡)) ≤ 2𝑘+𝑁 ( 1-5 ) 
Exclusive elongation under limited monomer concentration is a pseudo first-order reaction 
with elongation rate proportional to the monomer concentration at each time point [136][141]: 
 𝑑𝑀(𝑡)
𝑑𝑡
= 𝑘𝑎𝑝𝑝 ∗ 𝑚(𝑡) = −
𝑑𝑚(𝑡)
𝑑𝑡
, ( 1-6 ) 
which is classically solved as [148]: 
 ln (
𝑚(𝑡0) − 𝑚(𝑡∞)
𝑚(𝑡) − 𝑚(𝑡∞)
) = 𝑘𝑎𝑝𝑝𝑡, ( 1-7 ) 
with t0 the reaction start and t∞ the time where equilibrium is reached. By conversion, the time 
course of a measured monomer concentration in depleting conditions adopts:  
 𝑚(𝑡) = [ 𝑚(𝑡0) − 𝑚(𝑡∞)]𝑒
−𝑘𝑎𝑝𝑝𝑡 + 𝑚∞, ( 1-8 ) 
𝐹𝑗−1 + 𝑆                       𝐹𝑗   
koff 
kon 
𝐹𝑗 + 𝑆                       𝐹𝑗+1 
 
⋮ 
   
 
koff 
kon 
𝐹𝑚−1 + 𝑆                       𝐹𝑚   
kon 
koff 
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and m(t0), m∞ and kapp can be easily fitted with open-access software. Analogously, kinetic 
parameters can be fitted from the time-course of fibril mass concentration change ΔM(t):  
 
∆𝑀(𝑡) = 𝑀(𝑡) − 𝑀(𝑡0) = 𝑚(𝑡0) − 𝑚(𝑡) = 
     = [𝑚(𝑡0) − 𝑚∞][1 − 𝑒
−𝑘𝑎𝑝𝑝𝑡] ( 1-9 ) 
In quasi-constant monomer concentration like at the start of a reaction or under flow of excess 
monomer, the kinetics are zero order, and ΔM(t) is proportional to kapp. Therefore, steady state 
monomer conditions can be easily used to investigate influence factors like pH, temperature, 
or salt concentration [141]. 
Another borderline case is reaching a (quasi) equilibrium state at long incubation times in 
monomer-depriving conditions. The equilibrium dissociation constant KD is solely defined by 
the soluble peptide concentration m∞ in equilibrium at given conditions [147]. 
 𝐾𝑑 =
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
=
𝑀𝑛
𝑀𝑛−1 ∗ 𝑚∞
=
1
𝑚∞
 ( 1-10 ) 
As for crystallization or amorphous aggregation, the existence of an equilibrium allows 
aggregate growth under supersaturated conditions, and dissolution under free-molecule-
deprived conditions [149]. In many cases, the equilibrium of amyloid-type self-assembly is 
far on the side of fibrils, making amyloid structures quasi-irreversible in certain conditions 
[142]. For example, amyloid plaques accumulate in Alzheimer’s or Parkinson’s patients’ 
brains, because the formation of amyloid fibrils in presence of constitutively secreted 
monomers exceeds monomer release. Conversely, without invading soluble monomer, a 
fraction of the total peptide or protein mass will always be in non-bound state and can diffuse 
from the fibril [148][130][150]. Because the dissociation constant is directly linked to the 
Gibbs’ free energy ΔG, KD or m∞ at constant pressure and temperature can be used to 
investigate influence factors on the chemical potential of fibrillation [151].   
 ∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝐷 ( 1-11 ) 
T is the absolute temperature in Kelvin (K), and R is the universal gas constant (~8.314 J K-1 
mol-1). ΔG is negative for spontaneous (exergonic) processes, and positive for unfavourable 
(endergonic) processes. The Gibbs Helmholtz equation relates free energy to enthalpy (H) and 
entropy (S) changes:  
 ∆𝐺 = ∆𝐻 − 𝑇∆𝑆 ( 1-12 ) 
 Introduction  24 
 
Favourable enthalpic changes increase heat (exothermic reaction) or draw heat from the 
system (endothermic reaction). Amyloid-type fibrillation is often enthalpically favourable 
because of the multitude of interactions along the fibril. It is important to note that H bonds 
created among the backbone or side chain groups replace H bonds in bulk water and are thus 
not per se thermodynamically favourable. However, H bonds in a water-free, low dielectric 
environment such as inside water-free double sheets are relatively stronger than in solution 
[84]. Shielding of hydrophobic residues from water is an additional driving force for amyloid-
type self-assembly [152][153]. Generally, enthalpy changes in amyloid formation are 
temperature sensitive [153][154][155][133][147]. Higher order assembly of protofibrils or 
mature fibrils is often strongly exothermic and favoured at increased temperature [153][154]. 
The enthalpy change with increasing temperature (i.e. the heat capacity ΔCp) can be positive 
or negative depending on the solution conditions and the polymorphic type formed. For 
example, glucagon has been found to have positive ΔCp in presence of glycine and saline, but 
negative ΔCp in presence of sulphate [154].  
As aggregation restricts conformational degrees of freedom, the entropy of the peptide or 
protein assembly is smaller than the entropy of soluble peptide or protein. The entropy term in 
the Gibbs-Helmholtz equation is therefore positive and increasing for temperature increase if 
only the peptide or protein is considered. However, water exclusion from the assembly can 
increase the entropy of the entire system [82][153].  
Therefore, both terms of the Gibbs-Helmholtz equation can be either positive or negative 
depending on the solution conditions. This is reflected in the temperature dependence of 
amyloid formation. Many proteins only self-assemble if a critical unfolding temperature is 
reached and the native fold is destabilized. At moderate temperatures, the self-assembly 
process is often favoured by temperature increase with a measurable apparent activation 
energy (Arrhenius-like behaviour) [129][128]. However, at high temperatures, amyloid 
assemblies are destabilized, and the equilibrium is shifted towards unfolded monomers or 
randomly associated oligomers. For example, β2-microgobulin, insulin, SH3 domain, and hen 
egg-white lysozyme fibrils start to dissociate between 60 and 140 °C [153][156][157][126]. 
The thermodynamic explanation for this phenomenon is that enthalpically favourable 
interactions saturate at a specific temperature and cannot counteract the increasing entropic 
cost of self-assembly. Less ordered states like soluble monomers, oligomers or amorphous 
aggregate are then favourable [156]. If the monomer conformation inside a fibril is partially 
folded, increasing temperature may also prevent cooperative folding. For example, the 
formation of β-hairpins is a cooperative process that is disfavoured at higher temperature 
[135]. Disaggregation at high temperature is then consistent with the observation that any 
ordered structure can only form at low-enough temperature [158].   
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2 Scope of this project 
Self-assembly can drastically increase the chemical, physical and biological stability of 
peptides and proteins. Amyloid fibrils have not been taken into account as drug formulations 
or drug delivery vehicles for a long time because of their association with amyloid-related 
diseases. Increasing evidence for the safety of amyloid fibrils, and the toxicity of prefibrillar 
aggregates, demands the consideration of amyloid structures in pharmaceutical applications 
[4][5]. Protection of proteins and peptides in amyloid nanostructures provides an elegant 
means to form a stable, reversible self-delivery reservoir with controlled release of monomers 
from the fibril termini, given an undersaturated environment [5]. This project investigates the 
potential use of s.c. delivered, ex vivo self-assembled Oxyntomodulin as a long-acting drug 
delivery system. Oxyntomodulin is chosen as a model peptide for the following reasons:  
• Oxyntomodulin potentially has superior effects in T2DM and obesity compared to 
marketed drugs, but no Oxyntomodulin-based compound has been filed for drug 
approval. Because the glucose dependency of Oxyntomodulin’s insulinotropic action 
excludes the risk of hypoglycaemia, and no adverse effects like nausea are known, 
high doses can be administered to achieve weight control as an additional beneficiary 
action in overweight T2DM patients.  
• Long-action formulations of T2DM drugs are favoured by patients and health care 
organisations to reduce discomfort and complications related to noncompliance with 
drug prescriptions.  
• Extension of Oxyntomodulin’s remarkably short plasma half-life by classical methods 
like amino acid substitutions or increase of the hydrodynamic radius proved very 
difficult due to the sensitivity of dual receptor agonism to structural changes. 
• Self-assembly allows protection from external influences without the need for 
molecular alterations. Every peptide sequence can potentially form amyloid-like 
fibrils, given the right conditions. Methods and results of this project can thus be seen 
as a proof of concept and extended to other molecules. 
• Oxyntomodulin is charged at physiologic pH, which increases the probability that 
Oxyntomodulin fibrils are metastable in vivo. Released peptide can be carried away in 
constant flow of peptide deprived interstitial fluid, possibly reaching pharmaceutically 
meaningful plasma concentrations.  
• Oxyntomodulin self-assembly has not been reported in literature at the start of this 
project. Due to structural similarity to the well-characterized peptide hormone 
Glucagon, investigation of Oxyntomodulin self-assembly is scientifically valuable for 
a better understanding of processes in fibrillation.  
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This thesis comprises a description of condition screening and optimization for injectable self-
assembled Oxyntomodulin; microscopic and physicochemical characterization of the 
formulation; investigations of kinetic and thermodynamic processes during self-assembly and 
peptide release; the characterization of an alternative self-assembled state; and an 
investigation of the cross-seeding tendency of Oxyntomodulin fibrils in presence of the 
structurally related peptides glucagon and Aib-2-Oxyntomodulin. Parallel to this project, 
postdoctoral researcher Myriam Ouberaï coordinated in vivo pharmacokinetic and 
pharmacodynamic studies in collaboration with MedImmune. Because I was only peripherally 
involved in in vivo studies, in vivo results are not included in the experimental section of this 
thesis. All experiments and discussions shown are exclusively my work unless clearly noted 
otherwise.  
Chapter 3 describes the steps taken to achieve an injectable Oxyntomodulin fibril formulation. 
Conditions are screened by ThT fluorescence and AFM imaging. Promising conditions are 
upscaled in vials, and critical factors on self-assembly time, conversion yield, visual 
appearance of the formulation, and fibril morphology are derived. Seeding with pre-formed 
Oxyntomodulin fibrils is investigated as an accelerated and more reproducible method to 
produce self-assembled nanostructures. The final formulation is designed to fulfil the 
following parameters: 
• the presence of self-assembled fibrils with low polydispersity and sufficient length to 
release monomers over a time course in the range of days or weeks 
• fibrillation yield > 95 % 
• absence of unstructured aggregate or precipitate 
• reversibility of self-assembly in free peptide deprived conditions  
• viscosity suitable for s.c. injection 
• reproducibility and scalability within sample amounts needed for in vivo studies  
• minimal use of additives 
In chapter 4, the formulation optimized for in vivo testing is structurally characterized. A 
coarse fibril structure is derived from AFM and Cryo EM imaging, limited peptidolysis, 
FTIR, CD, ThT and Tryptophan fluorescence.  
For any application of self-assembled peptides or proteins, a comprehensive understanding of 
the influence factors on fibril characteristics is important to define reproducible conditions 
and prevent complications. Chapter 5 comprises kinetic and thermodynamic characterization 
of self-assembled Oxyntomodulin. Fibril elongation and peptide release are tested under 
different solution conditions by kinetic QCM-D and ThT assays, AFM imaging, ITC, and the 
time course of free peptide conversion. Parameters include seeding strength, ionic strength, 
soluble peptide concentration, and temperature.  
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Chapter 6 describes a method to grow an alternative Oxyntomodulin fibril structure by 
altering incubation conditions. The structure is characterized similar to chapter 4, with a focus 
on Cryo EM. 
Because of the structural similarity with human Glucagon, it is important to test if 
Oxyntomodulin fibrils can induce Glucagon self-assembly. Chapter 7 shows QCM-D 
experiments to investigate the cross-seeding ability of Oxyntomodulin fibrils in presence of 
glucagon. Moreover, self-assembly of the DPP-4 protected analogue Aib-2-Oxyntomodulin is 
compared to Oxyntomodulin self-assembly, and cross-seeding is tested. 
All experimental chapters can be read widely independently. Results of each chapter will be 
discussed in context of the respective literature in each of the experimental chapters. 
Summary and interpretation will be given in chapter 8, in combination with a suggestion for 
future work. 
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3 Screening and optimization of Oxyntomodulin self-
assembly 
3.1 Challenges in Oxyntomodulin self-assembly 
This chapter describes methods for reproducible self-assembly of Oxyntomodulin. The end 
product was designed for in vivo studies at MedImmune, and further used for characterization 
of the fibril architecture in chapter 4 as well as investigation of fibrillation kinetics and 
thermodynamics in chapter 5. Therefore, a number of methodic restrictions and quality 
parameters were defined before the start of screening and optimization. 
While Oxyntomodulin potentially self-assembles in a multitude of experimental conditions, 
work presented here is focused on the s.c. injectability of the final sample. This excluded 
additives that are not widely acknowledged as biocompatible, methods that cannot be 
upscaled to sample amounts required for in vivo studies, and processes that are not repeatable 
in sterile conditions.  
Because large s.c. injected particles are not expected to reach the bloodstream, regulations 
concerning particle diameter are not as strict as for i.v. injection. The particle size and 
concentration are however restricted by the force and pain associated with the injection of a 
viscous sample. Consequently, Oxyntomodulin fibrillation was aimed to be free of large 
(> 5 μm) structures. Possible gelation needed to be reversible by moderate dilution or shear 
inside a syringe. Considering injectability and reproducibility, samples should further be 
exempt from amorphous or otherwise unstructured aggregate. 
Because of the potential toxicity of fibrillar intermediates, oligomeric species were not 
desired in final Oxyntomodulin samples. Due to the potentially transient or instable nature of 
oligomers in experimental conditions, there is no standardized method to distinguish 
oligomers from active, monomeric peptide. As a precaution, the sum of measurable soluble 
peptide in storage conditions was required to be below 5 % (w/w) of the total sample 
concentration. Regarding reproducibility and defined fibrillar conditions, samples with only 
one fibrillar morphology were preferred, and conditions with a clearly polymorphic AFM 
appearance were excluded. 
Practically, there were three major challenges for optimization:  
(1) The fibrillar and reversible nature excluded several classical methods to determine the 
size, purity and concentration of aggregates. Especially methods including dilution or 
acetic conditions like size exclusion chromatography (SEC) or high-performance 
liquid chromatography (HPLC) could not be performed on samples containing 
aggregates because of potential disaggregation in measurement conditions. 
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Furthermore, the separation of self-assembled structures from soluble peptide required 
centrifugation and filtration, increasing sample amounts per condition. 
(2) There are no in-house facilities to produce Oxyntomodulin in pharmaceutical quality, 
and the peptide is very costly. Screening, optimization and characterization are 
therefore limited by the peptide amounts available.  
(3) As described in chapter 9.2, Oxyntomodulin self-assembly cannot readily be screened 
by ThT fluorescence assay. ThT binds nonfibrillar Oxyntomodulin species but does 
only weakly bind protofibrils, leading to false positive and false negative read-outs. 
Gelation limits maximum screenable concentrations, but low concentrations prevented 
nucleation in reasonable time frames. ThT could therefore only be used to investigate 
elongation in presence of pre-formed seeds.  
Due to these reasons, a condition pre-screening was performed with the Oxyntomodulin 
analogue Oxm2-37, which was available in abundance. Oxm2-37 has the same molecular 
structure as Oxyntomodulin apart from truncation of the N-terminal Histidine and could be 
screened by ThT assays. Promising conditions were then investigated with full-length 
Oxyntomodulin. 
3.2 Material and methods 
Oxyntomodulin and Oxm2-37 were provided by Bachem, Switzerland. Both peptides were 
freeze-dried acetate salts with a purity of 97 %, and stored as dry aliquots at -20 °C. Salt 
solutions and buffers were prepared as 250 or 200 mM stocks. Salts, acids, bases, buffering 
agents and ThT were delivered by Sigma-Aldrich (UK) in analytical quality. HPLC grade 
water was bought from Fisher, UK. Phosphate-buffered saline (PBS, Sigma) was prepared by 
dissolution of PBS tablets. Stock solutions were passed through a 0.2 µm syringe filter into a 
sterile flask. In some long-term experiments, 0.02 wt.% sodium azide (NaN3) was added for 
prevention of microbial growth.  
3.2.1 Preparation of peptide solutions 
An aliquot was defrosted at room temperature (RT) in a vacuum exsiccator for about 30 min 
to prevent condensation on the container. 130 % of the needed peptide mass was weighed into 
a single-use glass vial, and dissolved in 100 % of the theoretical solvent needed, in order to 
make up for contained acetate mass. Generally, peptide dissolved in water up to 25 mg mL-1 
within few minutes; shaking or pipetting was not necessary. The clear solution was filtered at 
13 000 rpm for 5 min in a disposable 0.22 μm cellulose acetate filter (Amicon ultra) in order 
to remove dust or pre-formed aggregates. Concentration was measured in an aliquot of the 
filtrate by the UV280 absorption on a NanoDrop 2000 spectrophotometer. The 0.1 % 
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(1 mg mL-1) absorption coefficients for Oxyntomodulin (1.906) and Oxm2-37 (1.996) were 
calculated from the theoretical extinction coefficients of the peptide sequences using the 
online tool Expasy ProtParam (https://web.expasy.org/protparam/). Peptide solutions were 
diluted to the desired concentration, stored at 8 °C, and used within 2 hours.  
3.2.2 Detection of amyloid fibrils by ThT fluorescence 
ThT fluorescence screenings were performed in a Fluostar Omega microplate reader equipped 
with 440 and 480 nm wavelength filters for excitation and emission, respectively (BMG 
Labtech, Germany). The microplates (Corning® 3881, 96 well half area black with clear flat 
bottom polystyrene non-binding surface, provided by Jencons VWR, UK) were incubated in 
situ at 37 °C for up to 5 d. Aluminum microplate sealing tape (Corning®, delivered by Sigma-
Aldrich, UK) was used to prevent evaporation during incubation. ThT stock solutions were 
prepared at 1 mM in water and stored at 8 °C protected from light for a maximum of 3 months 
[123]. ThT was used at 50 uM in all conditions. Fluorescence was read every 10 or 20 min by 
orbital averaging of six flashes per well. Microplates were either incubated without agitation, 
or shaked for 5 min (600 rpm, 2 mm orbit) prior to each measurement. ThT fluorescence 
screenings comprised a peptide concentration range of 0.1 to 10 mg mL-1. The buffer pH 
range was 2 to 9 for Oxm2-37, and 6-8 for Oxyntomodulin. Self-assembly was additionally 
screened in PBS and in unbuffered saline containing 7.7 to 150 mM NaCl. All conditions 
were triplicates with 50 or 100 µL per well. Triplicates of 50 µM ThT in water were used as a 
negative control. Samples classified as ThT-positive showed a more than 2-fold ThT signal 
increase with more than 10-fold signal/noise ratio. Aliquots of all ThT positive and some ThT 
negative conditions were imaged by AFM.  
3.2.3 Oxyntomodulin fibrillation by primary nucleation or seeding 
Oxyntomodulin solutions were prepared in HPLC grade water or at low NaCl (≤ 50 mM) 
concentration. The solutions were incubated in sealed glass vials at 37 °C in a MaxQ 4450 
shaker/incubator (Fisher Scientific, UK) with continuous orbital shaking (orbit 1.9 mm) at 
200 rpm. The number of revolutions reflects the agitation stress used in Oxm2-37 ThT 
screening, considering that rotational energy scales with orbit diameter, and that the shaking 
in ThT screening was intermittent due to the reading time. Samples were either incubated 
with agitation until no further aggregation was detected, or stored at 37 °C in quiescent 
conditions after the onset of fibrillation.  
Samples were visually controlled for precipitation or gelation, and aliquots were imaged by 
AFM to detect aggregates or fibrils (see 3.2.4). The conversion yield was assessed as 
described in 3.2.5. 
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Fibrillated samples were used to seed freshly prepared Oxyntomodulin solutions. Seeding was 
used to shorten the production time and inherit the seed morphology to achieve more 
homogeneous daughter samples. Because elongation rates scale with the number of growth 
competent fibril ends, the mass concentration and length of mother fibrils were measured 
before seeding (see 3.2.5 and 3.2.4, respectively). Short fibrils were either produced by 
fibrillation of NaCl-containing conditions under rotational stress, or by fragmentation of 
longer fibrils in a sonication bath (FB15049, FisherBrand®) for up to 15 min. Seed 
concentrations of 0.1 to 5 % (m/m) in respect to soluble peptide were tested. 
Although not included in this thesis, a range of experiments was performed with addition of 
0.02 % NaN3 as an antimicrobial agent. It was later found that NaN3 affected fibril 
morphology and equilibrium, so that antimicrobial agents were omitted further on. 
Contamination did not seem to be a problem in handling of Oxyntomodulin samples. 
3.2.4 Atomic force microscopy 
AFM measurements were performed in tapping mode on a PicoPlusTM (Molecular Imaging) 
with a PicoSPMII controller. The AFM probes were HQ:NSC36/No Al (MikroMasch®, 
Windsor Scientific LTD, UK) and had a tip radius < 8 nm and force constants between 0.6 
and 2.0 N/m. The scanning rate was 0.6-0.9 lines per second, at a maximum imaging area of 
9x9 µm and resolutions of 512x512 or 1024x1024 pixels. 2-5 µL samples were deposited on 
freshly cleaved mica and dried in air for at least 30 min before imaging. Undiluted samples 
with salt were rinsed by pipetting 100 µL HPLC grade water on a tilted dried mica chip, 
followed by immediate drying in a stream of compressed air. In order to analyze individual 
structures in a crowded environment, samples were dispersed in water in up to 100-fold 
dilutions.  
Images were plane-levelled and corrected for horizontal scars with the open access software 
Gwyddion, version 2.51 (http://gwyddion.net/). Fibril heights and lengths were measured 
using the line extraction tool of Gwyddion.   
3.2.5 Concentrations and conversion yield measurement in self-
assembled samples 
The soluble (free) peptide concentration is measured in the sedimentation supernatant of a 
sample at 13 000 rpm for 30-60 min. Salt-free samples and samples containing short fibrils do 
not sediment readily and are prone to resuspension. To prevent measuring fibrils, the 
supernatant is additionally filtered with a 50 kDa molecular weight cut-off (MWCO) filter 
(Amicon Ultra 0.5 mL) at 13 000 rpm for 20 min. Note that filtration alone is not suitable to 
separate soluble peptide from aggregated peptide, because aggregates tend to clog the filter 
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and trap soluble species. Peptide concentration is then measured in the filtrate by NanoDrop 
analogously to 3.2.1. 
Aggregated peptide concentration in a pelleted or otherwise purified sample is assessed by 
measuring the total peptide concentration. Three aliquots are diluted twenty-fold in 10 mM 
HCl and incubated at 37 °C for 60 min. The concentrations are measured by NanoDrop and 
averaged. Aggregate concentration equals the total concentration in the pellet less the soluble 
peptide concentration. 
The conversion yield can be calculated from soluble peptide concentration m(t) or aggregated 
peptide concentration M(t) and the total peptide concentration m(t0). Either or both methods 
are used in this thesis depending on sedimentation and further use of the sample. 
 
𝑌(𝑡) =
𝑚(𝑡0) − 𝑚(𝑡)
𝑚(𝑡0)
∗ 100 % =
𝑀(𝑡)
𝑚(𝑡0)
∗ 100 % ( 3-1 ) 
   
3.2.6 Rheological characterization 
A 10 mg mL-1 gel in water was diluted to 1 mg/mL in water or 0.9 mg mL-1 NaCl. The 
viscosity of each dilution was measured by a rate sweep test in a Physica MCR 301 rheometer 
(Anton Paar, Germany). The rheometer was equipped with a flat steel plate and a 1 ° angle 
steel cone with 40 mm diameter (CP40-1, Anton Paar, Germany). The equipment was heated 
to 37 °C and primed in air before use. 350 µL of a dilution was loaded on the plate. The cone 
was approached to the automatically determined measurement position (~0.5 mm distance 
between cone and plate). The equal distribution of the sample and the eventual inclusion of 
bubbles was examined by eye. After a 5 min equilibration to heat the sample to 37 °C, the 
shear stress was measured at cone shear rates decreasing logarithmically from 1000 s-1 to 1 s-1 
in 13 steps, followed by a logarithmic increase of shear rate from 1 s-1 to 1000 s-1 in 13 steps. 
Viscosity [mPa*s] was calculated by dividing the measured shear stress [mPa] by the applied 
shear rate [s-1]. Viscosity curves are presented as double logarithmic plots of shear rate and 
viscosity.  
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3.3 Efficient Oxyntomodulin nucleation and monomorphic 
elongation require different environments 
Because Oxyntomodulin was not available in high enough quantity for extensive screening, 
nucleation conditions were pre-screened with Oxm2-37 in agitated ThT assays at 37 °C. 
Important results are shown in Appendix 9.1. Over three days, Oxm2-37 at 10 mg mL
-1 
fibrillated in a range of conditions, with fastest nucleation in salt-containing solutions. Self-
assembly was fast and quantitative in pH range 6.0-7.4, however buffering with phosphate 
salts seemed to prevent formation of long fibrils and promote amorphous aggregation. Only a 
small amount of fibrils were formed at pH 5 and pH 8. In presence of 50-150 mM NaCl, 
Oxm2-37 formed fibrils at concentrations from 0.5 to 10 mg mL
-1. Fibril length in presence of 
NaCl was inversely correlated with agitation stress, suggesting that fragmentation delimits 
elongation. Presence of salts generally favored assembly of single fibrils to higher order 
structures. Remarkably uniform, long fibrils were formed in water at 10 mg mL-1, but 
nucleation was comparably slow and not seen at lower peptide concentrations.  
The ionic strength dependency of nucleation can be explained with the positive charge of 
Oxm2-37. Charge screening by solution anions stabilizes oligomeric and polymeric assemblies, 
while electrostatic repulsion occurs at low ionic strength. Relatively small anions like chloride 
may screen charges in fibrillated assemblies more effectively than large anions like 
phosphate. It is noteworthy that fibrillation in water contained minor amounts of acetate 
stemming from the peptide production process. 
Human Oxyntomodulin was expected to have similar, but not the exact same fibrillation 
behavior as Oxm2-37 because of an additional N-terminal Histidine residue in full-length 
Oxyntomodulin. N-terminal Histidine is crucial for glucagon- and GLP1-receptor activation 
[49]. Histidine slightly increases the isoelectric point and provides aromatic and H-bridge 
interactions if included in an amyloid-type core sequence. Moreover, the terminal location of 
Histidine may favor side-by-side interaction of peptides that favor assembly polymorphism as 
described in 1.2.2.  
Due to these differences, fibrillation conditions known from Oxm2-37 had to be repeated with 
Oxyntomodulin. Screening was attempted with full-length Oxyntomodulin in a five-day, 
agitated ThT assay at 37 °C. ThT curves and AFM images are shown in Appendix 9.2. To 
find the best salt conditions, an increasingly chaotropic selection of salts (Na2SO4, NaCl, NaI, 
NH4Cl, GdnCl) were screened at 25 and 100 mM at a peptide concentration of 1 mg mL
-1. pH 
was tested in 0.5 pH unit steps from pH 6 to pH 8 in 25 mM phosphate buffer. All salt-
containing conditions showed a marked, approximately sigmoidal increase of ThT 
fluorescence within 48 h. However, AFM imaging after 48 h only showed fibrillation in the 
samples containing NaCl, while other salts caused formation of non-fibrillar oligomers or 
unstructured precipitate.  
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In an equivalent ThT fluorescence assay, Oxyntomodulin self-assembly was tested at 1, 5, and 
10 mg mL without salt addition. All salt-free conditions showed fibrils in AFM images after 
48 h. Interestingly, no ThT fluorescence increase was seen at 1 mg mL-1, and only moderate 
signal was seen at higher concentrations. This may imply presence of protofibrillar species 
with low affinity to ThT [123]. Beginning gelation at 5 and 10 mg mL-1 further restricted the 
fluorescence yield. 
Because of the restrictions due to gelation, false positive and false negative results seen in 
ThT assays of Oxyntomodulin nucleation, no further screening of fibrillation conditions were 
performed by fluorescence assays. However, kinetic ThT assays proved useful to study 
influence factors on elongation in presence of pre-formed fibrils (see chapter 3.4 and 4.1.1).  
Screened conditions where fibrillation was seen by AFM were investigated for upscaled self-
assembly. Especially, 10 mg mL-1 solutions in water or with low NaCl concentration were 
tested because of the formation of long and defined fibrils, and quick nucleation, respectively.  
Oxyntomodulin solutions were incubated in glass vials at 37 °C with 200 rpm continuous 
shaking in a MaxQTM 4450 shaker/incubator. Fibrillation was followed by visual inspection 
and AFM imaging. 
10 mg mL-1 Oxyntomodulin solution in water did not nucleate over 3 months at 37 °C, room 
temperature, or in a fridge, if no agitation was provided (results not shown). However, after 
continuous shaking at 200 rpm and 37 °C, initial fibrils could be seen by AFM after 6 d. After 
10 d, a clear gel consisting of long, unbranched and smooth fibrils was formed (see Figure 
4-1). Fibrils were several micrometers long and about 4-15 nm high, with the majority height 
of single fibrils being ~6 nm. The fibril heights may be subject to uncertainty because of 
soluble peptide in the imaging background. After 14 d, the conversion yield was 37 %. Fibrils 
did not sediment readily even after long centrifugation times, so that the fibril concentration 
could not be increased by removal of soluble peptide.  
Because of the limited yield of Oxyntomodulin fibrils produced in water, analogous steps 
were taken in 25 mM NaCl. Gelation was seen after 4 d of incubation, and incubation was 
stopped after 7 d. Centrifugation at 13000 rpm for 30 min separated a dense, cloudy fibrillar 
pellet with ~45 mg mL-1 from clear supernatant with no measurable soluble peptide within 
limits of detection. The fibrils were approximately 50-200 nm long and associated laterally 
(see Figure 4-2). Aliquots of the 7 d pellet produced in 25 mM NaCl were 20-fold diluted in 
water, PBS, and 10 mM NaCl, and the cumulative peptide release from the fibrils was 
measured over 48 h. Release profiles are shown in Figure 4-2 H. In water, fibrils showed a 
burst release of ~50 % within the first 1.5 h, and ~80 % peptide release by 48 h. Less than 
10 % release was seen in PBS. No free peptide could be measured by resuspension in 10 mM 
NaCl (data not shown). Oxyntomodulin fibrillation is thus generally reversible and sensitive 
to environmental changes. 
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Figure 3-1: Incubation of a salt-free 10 mg mL-1 Oxyntomodulin solution at 200 rpm 
and 37 °C creates long and straight fibrils after 2 weeks 
10 mg mL-1 solutions of Oxyntomodulin incubated at 37 °C and 200 rpm. A and B, at the 
start of incubation, AFM shows soluble peptide in layers (100x diluted sample); C and D, 
incubation in water for 24 h; E and F, incubation in water for 6 d; G and H, 100x diluted 
pellet after 14 d incubation; I, height profiles along line 1 and 2 in image H. Profile lines 
were chosen to not include fibrils over-crossing other fibrils. AFM images were processed in 
Gwyddion to remove imaging scars and background signal. Resolution: 512x512 pixel at 
scanning size 9x9 µm (A, C, E, G); 1024x1024 pixel at scanning size 2x2 µm (B, D, F, H).  
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Figure 3-2: Incubation of a 10 mg mL-1 Oxyntomodulin solution in 25 mM NaCl at 200 
rpm and 37 °C leads to fast formation of short and reversible fibrils  
10 mg mL-1 solutions of Oxyntomodulin incubated in 25 mM NaCl at 37 °C and 200 rpm. A 
and B, 24 h; C and D, 4 d, 100x dilute in water; E and F, 7 d, 100x diluted in water. G, 
height profile along the line in E. AFM images were processed in Gwyddion to remove 
imaging scars and background signal. Resolution: 512x512 pixel at scanning size 9x9 µm 
(A, C, E); 1024x1024 pixel at scanning size 2x2 µm (B, D, F). H: Peptide release after 20-
fold dilution of the 45 mg mL-1 Oxyntomodulin fibril pellet in water (black circles) or PBS 
(open triangels) and quiescent incubation at 37 °C. Peptide concentration in the supernatant 
was quantified after 5 min, 1.5 h, 6 h, 24 h, and 48 h. Supernatants were replaced by fresh 
solvent. Release is percentual of the total release in 10 mM HCl.  
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In the following experiments, NaCl concentration was reduced to 14.4 mM. This was for 
practical reasons, because gels with slightly lower salt concentrations formed more 
homogeneous gels and were easier to pipette. 0.9 mg mL-1 (14.4 mM) was chosen because it 
can be conveniently diluted from physiologic saline (9 g L-1) for sterile production of samples 
for in vivo studies.  
To find suitable conditions for nucleation and elongation, 10 mg mL-1 Oxyntomodulin 
solutions with 0.9 mg mL-1 NaCl were incubated at room temperature, 37 °C, and 37 °C with 
200 rpm agitation. At room temperature, a turbid gel with approximately 90 % conversion 
yield formed after 8 weeks. As shown in Figure 4-3, individual fibrils at room temperature 
were 0.2-1 μm long and 3-12 nm in diameter. Fibrils associated to thicker bundles.  
At 37 °C, the solution became viscous after 2 weeks with few fibrils, and formed a 
transparent gel with longer fibrils formed after 4 weeks (see Figure 4-4). Only 50 % 
conversion yield was reached after 8 weeks. Fibrils were 5-10 nm high and contained straight 
and twisted species. 
A B 
C D 
Figure 3-3: Incubation of a 10 mg mL-1 Oxyntomodulin solution in 0.9 mg mL-1 NaCl at 
room temperature without agitation creates short fibrils after 8 weeks 
Incubation of 10 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl without agitation. A and B, 
2 weeks; C and D, 8 weeks. AFM images were processed in Gwyddion to remove imaging 
scars and background signal. Resolution: 512x512 pixel at scanning size 9x9 µm (A, C); 
1024x1024 pixel at scanning size 2x2 µm (B) and 4x4 µm (D). 
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Figure 3-4: Incubation of a 10 mg mL-1 Oxyntomodulin solution in 0.9 mg mL-1 NaCl at 
37 °C without agitation causes slow formation of polymorphic fibrils 
Incubation of 10 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl at 37 °C without agitation. A 
and B, 2 days; C and D, 2 weeks; E and F, 4 weeks; G and H, 8 weeks. Blue arrows, 
examples of twisted fibrils. AFM images were processed in Gwyddion to remove imaging 
scars and background signal. Resolution: 512x512 pixel at scanning size 9x9 µm (A, C, E, 
G); 1024x1024 pixel at scanning size 2x2 µm (B, D, F, H). 
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Shaking at 37 °C produced an opaque gel with 97-100 % conversion yield within 1-3 days. 
These fibrils were short even if the sample was incubated without agitation after nucleation, 
but nucleation times, gelation and fibril morphology was consistent over 5 samples and three 
batches of peptide. Fibrils formed in 0.9 mg mL-1 saline could be stored at room temperature 
or in the fridge for at least 12 months without visible alterations of gel appearance or fibril 
morphology. Dilution in 0.9 mg mL-1 saline did not shift the equilibrium within measurable 
concentrations, but fibrils were reversible after dilution in water similar to the reversibility 
shown in Figure 4-2 H. The fibrillation process was indistinguishable if the pH was adjusted 
A B 
C D 
E F 
Figure 3-5: Incubation of a 10 mg mL-1 Oxyntomodulin solution in 0.9 mg mL-1 NaCl at 
37 °C with 200 rpm agitation causes fast formation of short fibrils 
Incubation of 10 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl at 37 °C with continuous 
agitation at 200 rpm. A and B, 2 days; C and D, 2 weeks; E and F, 8 weeks, 10x dilute. AFM 
images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512x512 pixel at scanning size 9x9 µm (A, C, E); 1024x1024 pixel at scanning 
size 4x4 µm (B, F); 1024x1024 pixel at scanning size 2x2 µm (D). 
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to subcutaneous pH 7.4 with NaOH at the start of incubation5 (data not shown).  
In conclusion, Oxyntomodulin nucleation and the development of well-structured fibrils seem 
to require different environments.  
Fibrillation in presence of NaCl is fast and quantitative, but self-seeding is too extensive to 
allow the formation of long fibrils even if no agitation is applied. Presumably, rapid depletion 
of soluble peptide in presence of numerous fibril termini and charge-screening electrolytes is 
the limiting factor for fibril length. This is aggravated in agitated conditions, where 
fragmentation decreases average fibril size and increases fibril numbers. Conversely, 
conditions disfavoring Oxyntomodulin’s nucleation – such as absence of salt or agitation – 
allow the elongation of fewer fibrils. In these conditions, self-assembly is not quantitative, so 
that soluble peptide is available even after long incubation times. Limitations to fibril yield 
can be partly due to steric hindrance of diffusion and termini availability in formed hydrogels. 
Fibrils formed in presence of salt dissolve after dilution in water, proving that the reaction 
equilibrium is further on the free peptide side of the polymerization reaction in the absence of 
electrolytes. The thermodynamic equilibrium of soluble and self-assembled peptide 
additionally delimits fibrillation in water.  
It was therefore not possible to satisfy the parameters set for quality, quantity, and speed of 
Oxyntomodulin self-assembly in a one-step reaction.  
 
  
 
  
 
5 Data are not shown here because the fibril characterization in chapters 4 and 5 was performed without pH 
adjustment. pH-adjusted fibril batches were used for in vivo studies in [6].  
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3.4 A three-step seeded method to efficiently produce uniform 
Oxyntomodulin fibrils at high yield 
To combine fast nucleation, well-ordered elongation and high yield in Oxyntomodulin self-
assembly, the polymerization reaction was decoupled into three steps. Short fibrils were 
formed in fast nucleation conditions and elongated in conditions that disfavor nucleation, so 
that the seed amounts and elongation conditions can be directly controlled. Elongated fibrils 
were then either separated from remaining free peptide, or the equilibrium was shifted to the 
fibril side by addition of salt.  
Short fibrils were grown under agitated conditions with NaCl equivalent to Figure 4-5 and 
used as seeds for elongation in water. Seeding at 0.5 % (seed mass: free peptide mass) without 
further processing of seed fibrils produced elongated fibrils in water at total peptide 
concentrations from 1 to 10 mg mL-1. At 1 mg mL-1, seeds initially disaggregated below 
detection limits by AFM, and few, thin fibrils formed after 11 d (results not shown). At 
5 mg mL-1, elongation could be seen from 24 h on, but the fibril morphology did not reflect 
the seed morphology. While seeds were straight and did not split and merge, daughter fibrils 
at 5 mg mL-1 contained several twisted types and higher order assemblies (see Figure 4-6 A-
D). Separation of the soluble fraction from the gel fraction after 13 d resulted in continued 
growth of twisted species in the soluble fraction, implying that different seeds were formed 
during the elongation process (see Figure 4-6 F and G). At 10 mg mL-1, a cloudy gel with 
long fibrils formed after 7 d. As shown in Figure 4-7, fibril morphology was similar to the 
seed type, with the bulk of fibrils consisting of straight, 6-8 nm high fibrils that occur single 
or laterally aligned. Very few twisted species coexisted with the straight type. Increase of seed 
concentration to 4.5 % in 10 mg mL-1 salt-free Oxyntomodulin produced a clear gel after 24 h 
with indistinguishable fibril morphology (results not shown).  
It was assumed that the occurrence of polymorphism in seeded batches was a result of 
insufficient seeding. If the seed length were 200 nm in average, contained only two monomers 
per cross-section, and there were two growth competent ends available at all times, the 
number of fibril ends to monomers in the fibril would be 1:425 (assuming 4.7 Å β-strand 
spacing), so that even at 10 % seeding strength, the number ratio of monomers to fibril ends 
would not exceed 4250. Considering steric hindrance in a crowded environment and statistical 
differences in the growth competence of fibril termini, this number could easily exceed 
10000. Due to the considerable amount of free peptide during elongation, spontaneous or 
surface-catalyzed nucleation could then produce different fibril species with little structural 
similarity to the seed fibrils. Here, seeding with more fibrils was not an option because it 
could increase salt concentration over a critical nucleation level. It was however known from 
literature that fibril length can be reduced and homogenized by sonication [159][129][147]. 
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Figure 3-6: Seeding of a salt-free 5 mg mL-1  Oxyntomodulin solution with 0.5 % fibril 
seeds at 37 °C without agitation promotes formation of polymorphic fibrils  
Quiescent incubation of 5 mg mL-1 Oxyntomodulin in water at 37 °C with 0.5 % short seed 
fibrils. A and B, 7 days; C and D, 13 days, 100x diluted; E, gel formed at 11 d, F and G, 
supernatant after 13 d re-incubated for 6 d, 100x dilute. Note the fibril splitting and merging 
seen in C, F and G, as well as the different heights and degrees of twisting. AFM images were 
processed in Gwyddion to remove imaging scars and background signal. Resolution: 512x512 
pixel at scanning size 9x9 µm (A, C); 1024x1024 pixel at scanning size 2x2 µm (B, D, G). 
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Figure 3-7: Seeding of a salt-free 10 mg mL-1  Oxyntomodulin solution with 0.5 % fibril 
seeds at 37 °C without agitation causes conversion to long fibrils within 7 d 
Quiescent incubation of 10 mg mL-1 Oxyntomodulin in water at 37 °C with 0.5 % short seed 
fibrils. A and B, 24 h; C and D, 7 days; E and F, 7 d, 100x dilute; G, gel formed at 7 d. AFM 
images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512x512 pixel at scanning size 9x9 µm (A, C, E); 1024x1024 pixel at scanning 
size 2x2 µm (B, D, F). 
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Fibril fragmentation was tested in a sonication bath. The pellet of an aqueous sample grown 
for 13 d at 10 mg mL-1 in presence of 1 % short fibrils was diluted to 1 mg mL-1 in water and 
sonicated for different times. Fibril length was assessed by AFM. As shown in Figure 4-8 and 
Figure 4-9, initial fibrils were >3 µm long and shortened increasingly during sonication. The 
fibrillar shape was maintained even after 30 min sonication. Fibril length shortened slightly if 
not used instantly due to the dilution in water, however no complete dissolution or reassembly 
was seen over the course of 48 h (results not shown).  
A B 
C D 
F E 
Figure 3-8: Fragmentation of salt-free 0.5 mg mL-1 Oxymtomodulin fibril samples by 
sonication (I) 
A and B, 26 mg mL-1 fibril stock before sonication, 100x dilute. C and D, fibrils after 30 s 
sonication, 10x dilute; E and F, fibrils after 60 s sonication, 10x dilute. AFM images were 
processed in Gwyddion to remove imaging scars and background signal. Resolution: 512x512 
pixel at scanning size 9x9 µm (A, C, E); 1024x1024 pixel at scanning size 2x2 µm (B) and 
4x4 µm (D, F). 
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Sonicated fibrils were then used to seed freshly prepared Oxyntomodulin solutions. 
Elongation of 15 min sonicated fibrils was tested in presence of 0.9 mg mL-1 saline and in 
salt-free conditions. In presence of NaCl, conversion to fibrils was quantitative within 24 h 
from 0.5 to 10 mg mL-1, but only relatively short, clumped fibrils were formed (see Figure 
4-10 A and B). Samples were difficult to handle due to the sticky nature of the gels.  
Seeding aqueous samples with 15 min sonicated fibril samples created clear gels with long, 
predominantly single fibrils within 24 h (see Figure 4-10). Further incubation led to a 
conversion yield of approximately 50 % by day 7 and 65 % by week 8, which did not increase 
A B 
C D 
F E 
Figure 3-9: Fragmentation of salt-free 0.5 mg mL-1 Oxymtomodulin fibril samples by 
sonication (II) 
A and B, fibrils after 2 min sonication. C and D, fibrils after 10 min sonication; E and F, 
fibrils after 30 min sonication. AFM images were processed in Gwyddion to remove imaging 
scars and background signal. Resolution: 512x512 pixel at scanning size 9x9 µm (A, C, E); 
1024x1024 pixel at scanning size (B, D, F). 
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at longer incubation times. Salt-free fibrils could be produced reproducibly and were used for 
biophysical characterization in chapter 4. Fibrillation kinetics were followed in a seeded ThT 
assay without agitation at 1, 5, and 10 mg mL-1 in water (see Figure 4-11). Consistent with 
the theoretical kinetics of exclusive elongation ( 1-9 ), approximately linear signal increase 
was seen6. Linear elongation kinetics and the monomorphic fibril appearance suggest that 
addition of 1 % sonicated fibrils provided enough seeds to prevent secondary nucleation.  
 
 
6 Kinetic ThT assays at more than 1 mg mL-1 peptide concentration could not be performed in 
presence of NaCl, because the fluorescence signal was quenched by gelation.  
A B 
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Figure 3-10: Seeding of a salt-free 10 mg mL-1 Oxyntomodulin solution with 1% 
fragmented fibrils leads to fast formation of long fibrils  
Seeding of 10 mg mL-1 Oxyntomodulin solutions with 1 % seeds fragmented by 15 min 
sonication. A and B, Elongation in 0.9 mg mL-1 NaCl after 48 h, 100x dilute. C and D, 
Elongation in water after 48 h; E and F: Elongation in water after 6 d, 100x dilute. AFM 
images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512x512 pixel at scanning size: 9x9 µm (A, C, E); 1024x1024 pixel at scanning 
size 4x4 µm (B, D, F). 
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Addition of saline to elongated fibrils in water shifted the equilibrium to the fibril side within 
24 h. Individual fibril morphology was maintained, although fibrils showed more lateral 
association after addition of salt. For further biophysical and kinetic studies in chapters 4 and 
5, the fibrillar fraction was concentrated by sedimentation at 13000 rpm, washed in 10-fold 
volume of water, and stored at 10-20 mg mL-1 in the fridge. No alteration in gel or fibril 
morphology was seen within one year. Fibril stocks could be used to seed new, 
morphologically indistinguishable samples by the same process of (1) fragmentation by 
sonication for 15 min at 1 mg mL-1 in water (=seeds), (2) elongation by quiescent one-week 
incubation at 37 °C after seeding a 10 mg mL-1 salt-free Oxyntomodulin sample with 1 % 
sonicated fibrils (=protofibrils), and (3) shifting of the equilibrium by addition of NaCl to 
elongated samples (= mature fibrils). A new fibril generation could be produced by steps (1) 
to (3) within nine days including imaging and measurement of conversion yield. 
For in vivo studies, seeded 10 mg mL-1 aqueous gels were diluted to 0.9 mg mL-1 NaCl and 
1 mg mL-1 total peptide concentration. This formed a viscous fluid as described in [6]. The 
rheological behaviour of the viscous fluid was characterized in a rate sweep test. Prior to 
analysis, a 17 mg mL-1 gel was diluted to 1 mg mL-1 in water or 0.9 mg mL-1 NaCl. The 
viscosity curves are shown in Figure 4-12.   
Figure 3-11: ThT kinetics of Oxyntomodulin seeding with sonicated fibrils in water 
Seeding of 1 mg mL-1 (blue), 5 mg mL-1 (red) or 10 mg mL-1 (green) Oxyntomodulin with 
1 % (w/w) seed fibrils in presence of 50 µM ThT. Seeds were derived from 10 min sonication 
of mature fibrils in water. Images show averages of triplicate data with 10 fluorescence 
readings per hour. No agitation was applied apart from the movement of the microplate under 
the detector.  
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Samples showed shear-thinning behaviour with a linear dependency of logarithmic shear rate 
and viscosity at low shear stress, which is characteristic for a weak gel [160]. It is noteworthy 
that the maximum and minimum viscosity is lower for samples containing salt than for 
formulations in water, which is advantageous for needle injections. Samples could be injected 
subcutaneously with a 27-gauge needle, as advised by Dr Jay Pathak, drug formulation 
specialist at MedImmune, Gaithersburg, USA. 
 
  
Figure 3-12: Oxyntomodulin gel viscosity 
Rate sweep test in a Physica MCR 301 rheometer equipped with a flat plate and a 40 mm 
1° angle cone. Shear stress was measured at 37 °C in response to a shear rate reduction from 
1000 s-1 to 1 s-1 (black) and reverse (red). A 17 mg mL-1 Oxyntomodulin gel was diluted to 
1 mg mL-1 in (A) water and (B) 0.9 mg mL-1 NaCl and measured immediately.  
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4 Structural constraints of Oxyntomodulin fibrils  
As described in chapter 3, Oxyntomodulin readily self-assembles to fibrils in a range of 
conditions. A seed-elongation method was developed to prepare visually homogeneous 
sample gels that contained several µm long fibrils. In elongation conditions without salt 
addition, a protofibrillar type with predominantly single, straight, unbranched fibrils was 
formed. Addition of salt shifted the conversion yield from ~50 % to ~100 %. Fibrils were then 
predominantly clustered to laterally aligned bundles. The aim of this chapter is to:  
(1) test if the protofibrils and fibrils display amyloid-type characteristics 
(2) assess if protofibrils and fibrils are distinguishable at molecular level, and 
(3) identify constraints to the fibril architecture at molecular level. 
4.1 Methods  
4.1.1 ThT and intrinsic Tryptophan fluorescence 
ThT fluorescence was used to probe binding of the amyloid specific dye to soluble 
Oxyntomodulin, mature Oxyntomodulin fibrils, and protofibrils in water. Triplicate 100 μL 
aliquots at 1 mg mL-1 containing 50 μL ThT were scanned in Corning 3880 microplates in a 
F-7000 FL (Hitachi, Japan) plate reader. Top reading mode was used at 440 nm excitation and 
450 to 600 nm emission, at a slid width 5 nm. Results of protofibrils in water were corrected 
for 35 % free peptide in the protofibril sample by scaling of fluorescence yield to 1 mg mL-1 
fibril content. 
Intrinsic tryptophan fluorescence was measured to compare the microenvironment 
hydrophobicity in soluble and fibrillar Oxyntomodulin. The samples and setup were 
analogous to ThT fluorescence measurements on the Hitachi plate reader, however no ThT 
was added. Samples were excited at 277 nm and emission was recorded at 285 to 500 nm at a 
slid width of 2.5 nm and a response time of 2 s. Results of protofibrils in water were corrected 
for free peptide by subtracting the signal of a 0.35 mg mL-1 concentrated soluble peptide 
background signal, and scaling the corrected fluorescence yield to 1 mg mL-1 fibril content. 
This is different to correction in ThT fluorescence measurement because Trp fluorescence is 
present in soluble Oxyntomodulin, while ThT fluorescence in soluble peptide and water are 
indistinguishable.  
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4.1.2 Secondary structure by Attenuated Total Reflection Fourier 
Transform Infrared Spectroscopy 
ATR-FTIR spectra of soluble and fibrillar Oxyntomodulin were recorded on a Frontier FTIR 
spectrometer (PerkinElmer, US) within a wavenumber range from 2000 to 1000 cm-1, with 
1 cm-1 resolution and 8 accumulations per sample. A 2 μL sample of 1 mg mL-1 total peptide 
concentration was deposited on the crystal window and left to dry in air before scanning. A 
background scan in air was deduced from the spectra. Results of protofibrils were corrected 
for free peptide analogous to Trp fluorescence spectra, and all spectra were normalized to the 
amide II signal at 1550 cm-1. 
4.1.3 Secondary structure by Circular Dichroism 
Far-UV CD spectra were recorded from 260 to 180 nm on a Jasco J-815 spectropolarimeter 
(Jasco, US), with a scanning resolution of 1 nm, 20 nm s-1 scan speed, and automatic 
averaging of 4 scans per sample. (+)-10-camphorsulfonic acid was used as a standard to 
calibrate the instrument according to manufacturer’s instructions. Fibril- and soluble peptide 
spectra were recorded at 1 mg mL-1 total peptide concentration in a quartz cuvette with 
0.1 mm path length7 (Starna, UK) at 25 °C with 10 min thermal equilibration before 
measurement. Measurements were independently repeated three times. The solvent signal was 
deduced from measured spectra, and corrected spectra were deconvoluted with the online tool 
DichroWeb (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) to estimate the percentage 
contributions of helices, sheets and turns to the overall spectrum. The best fits compared to 
molecular library set 6 are computed with the algorithms CONTIN-LL, SELCON3 and 
CDSSTR [161][162]. Prior to analysis in DichroWeb, results of protofibrils were corrected 
for 35 % free peptide in the measured sample analogous to spectrum correction in Trp 
fluorescence. Algorithm fits are averaged for each triplicate measurement, and results are 
expressed as averages ± standard deviations of triplicates. 
4.1.4 Identification of amyloid core structure by limited peptidolysis  
Soluble peptide and fibrils were digested with trypsin at 37 °C and pH 8 (NaOH in water) or 
in PBS pH 7.35. Trypsin (mass spectrometry grade, Sigma Alrich) was reconstituted from 
freeze-dried aliquots according to manufacturer’s instructions, and used at 5 % (w/w) with 
0.5 mg mL-1 peptide or fibrils. Aliquots were separated by HPLC in a 1260 Infinity II system 
with a ZORBAX 300SB-C18 analytical column (Agilent Technologies, UK), bead size 5 µm, 
 
7 CD is sensitive to the combination of concentration and pathlength, and deconvolution algorithms only accept a 
certain range of absolute absorbance (Calero and Gassett, 2005). Oxyntomodulin samples were also tested at 
0.5 mg mL-1 and in 0.01 and 10 mm cuvettes, however the combination of 1 mg mL-1 and 0.1 mm path length 
gave the most reproducible and evaluable data.  
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250 mm. Samples were eluted at 1 mL min-1 flow rate in a linear gradient from 100 % solvent 
A (94.9 % water, 5 % Acetonitrile, 0.1 % trifluoric acid) to 80 % solvent B (94.9 % 
Acetonitrile, 5 % water, 0.1 % trifluoric acid) over 30 min, followed by a 5 min rinsing step at 
100 % B. Elution was detected at 214 and 280 nm. The system was cleaned with 100 % 
acetonitrile for 20 min and stored in solvent B. Samples were centrifuged at 13000 rpm for 
30 min prior to injection to avoid clogging of the column with particles. Self-digestion of 
Trypsin was tested in the same conditions.  
4.1.5 X-ray fiber diffraction 
X-ray diffraction patterns were recorded on a Bruker D8 Quest X-ray diffractometer. Sample 
preparation was done according to [116]. Briefly, a drop of 10 mg mL-1 fibril sample was 
placed between two wax-sealed capillaries. After drying overnight, a stretched, partly aligned 
fibril thread formed. The fibril thread was aligned in the beam path and exposed for 120 s. 
4.1.6 Fibril imaging by Cryo Electron Microscopy 
Sample preparation and image capture were a service of FEI at the Nanoscience Centre, 
University of Cambridge. Samples were blotted and flash frozen in liquid ethane using a 
Vitrobot MKV and quantifoil R1.2/1.3 300 mesh grids, made hydrophilic by glow discharge 
at 0.39 mbar for 60 s at 25 mA. The Vitrobot was operated at 4 °C, 100 % relative humidity, 
25 s blot time, and 2 μL sample application volume at 1 mg mL-1 total peptide concentration 
in the sample. Blot force was calibrated to create a wedge of thick ice on roughly one third of 
the grid, with a gradient of ice thickness on the other two thirds of the grid, corresponding to a 
setting of -6 on the instrument. Vitrifies samples were stored in liquid nitrogen. Images were 
acquired on a Titan KriosTM (FEI, ThermoScientificTM) run at 300 kV. Mature fibrils were 
detected with an Atlas 2 electron detection camera. Images of protofibrils and the twisted 
fibril species in chapter 6 were recorded as movies with a Falcon 3 direct electron detector, 
followed computational image reconstruction in MotionCore from acquired movies, to correct 
for drift caused by beam-induced motion. Vitrified samples were stored in liquid Nitrogen. 
Files were obtained in .mrc format and had a resolution of 1.07 pixels per Å. Images were 
processed with the automatic brightness and contrast tool in Fiji (ImageJ) and exported in 
.jpeg format. Polygon selections were transformed with the FFT (fast Fourier transform) tool 
to display the diffraction pattern of single fibrils. The line selection tool was used to measure 
lateral dimensions and plot profiles as a function of grey values.  
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4.2 Oxyntomodulin fibrils display amyloid-specific fluorescence 
As reviewed in chapter 1.2.2, ThT is a marker for cross-beta alignment, while Tryptophan 
fluorescence is a measure for the hydrophobicity of the microenvironment of a Tryptophan 
residue. ThT and intrinsic Tryptophan fluorescence were measured in free peptide, 
protofibrils and fibrils. Fluorescence emission curves are shown in Figure 5-1.  
Freshly dissolved peptide does not bind ThT, consistent with the random- and α-helical 
conformation of soluble Oxyntomodulin reported in the literature [48]. Protofibrils show very 
weak ThT binding, confirming the low ThT binding in screening (Figure 9-13) and aqueous 
seed elongation (Figure 4-11). ThT fluorescence was more than 10-fold higher in samples 
that contained 0.9 mg mL-1 NaCl at the same fibril concentration.  
Different levels of ThT binding are not per se an evidence for a difference in amyloid 
structure. Weak ThT binding can imply a less structured fibril architecture, e.g. the presence 
of an amyloid core that is partially shielded by unstructured sequences. However, it is well 
known that ThT has lower affinity to thinner structures on or off the pathway to mature fibril 
formation, and markedly decreased affinity to positively charged surfaces because of the dye 
molecule’s positive charge [123][124].  
  
Figure 4-1: ThT and Tryptophan fluorescence of soluble, protofibrillar and fibrillar 
Oxyntomodulin 
Left, ThT fluorescence curves of soluble (transparent), protofibrillar (grey) and fibrillar (black) 
Oxyntomodulin samples, measured by excitation at 440 nm and emission at 450 to 600 nm. 
Right, fluorescence of the Tryptophan residue at amino acid position 25 in soluble 
(transparent), protofibrillar (grey) and fibrillar (black) Oxyntomodulin samples, measured by 
excitation at 277 nm and emission from 285 to 500 nm at a slid width of 2.5 nm. Both 
fluorescence curve types are formed with the same samples at room temperature on a Hitachi 
F-7000 FL fluorescence plate reader. Results of triplicate averages ± standard deviation are 
shown at a slid width 5 nm (ThT) and 2.5 nm (Trp).  
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Both protofibrillar and fibrillar Oxyntomodulin samples exhibited a blue-shifted emission 
peak of intrinsic Tryptophan fluorescence, compared to soluble peptide. This proves that the 
Tryptophan residue at amino acid position 25 in the Oxyntomodulin sequence is incorporated 
in a more hydrophobic environment inside fibrillar structures, as seen for the core structures 
of amyloid-like proteins [125]. The more marked blue shift in mature fibrils compared to 
protofibrils may imply a denser or more structured local packing, possibly facilitated by 
masking of surface charges in presence of electrolytes. Independent of fibril core structures, 
the lateral assembly of fibrils in salt-containing environments is also expected to shield 
residues from the solvent. It is not possible to distinguish the contributions of either effect in 
this experiment.  
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4.3 Insights into secondary structure of Oxyntomodulin fibrils 
The secondary structure of soluble, protofibrillar and fibrillar Oxyntomodulin was assessed by 
ATR-FTIR and CD. FTIR and CD are orthogonal spectroscopic methods that can be used to 
measure helical, sheet, and turn conformations. While CD is traditionally used for soluble 
proteins [163], FTIR has been extensively used for investigations of self-assembled structures 
[164][165][127][126][166][167]. The methods are complimentary in that FTIR can 
distinguish between parallel and antiparallel β-sheet alignment, and CD can distinguish 
between 310 and α-helix [126][127][48]. CD signals are easier to quantify, allowing an 
estimation of secondary structure contents in a structure.  
Infrared spectroscopy measures the interaction of infrared radiation with a sample. In FTIR, 
the wavenumber8 shifts measured by an interferometer are reverse-transformed to an 
absorption spectrum. Generally, absorption occurs when the frequencies of radiation and 
vibration of a polar bond are equal, and when vibration causes a change in dipole moment. 
The magnitude and exact wavelength of absorption depend on the polarity of vibrating bonds 
and can thus be influenced by neighbouring groups [166]. In Attenuated Total Reflection 
(ATR) spectroscopy, infrared light propagates by total reflection inside a crystal before 
detection. Light reflection at the sides of the crystal creates evanescent waves that protrude 
into the surrounding medium. Deposition of a sample on one side of the crystal absorbs the 
radiation of evanescent waves, so that the detected intensity is dampened. Because the 
intensity of the evanescent wave decays exponentially with distance from the crystal surface, 
the measurement of very thin films such as dried proteinaceous samples is possible, and IR 
absorption by water is avoided [168]. IR absorption in proteins and peptides can occur at all 
polar bonds including backbone and side-chain bonds. The amide I band (1700-1600 cm-1) 
has the strongest absorption of infrared light, little contributions of side-chain interactions, 
and sensitivity to hydrogen bonding pattern in the molecule or supramolecular arrangements. 
Amide I absorption is mainly caused by C=O stretching vibrations with minor contributions 
from C-N stretching and N-H bending vibrations [168][169]. In a hydrogen-bonded secondary 
structure, coupling of transition dipoles causes interference of vibration modes. The 
superposition of local modes in a secondary structure is termed normal mode [127].  
Native β-sheets absorb between 1623 and 1643 cm-1 with a possible weaker band from 1689 
to 1693 cm-1; α-helices between 1662 and 1645 cm-1 with a typical maximum between 1654 
and 1658 cm-1; 310 helices between 1660 and 1666; β-turns between 1666 and 1687 cm-1, and 
random alignment between 1646 and 1650 [169]. Because of the alternating alignment in 
antiparallel β-sheets, the direction of local and normal modes has a larger contribution 
rectangular to the sheet plane than in parallel alignment [127]. Native antiparallel β-sheets 
 
8 By IUPAC guidelines, IR absorption spectra are plotted as a function of decreasing wavenumber. Wavenumber 
is the inverse of wavelength and expressed in cm-1. 
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thus show a strong band near 1630 cm-1 corresponding to the modes in sheet direction, and an 
additional weaker band near 1685 cm-1 corresponding to C=O stretches in strand direction 
[166]. In parallel sheets, C=O stretches from local and normal modes align. Due to coupling 
of transition dipoles, the main absorption peak of parallel β-sheets is slightly blue-shifted 
(higher wave number) compared to antiparallel β-sheets of the same dimensions, with less or 
absent contribution of a second band at higher wavenumbers [126][127][166]. Because of 
overlapping bands, band broadening due to sample inhomogeneities, and shifted peaks due to 
twisting of extended secondary structures, band assignment is not always inambiguous [166].  
In ext ended β-sheets such as in the cross-β alignment of amyloid fibrils, local and normal 
modes interfere constructively, generally leading to red-shifted β-sheet absorption bands 
compared to native proteins. Typically, amyloid fibrils show the highest absorption band 
between 1615 and 1630 cm-1, corresponding to orchestrated β-sheet absorption [164][126]. 
The extent of red-shift is a measure for the size and rigidity of amyloid structures. Large, 
well-ordered amyloid structures absorb near 1620 cm-1, and smaller, less ordered fibrils 
absorb near 1630 cm-1 [127]. Further parallel sheet absorption bands can be seen between 
1660 and 1670 cm-1 [126].  Parallel and antiparallel sheet alignment can thus not be 
distinguished by the wavenumber of the main absorption band. Antiparallel β-sheets in 
amyloid fibrils create a high frequency band around 1685 cm-1, however similar bands may 
stem from twisted parallel β-sheets. Therefore, the presence of a strong absorption band 
between 1615 and 1630 cm-1 in absence of a high wavenumber FTIR band is a strong 
indicator for parallel β-sheet, but the presence of an absorption band around 1685 cm-1 is only 
an indicator for antiparallel alignment [164][126][127][166]. FTIR cannot distinguish β-
arches and β-turns in amyloid configuration [127].  
Soluble Oxyntomodulin showed a single maximum at 1654 cm-1, corresponding to a 
predominantly α-helical conformation in solution. A slightly broadened shoulder at higher 
wavelength and at 1645 cm-1 indicates presence of unstructured arrangements. This is in 
agreement with reported structural characteristics of native Oxyntomodulin [48]. 
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Oxyntomodulin protofibrils and mature fibrils show remarkably similar absorption spectra. 
Absorption in mature fibrils is generally weaker, however this may be due to steric shielding 
from radiation by partially aligned fibrils. The absorption bands overlap within experimental 
error. The main absorption band is a sharp peak centred around 1624 cm-1, indicating a well-
ordered β-sheet. A further β-sheet absorption band is seen at 1640 cm-1. A broad peak 
between 1660 and 1670 additionally indicates parallel β-sheet, but may also contain 
contributions from residual α-helix conformation. Absorption beyond 1675 cm-1 is lower than 
for soluble Oxyntomodulin and lacks a peak. Therefore, FTIR strongly indicates that the 
architecture of Oxyntomodulin protofibrils and fibrils is a well-ordered, parallel β-sheet. 
Although weak, the shoulder at 1667 cm-1 suggests a turn within the molecule. A folded arch- 
or turn-conformation would be in accordance with the 6 nm diameter of protofibrils, which is 
about half the stretched length of a 37 amino acid peptide.  
Because of the ambiguous band assignment in FTIR, Oxyntomodulin structures were 
additionally measured by Far-UV CD. CD measures the difference between a sample’s 
absorption of right- and left-circularly polarized light as a function of wavelength. 
Contributions from helices, sheets and turns can be quantified by computational fitting to a 
library of structures with known secondary structure [162][170]. CD deconvolution 
algorithms cannot distinguish between different types of helices, sheets and turns. As the 
existing libraries are predominantly composed of (crystal) structures of globular proteins, the 
quantification of secondary structure composition in self-assembled peptides is only to be 
Figure 4-2: ATR-FTIR spectrum of soluble and fibrillar Oxyntomodulin 
1 mg mL-1 samples dried on ATR crystal before measurement. Spectra are normalized to the 
signal at 1650 cm-1. Open circles: soluble Oxyntomodulin; black circles: fibrils; grey circles: 
protofibrils, spectrum corrected for 35 % soluble peptide. 
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taken as an estimate [163]. The ratio of molecular ellipticity at 222 and 208 nm is a measure 
for the ra tio of α-helix and 310 helix [48]. 
Soluble Oxyntomodulin has a predominantly helical CD spectrum. The transient nature of 
helical peptide structure in solution is reflected by contributions from unordered structures. 
Presence of a turn and a differential negative absorption at 222 and 208 nm implies the 
presence of a 310 helix in addition to an α helix. Values are in accordance with published data 
on Oxyntomodulin, within experimental error [48].  
Figure 4-3: Secondary structure contributions in soluble and fibrillar Oxyntomodulin 
by Far-UV CD 
Top: background-corrected CD spectra of 1 mg mL-1 Oxyntomodulin samples in wavelength 
range 240-185 nm. Open circles, soluble Oxyntomodulin; grey, protofibrils without 
correction for soluble peptide; black, fibrils. Shown is average of 3 independent 
measurements with 4 averaged runs each, ± standard deviation (n=3). Bottom: data 
deconvoluted with the online tool Dichroweb using the algorithms CONTIN-LL, SELCON 3 
and CDSSTR for each sample. Shown are averages of 3 independent sample runs ± standard 
deviation. Transparent, dotted: helix; grey, striped: sheet; dark grey, solid: turns.  
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Fibrils and protofibrils do not contain helices at considerable amounts. Rather, the spectra 
suggest a predominant sheet structure with turn conformations. Protofibrils show a more 
ordered structure than fibrils, however this may be a result of light scattering at higher order 
fibril structures seen in salt-containing conditions. Generally, the results correspond to 
secondary structure elements derived from ATR-FTIR spectra. 
From FTIR and CD, it is not clear if the whole Oxyntomodulin molecule is incorporated into 
the amyloid core. Spectroscopic measurements cannot distinguish if spectral contributions 
implying unstructured sequences stem from less defined regions in turns, or from entirely 
unstructured parts of the molecule. Unlike the fibril core structure, unstructured regions are 
prone to enzymatic degradation [171][172][173][174]. Trypsin is a widely used peptidolytic 
enzyme which cleaves after Lysin, Arginine and Cysteine. Trypsin is active in neutral to 
weakly basic environment, with optimal activity at pH 8. Oxyntomodulin has 6 tryptic 
cleavage positions; after K12, R17, R18, K30, R31 and R33 (see Figure 2-2).  
Tryptic digestion of soluble and fibrillar Oxyntomodulin was performed at 37 °C in an 
unbuffered environment at pH 8 (NaOH), and in PBS pH 7.35. Digestion was followed by 
HPLC separation after 1 and 24 h. Trypsin was prone to self-digestion, so that further 
incubation was not conclusive. After 1 h, the monomer peak of soluble Oxyntomodulin at 
16.0 min had nearly disappeared, while only small peaks could be seen for fibrillar 
Oxyntomodulin (not shown). After 24 h, five main peaks were detected at 16.9, 9.0, 7.8, 16.5, 
and 6.3 minutes retention time, in decreasing order of absorption at 214 nm. Additional 
smaller peaks between 4 and 17 min indicate partial cleavage due to the proximity of cleavage 
positions 30, 31 and 33 (see Figure 4-4). Fibril digestion produces the same peaks after 24 h. 
Overall quantities are approximately 60 % lower due to centrifugation of residual fibrils 
before sample injection. Similar results were found at pH 8 in absence of phosphate.  
The absence of preferentially cleaved sequences in presence of peaks corresponding to 
complete Oxyntomodulin digestion indicates that fibrils are not directly digested, but that 
soluble peptide in equilibrium is enzymatically cleaved. Peptidolysis effectively removes 
soluble peptide from the polymerization equilibrium, analogous to peptide removal in a 
stream of peptide-deprived liquid. This is indirect proof that an equilibrium of soluble and 
fibrillar Oxyntomodulin exists even in salt-containing conditions like PBS. Although 
peptidolysis did not prove unstructured regions within Oxyntomodulin fibrils, short 
unstructured elements are possible, because Trypsin requires several accessible amino acids 
for cleaving.  
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Figure 4-4: Tryptic digestion of soluble and fibrillar Oxyntomodulin 
HPLC chromatograms of 0.5 mg mL-1 Oxyntomodulin (top) and mature Oxyntomodulin 
fibrils (bottom) after 24 h of incubation with trypsin in PBS pH 7.35 at 37 °C. Samples were 
centrifuged before analysis to remove eventual particles. Solvent front, 3-4 min. Native 
Oxyntomodulin eluted at 16.0 min.  
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4.4 Insights into tertiary structure of Oxyntomodulin fibrils 
X-ray diffraction is traditionally used to reveal the cross-beta diffraction pattern of amyloid 
fibrils. Aligned fibrils show a strong 4.7-4.8 Å diffraction pattern on the meridian, which 
corresponds to the inter-strand spacing along the fibril axis. A weaker equatorial reflection at 
8-12 Å measures the distance between opposing sheets, which is dependent on the size of side 
chains, their ability to interdigitate, and the presence or absence of water molecules between 
the sheets [116][71].   
X-ray diffraction of Oxyntomodulin fibrils revealed weak reflections at approximately 4.7 and 
8.6 Å. The 4.7 Å reflection overlaid with the strong background signal of wax diffraction, so 
that a clear indication for cross-beta architecture could not be derived from X-ray diffraction. 
The presence of an 8.6 Å diffraction is interesting from a structural perspective, because the 
indicated inter-sheet spacing is smaller than for most reported amyloid structures. Such close 
interaction requires a dry interface with side-chain interdigitation. The same spacing has been 
reported for amyloid-like structures of TDP-43, which have a β-hairpin architecture [96]. X-
ray diffraction thus provides further indication for a folded conformation of Oxyntomodulin 
within fibrils. A turn conformation with the whole hairpin in one sheet (as in TDP-43) 
requires antiparallel sheet alignment, which contradicts the parallel FTIR spectrogram. An 
arch conformation where the peptide spans two sheets allows close packing of opposing 
sheets while providing parallel strand alignment.  
8.6 Å 
4.7 Å 
Figure 4-5: X-Ray diffraction indicates a dry interface in Oxyntomodulin fibrils 
X-Ray fibre diffraction of aligned Oxyntomodulin fibrils, measured on a Bruker D8 Quest X-
ray diffractometer. Weak reflections can be seen at 4.7 and 8.6 Å, indicating inter-strand and 
inter-sheet distance, respectively. 
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Cryo transmission electron microscopy was performed to consolidate and complement results 
from AFM, FTIR, CD and X-ray diffraction. Transmission electron microscopy produces 2D 
projections of the electron density of objects, allowing a theoretical resolution in the range of 
the electron beam’s wavelength.  In Cryo EM, surrounding vitreous ice protects the structures 
from radiation damage without the necessity of negative staining. Flash freezing furthermore 
captures the hydrated state, allowing imaging in the 3D conformation adopted in solution 
[175]. This is a marked difference to AFM, where samples are dried on a substrate before 
imaging. TEM does not directly measure height but can provide limited depth perception via 
the electron density of a structure [86][176]. In addition to lateral dimensions and electron 
density, diffraction information is accessible by reverse Fourier transformation of digitized 
electron micrographs or selected features [99][87].  
Cryo electron micrographs were taken of the same mature Oxyntomodulin fibril batch as used 
for in vivo experiments in [6]. The fibrils were several micrometres long and contained 
approximately parallel aligned ~6-7 nm wide, smooth substructures, which also appeared as 
single fibrils (see yellow arrows in Figure 5-6). The diameter and appearance of these 
substructures is indistinguishable of protofibril AFM images, including the uncurled 
appearance and long-distance bending. The electron dense outer walls and electron lucent 
centre of such fibrillar subspecies suggests a tubular architecture similar to Cryo electron 
micrographs of Aβ(11-25) peptide fibrils [99]. Fibril alignment occurred predominantly in a 
side-by-side way, resulting in ribbons of aligned fibrils that sometimes showed a long-
distance helical twist around a common axis. Less ordered three-dimensional bundles were 
also present. Assembled fibrils had overhanging single fibril ends and seemingly random 
numbers of substructures, suggesting that the alignment to superstructures is of physical (e.g. 
electrostatic) nature and not directly correlated to the elongation process.  
In summary, the fibril images further solidify the assumption that mature fibrils are 
superstructures consisting of laterally aligned protofilaments. To test this hypothesis, Cryo 
EM images were taken from protofibrils. Representative examples are shown in Figure 5-7. 
Protofibrils appeared as predominantly single, unbranched, several µm long and ~6-7 nm 
wide structures. Some protofibrils aligned to higher order fibrils, analogous to the fibril 
structures discussed above. The dimensions of protofibrils and fibril substructures were 
indistinguishable by Cryo EM images.  
At the time of protofibril imaging, an improved detection method was available which 
overlaid images taken from a movie to reduce blurring caused by minimal thermal drifts and 
vibrations during imaging. Thus, more structural information could be derived from 
protofibril images. Closer inspection of the electron density of protofibrils revealed that there 
are not always two striations lining the fibril, but often there are three electron dense areas 
intersected by two electron lucent areas.  
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Figure 4-6: Cryo EM indicates that fibrils are assemblies of protofibrils 
Cryo EM images of the mature Oxyntomodulin fibril batch used for in vivo studies. Fibrils 
were imaged on a Titan KriosTM G3i in transmission mode without motion correction. Whole 
images were corrected for brightness and contrast in Fiji. Scale bars, 500 Å. Yellow arrows 
show singled fibrillar structures with approximately 60 Å diameter that are indistinguishable 
from protofibril images in Figure 4-7. 
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If there are three striations, the fibril is ~70 Å wide instead of ~60 Å for the cross-sections 
with two stripes. In some images, a change of pattern and width was seen over the length of a 
fibril, suggesting that both observations are different projections of the same structure. An 
approximately triangular cross-section with arch-like folded peptides spanning the sides of the 
triangle is consistent with the features seen. If one side of the triangle is perpendicular to the 
image plane, the electron beam only passes through two electron dense areas, and the 
diameter corresponds to the altitude of a regular triangle (
1
2
√3 ∗ 70 Å = 60.6 Å). If the fibril 
is oriented in other angles, the theoretical electron density has three parallel maxima lines, and 
a width between altitude and side is seen. A cartoon representation is shown in Figure 5-10. 
Figure 4-7: Cryo-EM of protofibrils suggests triangular cross-section 
Cryo TEM images of the Oxyntomodulin protofibrils formed in salt-free conditions. 
Protofibrils were imaged on a Titan KriosTM G3i with a Falcon 3 detector with motion 
correction. Whole images were corrected for brightness and contrast in Fiji. Scale bars, 
500 Å. Only few fibrils are associated to bundles (red arrows) Examples for single fibrils are 
highlighted with blue and yellow arrows. Positions marked yellow have a 60 Å diameter and 
two areas of high electron density along the fibril axis. Blue arrows show examples where the 
same fibril converts to 70 Å with three areas of high electron density along the fibril axis.  
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Fast Fourier transforms of single fibril selections revealed a characteristic 4.7 Å diffraction 
pattern perpendicular to the fibril axis. This is consistent with the theoretical spacing of β-
pleated sheets. Remarkably, parallel striations with 4.7 Å spacing were directly visible in 
magnifications of single protofibrils in high resolution images (see Figure 5-8). The pattern 
could be detected over more than 0.1 µm long distances with no visible change in spacing or 
angle of the striations to the long axis, even if the fibril was bent. Stromer and Serpell argue 
that direct observation of a fibril’s β-sheet structure is suggestive of the presence of several β-
strands perfectly in register. Reinforcement of electron interactions by several peptide layers 
produces a high enough signal to make the fibril structure visible [86].  
Figure 4-8: Direct observation of the 4.7 A diffraction pattern by Cryo EM 
Cryo TEM images of the Oxyntomodulin protofibrils formed in salt-free conditions. 
Protofibrils were imaged on a Titan KriosTM G3i with a Falcon 3 detector with motion 
correction. Whole images were corrected for brightness and contrast in Fiji. Scale bars, 
100 Å. Striations approximately perpendicular to the fibril axis can be directly seen in images 
of single fibrils (A, B) or bundled fibrils (C, D). E-H, fast Fourier transforms of images A-D, 
respectively. Maximum reflections are at 4.6-4.7 Å. 
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In this work, not all fibrils had a characteristic 4.7 Å diffraction pattern and/or directly visible 
peptide layers. High and low resolution seemed clustered within images rather than within 
different fibrils. It is assumed that the fibril axis needs to be perfectly perpendicular to the 
incident angle of the X-ray beam so that aligned strands can produce a reinforced image. If 
the fibril is for example not level within the sample holder because of a locally imperfect ice 
layer, the image will blur and conceal the pattern. The grey value intensity along a fibril can 
reveal the regularity of the pattern, even if striations are not visible by eye (see Figure 5-9). 
Cross-β alignment is therefore present even if the alignment is not regular enough to directly 
visualize strands. By measurement of 60 individual fibrils with visible β-sheet pattern, it was 
found that the angle of striations is not perfectly perpendicular to the fibril axis, but 5-10 ° 
offset (results not shown). Analogous patterns were found in laterally assembled and twisting 
protofibrils. This implies an offset in strand alignment along the fibril such as illustrated in 
Figure 2-4 E. A possible explanation for sheet offset is the salt bridge formation between 
oppositely charged residues.  
Figure 4-9: Visualization of the cross-β strand spacing in Cryo EM images 
Cryo TEM images of the Oxyntomodulin protofibrils formed in salt-free conditions. 
Protofibrils were imaged on a Titan KriosTM G3i with a Falcon 3 detector with motion 
correction. Whole images were corrected for brightness and contrast in Fiji. Scale bars, 50 Å. 
Left, grey value plot of a line along the fibrils shown in the middle. Right, fast Fourier 
transform diffraction pattern. Top: grey value plot shows 4.7 Å cross-beta spacing even 
though no striations or 4.7 Å diffraction pattern is seen. Bottom: positive control with a 
diffracting fibril and sufficient alignment for direct visualization of strand spacing.   
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The existence of a regular 4.7 Å diffraction (and image-) pattern rules out the possibility of a 
β-turn configuration with both strands in the same sheet. Such a structure would show 
differences in the spacings along the fibril, with every other spacing > 4.7 Å. Furthermore, a 
ladder-like offset of opposing stands with side chain stacking over each other (such as in 
Figure 2-4 F) instead of between each other can be excluded, because this would create an 
additional regular diffraction pattern at < 4.7 Å. Moreover, direct visualization of peptide 
strands in amyloid fibrils is suggestive of several layers of perfectly aligned peptide 
backbones [99]. This implies that strands in a cross-section of Oxyntomodulin protofibrils are 
in-register and not, for example, spanning a continuous β-helix.  
Combining results shown in this chapter, a possible protofibril cross-section could have three 
arch-shaped monomers spanning a regular triangle with a hollow core. Sheets are arranged in 
a prism-like configuration, where the triangle motifs spanning the prism are slightly tilted 
from the axis. Each peptide may have a few amino acids that are not included in the arch 
conformation at either terminus. This structure is known from one fibrillar type of Aβ1-40 
[100]. A model for a possible coarse-grain 3D structure and its dimensions is shown in Figure 
5-10. The following structural constraints are considered: 
• From AFM, Cryo EM, FTIR and CD: Fibrils contain one or several protofibrils, 
therefore the molecular arrangement within a fibril is supposedly equivalent to the 
protofibril structure. 
• From AFM and Cryo EM: Protofibrils and the fibril substructures are approximately 
half as wide as the stretched Oxyntomodulin sequence. 
• From FTIR and CD spectroscopy: (Proto)fibrils have a high proportion of β-sheet, 
almost no α-helical content, and a turn element. 
• From FTIR: (Proto)fibril peptide strands within one sheet are parallel. 
• From enzymatic degradation: Fibrils do not entail cleavable unstructured regions, 
therefore none or only few amino acids can be excluded from the fibril core. 
• From ThT binding, X-Ray diffraction, Cryo-EM: Oxyntomodulin forms amyloid-like 
cross-β fibrils with a 4.6-4.7 Å diffraction pattern.  
• From Cryo-EM: Electron density in protofibrils and fibrillar substructures suggests a 
hollow core. Protofibrils show two or three lines of electron density maxima along the 
fibril axis with cross-sectional diameters corresponding to the side length and altitude 
of a regular triangle. Visibility of the regular 4.6-4.7 Å in magnified image sections 
excludes β-turn arrangement of a peptide within one sheet, as well as an offset 
alignment and/or a continuous β-helix. To accommodate the turn, one peptide must 
span two sheets in a β-arch conformation. The β-strands on either side of the turn need 
to be in the plane of electron beam incidence. β-strands in one sheet are 5-10 ° offset 
to the fibril axis.  
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Figure 4-10: Tentative 3D structure of Oxyntomodulin protofibrils 
Low-resolution 3D structure of an Oxyntomodulin protofibril and its structural motifs, with 
structural constraints gathered from Cryo-EM, AFM, FTIR, CD, enzymatic degradation and 
X-Ray diffraction. C, cartoon representation of the triangular motif that is consistent with 
structural constraints of a protofibril’s cross-section. β-sheets (arrows) are shown outwards 
twisted for illustration purposes. Dimensions of β-sheets, turns and unstructured regions are 
arbitrary. Monomers adopt a β-arch conformation that contributes β-strands to two opposing 
sheets, with possible small unstructured regions (drawn at the outside termini). Three 
monomers span a double-walled triangle. B, D: cartoon representations of an upwards (B) or 
sideways (D) projection of (C), with respective expected electron density sketched in (A) and 
(E). (F), magnification of a fibril part showing a cross-sectional electron density according to 
(A) in the top half and (B) in the bottom half. Scale bar, 100 Å. G, H: magnified sketch of 
theoretical electron density along a fibril with characteristic lengths. Striations offset is drawn 
at 7 ° from perpendicular to the fibril axis. I: cartoon representation of strand alignment, seen 
along the fibril. Long-distance twist is drawn as an arbitrary 1 ° offset of triangular subunits 
respective to each other. Blue arrows, outer sheets; orange arrows, inner sheets; blue lines, 
turns and possible unstructured regions. 
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The structural constraints discussed in this chapter cannot describe which amino acids are 
contained in either of the β-sheets, how long the sheets are exactly, how the turn is formed or 
if and where there is a possible unstructured region. It is furthermore unknown which parts of 
adjacent peptides in a triagonal substructure interact with each other. Because the fibrils are 
smooth and do not have a regular twist, an atomic-resolution structure cannot be derived from 
single-particle analysis of Cryo EM images. From the presented results, there is no indication 
for a differential composition of protofibrils and fibrillar substructures, and the only 
difference is the rather single or bundled appearance. However, it cannot entirely be excluded 
that fibril elongation in water or salt-containing conditions leads to locally changed 
morphology, e.g. the composition of a turn or the frequency of imperfectly aligned peptides.  
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5 Kinetics and thermodynamics of Oxyntomodulin fibrils  
5.1 Methods 
All fibril stocks used in the experiments of this chapter were 10 mg mL-1 fibril dispersion with 
no measurable soluble peptide, derived from a 3-step seeding method as described at the end 
of chapter 3.4. Two stocks were used for all experiments in this chapter. The stocks were 
indistinguishable by AFM and showed no difference in elongation kinetics by QCM-D (data 
not shown). All experimental data shown together are derived from one fibril stock. Peptide 
solutions were prepared according to 3.2.1, and free peptide was measured analogous to 3.2.5. 
AFM imaging was performed as in 3.2.4, and kinetic ThT assays without shaking were 
measured as described in 3.2.2.  
5.1.1 Oxyntomodulin fibril elongation and dissociation studies in 
bulk 
Peptide release from fibrils was measured after incubation of diluted aliquots of a mature 
fibril stock. As discussed in [6], the equilibrium of soluble Oxyntomodulin and fibrils in salt-
containing conditions is so far on the fibril side that no peptide is measurable within the 
detection limit of common spectroscopic measurements. Here, essentially salt-free conditions 
were used to qualitatively assess the release kinetic of the system. The fibril stock was diluted 
to 0.5 mg mL-1 in water incubated in 0.5 mL Eppendorf® vials sealed with Parafilm. Every 
sample was mixed by inversion once daily to overcome possible limitations by sedimentation 
or steric inhibition. Triplicate vials were measured for each condition and time point. No 
sample was measured more than once. Morphology and apparent shortening were followed by 
AFM imaging at each time point and condition. Soluble peptide concentrations were 
measured in the fibril supernatant after centrifugation and 50 kDa MWCO filtration, and fibril 
concentrations in the pellet were measured after acidic dissolution as a control. Tested release 
conditions comprised:  
• Initial fibril concentrations 0.5 mg mL-1 incubated at 37 °C for 1; 4; 24; 48 h 
• Initial fibril concentration 0.5 mg mL-1 incubated at 6 °C, 25 °C, 32 °C, 37 °C, 42 °C 
for 1, 4, 7 and 14 days, respectively 
The incubation temperatures were selected for mimicking typical storage conditions in fridge 
(6 °C) and at room temperature (25 °C), as well as limits for physiological temperature 
(subcutaneous temperature 32 °C, body temperature 37 °C, high fever 42 °C).  
A similar method was used for quantifying elongation at different temperatures: freshly 
prepared 0.5 mg mL-1 Oxyntomodulin solutions in 0.9 mg mL-1 saline were seeded with fibril 
fragments derived from bath-sonicating an aliquot of a mature fibril stock for 15 min. Seeded 
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triplicate Oxyntomodulin solutions were incubated in 0.5 mL Eppendorf® vials sealed with 
Parafilm, at the temperatures mentioned above. Elongation was followed by AFM imaging at 
each time point and temperature. Measurement of free peptide was performed analogously to 
peptide release experiments. As a control, fibril concentration was additionally assessed by 
acidic dissolution of pellets. 
Reversible stabilization by salts was tested by partially dissolving a 0.5 mg mL-1 fibril sample 
in water for 1 d, splitting the homogenized dispersion into 0.5 mL Eppendorf® vials, and 
adding 14.4 mM (the equivalent of 0.9 mg mL-1 NaCl) NaCl, LiCl, CsCl, or CsI. Soluble 
peptide concentration was measured before salt addition, and after 7 d with or without 
addition of salts.  
5.1.2 Quasi-real-time elongation and dissolution by Quartz Crystal 
Microbalance  
QCM-D experiments were performed on a QSense E4 Analyzer (Biolin Scientific) equipped 
with a High Precision Multichannel Dispenser (Ismatec). The instrument allowed 
simultaneous or sequential measurement of up to 4 sensors. Sensors used in this work 
(QSX303, Biolin Scientific) had an active sensing area of 1 cm2, silicone dioxide (SiO2) 
coating, and a surface shape that allowed equal flow over all parts of the active surface. The 
method described here was used for all QCM-D experiments in chapter 5.3, 5.4, 5.5 and 
chapter 7. Chapter 5.1.1 shows the method development, control experiments and 
determination of the mass sensitivity constant of Oxyntomodulin elongation on SiO2 QCM-D 
sensors.  
Sensor preparation Prior to experiments, sensors were cleaned by immersion in 2 % (w/v) 
Sodium Dodecyl Sulphate (SigmaAldrich, UK) and incubation at 37 °C for 45 min. The 
sensors were then rinsed with Ethanol and water, dried in a stream of Nitrogen, and cleaned in 
a UV/ozone ProCleanerTM (Bioforce Nanosciences) for 20 min. Sensors were either used 
without modification (blank), or with sonicated fibrils (seeds) physically adsorbed to the 
surface by drying of a seed dispersion on the SiO2 surface. Sonication was used to 
homogenize the length of the fibril population within and across experiments, and to enhance 
the sensitivity of sensing by increased availability of growth-competent fibril ends. To 
confine deposited sample drops to the active surface of the sensor during drying, a custom-
made PTFE block with a circular hole matching the active surface was clamped to each chip. 
Seed dispersions were diluted to 0.01 mg mL-1 in HPLC grade water (Fisher, UK), and 40 μL 
dilution was pipetted on each chip. Sensors were dried overnight and imaged by AFM before 
installation in the QCM-D machine. 4 sensors treated with the same seed stock were used for 
each experiment.  
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Measurement Sensors were equilibrated to the measurement temperature in 0.9 mg mL-1 
saline for at least 1 h before solvent or a freshly prepared peptide solution was flown over the 
surface at a rate of 0.1 mL min-1. Elongation was measured in constant stream of peptide for 
15 min, followed by a 10 min rinsing step with 0.9 mg mL-1 saline to prevent further 
elongation by the remaining peptide in the sensing chamber and tubes. Only frequency shifts 
from 2 min after the start of peptide flushing were taken into account to separate unspecific 
peptide adsorption from fibril elongation. Sensors were imaged by AFM before and after 
experiments to confirm elongation. Resonance frequency shifts and dissipation were recorded 
at 75-200 measurements per minute, depending on the number of simultaneously measured 
sensing chambers. Each sensor within an experiment experienced the same amount of 
flushing to minimize differences in fibril numbers on the surface. Results shown here are true 
triplicates, i.e. a condition was modified for the 4 chips in one experiment, and the whole 
experiment including seed preparation, deposition, equilibration and measurement was 
repeated on a different day. Due to differences in sonication efficiency, pipetting and drying 
in separate experiments, it was not possible to provide the same amounts of fibrils across 
triplicates. To correct for fibril number differences, one condition was measured in all 
experiments and used as an internal standard: 0.5 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 
saline at 37 °C.   
Measurements at different temperatures QCM-D is very sensitive to temperature changes. 
Analytes are heated to the sensing chamber temperature before passing the sensor. Elongation 
measurement at different temperatures required re-equilibration of the system for at least 
45 min after a temperature change. To exclude effects of previous incubation temperatures on 
elongation at different temperatures, the sequence of temperature measurement within one 
experiment was shuffled across triplicates (e.g. measurement from low to high and high to 
low temperature). The QSense E4 Analyzer is not equipped to control temperature below 
ambient temperature. For measurements below room temperature, the entire apparatus was 
incubated in a custom-built insulated box with cooling modules before and during 
measurement at 15 and 20 °C. An open petri dish with silica gel was incubated with the 
QCM-D apparatus to prevent condensation on the electric contacts. After measurement, the 
equipment was re-equilibrated without cooling for measurements of the two remaining 
sensors at 25 and 37 °C, to provide the internal standard and a further measurement point 
which overlapped with measurements above room temperature (25; 32; 37; 42 °C).  
Control experiments As a control for the integrity of fibrils during the experiment, a sensor 
with Oxyntomodulin fibril seeds was flushed with 10 % saline. To exclude frequency shifts 
by multilayer deposition or aggregation during the experiments, QCM-D frequency shifts 
were measured during exposure of a fibril-free sensor to a solution of 0.5 mg mL-1 
Oxyntomodulin at 0.1 mL min-1.  
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Analysis In ideal conditions, the relationship of mass and frequency in QCM-D is described 
by the Sauerbrey equation 
∆fn
n
≈ −∆m, where ∆fn is the change in the n-th overtone resonance 
frequency, and ∆m is the change in mass in a given time interval. Elongation of fibrils on the 
sensor surface results in linear frequency decrease, where the slope is a measure for the 
elongation rate [177]. In experiments with Oxyntomodulin, the first two minutes of 
interaction were dominated by adsorption of soluble peptide to the surface of the sensor that 
was not covered by fibrils. This time was not included in the analysis of elongation kinetics. 
Linear frequency decrease after physisorption indicates mass deposition by elongation of 
fibrils. The slope of  
f3
3
  frequency change during 8-10 min after adsorption was used as a 
measure of elongation kinetics. Elongation rates were expressed relative to the slope recorded 
at the internal standard condition to normalize for the amount of seeds deposited per batch. 
Fibril dissolution experiments were performed analogously, except that each sensor contained 
4 µg non-sonicated fibrils, and peptide-free medium was flushed over the surface.  
5.1.3 Fibril elongation enthalpies by Isothermal Titration 
Calorimetry 
ITC heating curves were recorded on an automated MicroCal Auto-iTC200 system (Malvern 
and GE Healthcare, UK). Cell and pipette were cleaned according to manufacturer’s 
instructions before use and between measurements. The cell contained 450 µL of a 
0.1 mg mL-1 seed solution with 15 min sonicated mature fibrils, in 0.9 mg mL-1 saline. The 
pipette solution was 1 mg mL-1 soluble Oxyntomodulin in 0.9 mg mL-1 saline. The pipette 
doubled for stirring the cell content at 1000 rpm. After thermal equilibration, 2 µL were 
injected into the cell for removing air from the syringe. 5 min later, 12 µL peptide were 
injected, and the thermal response was followed for 20 min. 3 injections of 12 µL were 
followed into the same solution, then the cell and syringe were cleaned, and another 
measurement was performed with a new seed solution. Measurements were triplicates of 2 µL 
+ 3*12 µL, but only the first 12 µL injection was taken into account for quantification, for 
reproducibility reasons. Triplicates were performed at 8 °C, 15 °C, 20 °C, 25 °C and 32 °C on 
one day, and at 25 °C, 32, 37 °C and 42 °C on another day. Differences in repeated conditions 
were non-significant; only one repeat is shown. Samples were split because the time needed 
for measurement and cleaning could cause alteration in the stored samples. 0.9 mg mL-1 saline 
was injected to the seed solution analogous to the measurements (triplicate) at each 
temperature to quantify the heat flux created by dilution. Water-to-water injection was used to 
control cleaning and measurement. Background signals were deducted from the 
measurements, and resulting heat flux (in µcal s-1) was integrated over time with the 
manufacturer’s customized origin software to estimate enthalpy (in µcal). Averaged triplicates 
were divided by the number of injected free peptide for plot representation in µcal mol-1. 
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5.2 Development of a QCM-D assay for quasi real-time 
measurement of Oxyntomodulin fibril elongation 
Quartz crystal microbalance with dissipation monitoring (QCM-D) is a quasi real-time, highly 
sensitive, label-free biosensing technique that measures the resonance frequency of a quartz 
sensor as a function of mass bound to the sensor. Binding events can be followed with up to 
200 measurement points and sub-nanogram sensitivity, according to manufacturer’s 
information. QCM-D requires low sample amounts and can be performed in different solvent 
conditions and temperatures. QCM-D has been used to measure fibril elongation kinetics and 
thermodynamics. In the absence of adsorption of crystallization events on the sensor, 
elongation of fibril seeds bound to the sensor creates a linear signal decrease that is a measure 
for the elongation rate [178][159][129]. Here, QCM-D was used to study the elongation of 
Oxyntomodulin fibril seeds attached to the surface of a QCM-D sensors in different solvent 
conditions.  
A QCM-D sensor is a piezoelectric quartz disk with a possible coating or functionalization on 
the solvent-exposed side. Application of a rapidly oscillating alternating current via gold 
electrodes stimulates the sensor to vibrate at its resonance frequency. Changes in resonance 
frequency are recorded computationally. An increase of the resonator`s mass, e.g. by 
adsorption or binding of molecules, results in dampening of the resonance frequency. The 
relation of mass and frequency is described by the Sauerbrey equation 
∆𝑓𝑛
𝑛
= −𝑎∆𝑚, where 
∆𝑓𝑛 is the change in the n-th overtone resonance frequency, ∆𝑚 is the change in sensor mass 
in a given time interval, and a is a mass sensitivity constant that depends on the properties of 
the deposited material [179][180]. For the sensors used here, a adopts the constant -
17.7 ng Hz-1 for formation of a rigid monolayer. In a liquid environment, additional frequency 
dampening can be caused by coupling of solvent and surface. Mass sensitivity is then a 
function of solvent viscosity and immobilization of solvent molecules on or between binding 
analytes (soft layer). For the known viscoelasticity of smooth, homogeneous soft layers on the 
surface (e.g. a protein monolayer), a can be modelled from the dampening of oscillations after 
interruption of the electrode current, expressed as the energy dissipation factor D [181]. The 
QCM-D used here measures D online from the exponential decay of frequency after 
disconnection from the drive.   
Fibril elongation on the surface of a QCM-D sensor can neither be assumed to be a rigid, nor 
as a soft layer. Fibrils need to be scarce to allow elongation without mutual restrictions in 
space, and the viscoelastic properties of the fibril-surface-system are unknown. Aternatively, 
the mass sensitivity can be calculated from an estimation of added fibrillar material to the 
surface. The fibril number density on the surface Γ and the length increase Δl can be assessed 
by AFM imaging of the fibrils on a sensor before and after an experiment. With the known 
fibril diameter d and sensing surface As, fibril shape approximation by a cylinder, and 
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assumption of a fibril density equivalent to the density in protein crystals, the mass sensitivity 
factor can be estimated [177]:  
 𝑛 = −
∆𝑚
∆𝑓
=
(
𝑑
2)
2𝜋 ∗ ∆𝑙 ∗ 𝜌 ∗ 𝐴𝑠 ∗ Γ
∆𝑓
 ( 5-1 ) 
Knowing n, the frequency difference during the elongation phase can be related to the average 
length- or mass-increase of fibrils. If fibril number is (in good approximation) constant during 
and across experiments, and fibril length increase is small enough to not cause partial fibril 
detachment, dissipation changes can be neglected. The slope of a single frequency overtone 
decrease is then a quantitative measure for the elongation kinetics.   
Resulting from the nature of the measurement and the fibrillar system, the following factors 
needed to be assessed to develop a QCM-D assay for kinetic and thermodynamic studies of 
Oxyntomodulin fibril elongation:  
• Adsorption of soluble peptide to the not-covered surface area should not interfere with 
the elongation signal. The elongation signal should be linear in good approximation. 
• Fibril length and concentration needed to be selected for providing enough fibril ends 
to produce measurable mass changes during experiments of different kinetics. Fibrils 
should be equally distributed over the surface and scarce enough in numbers to 
prevent frequent crossing-over during elongation. 
• No or only minimal fibril loss should be seen during an experiment. 
• Monomer concentration for elongation should not be selected too high to prevent 
influence of viscosity changes on measured frequency changes. 
• Experiments should be short enough to prevent spontaneous nucleation. 
• Experimental setup should be reproducible within one experiment and in repetitions 
with independently prepared seed dispersions and peptide solutions. 
• Elongation needed to be measurable by AFM to confirm QCM-D signals and estimate 
the mass sensitivity of Oxyntomodulin fibril elongation.  
To test if the adsorption of soluble Oxyntomodulin to the surface of a SiO2 surface creates a 
signal that interferes with fibril measurement, a fibril-free SiO2 sensor was exposed to a 
stream of freshly prepared 0.5 mg mL-1 solutions of Oxyntomodulin in 0.9 mg mL-1 saline. At 
a flow rate of 100 µL min-1, an analyte solution passed through tubing dead volume for about 
60-90 s before reaching the sensor’s surface.  
  
 Kinetics and thermodynamics of Oxyntomodulin fibrils  75 
 
As shown in Figure 6-1, adsorption of Oxyntomodulin to the surface caused a sharp 
frequency decrease for approximately 20-30 s, followed by a very shallow frequency decrease 
of -0.11 Hz min-1. Subsequent flushing with 0.9 mg mL-1 saline caused an increase in 
frequency, suggesting partial removal of peptide from the surface. AFM images of the sensors 
before and after exposure to peptide were indistinguishable, therefore it is assumed that the 
adsorbed material that does not detach during flushing forms a smooth layer. Because the 
background signal (A-B in Figure 6-1) was generally small compared to the measurement 
signal, and adsorbing peptide did not seem to interfere with fibril elongation, the free sensor 
surface was not passivated. 
The repeatable frequency range of fibril elongation was tested by repetitive injection of 0.1 to 
1 mg mL-1 Oxyntomodulin on sensors with 2 µg fibrils that were sonicated for 2 min prior to 
deposition. Every sensor experienced 5 cycles of peptide- and 0.9 mg mL-1 saline injection. 
Frequency slopes were measured from 2 min after the start of peptide injection to ensure that 
the surface was saturated with peptide and the fluid used for thermal equilibration was fully 
replaced by the peptide solution. Frequency slopes were approximately proportional to 
peptide concentration (see Figure 6-2).  
  
Figure 5-1: QCM-D frequency background of peptide adsorption and desorption 
A-D, Frequency shifts during injection of 0.5 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 saline; 
D-E, flushing with 0.9 mg mL-1 saline, on SiO2 coated QCM-D sensor without fibrils at 25 
°C. A-B, time required to pass the dead volume before sensor contact; B-C, adsorption 
dominated phase; C-D, frequency slope ~-0.11 Hz min-1 – this is the range where elongation 
is measured in following experiments; D-E, partial desorption during flushing without 
peptide.    
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At 0.1 mg mL-1, the slope was as shallow as -0.01 Hz min-1, and signals returned nearly to the 
starting value after flushing with peptide-free medium, indicating that signal changes were 
governed by layer adsorption rather than by elongation. AFM imaging after QCM-D 
measurement showed fibril length and density indistinguishable from imaging before 
measurement (see Figure 6-3 A-D). Between 0.25 and 1 mg mL-1, signals did not return to 
the initial value after peptide removal, and frequency slopes were significantly steeper than 
the adsorption signal on an empty sensor. Slopes were repeatable with a standard deviation 
below 0.005 Hz min-1 for 0.25 and 0.5 mg mL-1, indicating that elongation is not sterically 
Figure 5-2: Sensitivity and saturation of Oxyntomodulin elongation measurement by 
QCM-D 
Top: Elongation of surface-bound Oxyntomodulin fibrils by repetitive injection of 0.1 (blue), 
0.25 (red), 0.5 (green) and 1.0 (grey) mg mL-1 Oxyntomodulin for 5 min followed by rinsing 
with 0.9 mg mL-1 saline for 5 min, at 37 °C. Only the f3 frequency signal is shown. Bottom: 
average ± standard deviation (n=5) of frequency slope after nonspecific adsorption. Each 
sensor had 2 µg of 2 min sonicated fibrils physically adsorbed to the SiO2 surface.  
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hindered, and the sensitivity of frequency measurement is not impaired by viscosity, 
dissipation or saturation. The repeatability of elongation is suggestive of constant fibril 
concentration on the sensors and elongation along the surface. At 1 mg mL-1, the cumulated 
signal change was doubled in comparison to 0.5 mg mL-1, and higher variability of 
measurements may be associated to increased dissipation caused by fibrils elongating into the 
liquid. AFM imaging after QCM-D measurement showed approximately doubled length and 
fibril crossover in fibrils elongated at 1 mg mL-1 for a combined exposure time of 25 min.   
A B 
C D 
E F 
Figure 5-3: AFM imaging of QCM-D sensors confirms fibril elongation 
A, B: SiO2 QCM-D sensor with adsorbed fibril seeds before QCM-D experiment. C, D: 
Sensor after exposure to 0.1 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl for 5*5 min. E, F: 
Sensor after exposure to 1 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl for 5*5 min. AFM 
images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512*512 pixel at 4*4 µm scanning size (A, C, E), 1024*1024 pixel at 2*2 µm 
scanning size (B, D, F). 
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To avoid inaccurate measurement due to excessive fibril crossing or elongation into the bulk, 
elongation measurements were subsequently limited to single elongation periods of 5-20 min 
at or below 0.5 mg mL-1, and 15 min at 1 mg mL-1. In all following experiments, a reduced 
mass of fibrils sonicated for 15 min (in contrast to 2 min) was adsorbed to sensor surfaces.  
Increased fragmentation was supposed to homogenize the fibril length and gain sensitivity by 
the availability of more fibril ends, while consuming less fibril material. 
Elongation measurement in absence of covalent fibril attachment is in contrast to literature 
examples, where fibril seeds were chemically conjugated to an activated surface before 
incubation in the QCM-D [182]. To show that the positively charged Oxyntomodulin fibrils 
interact strongly enough with the polar charged SiO2 surface, fibril numbers were counted by 
AFM before and after elongation experiments. Typical fibril number densities of 26-40 µm-2 
were measured after drying of a drop containing 0.2 µg of 15 min sonicated fibrils per sensor 
(= per cm2), by counting fibrils in two 4*4 µm AFM frames of 4 sensors each. No changes in 
fibril number densities were seen after injection of 0.5 mg mL-1 peptide in 0.9 mg mL-1 saline 
at 37 °C for 5, 10, 15, and 20 min, respectively, and rinsing with 0.9 mg mL-1 saline. 
The average seed length of 15 min sonicated fibrils before QCM-D experiments was 
76±2 nm, assessed from measuring 400 fibril lengths each in three independently sonicated 
and deposited fibril seed batches. Seed diameters were approximately 20-40 nm by AFM, but 
could not be measured exactly on QCM-D sensors due to the rough nature of the SiO2 coated 
gold surface. Assuming cylindrical shape, 76 nm average length, 0.2 µg deposited material 
and the density of a protein crystal (1.2 g cm-3), the average diameter was calculated to be 28 
nm, or 4-5 protofibril diameters in cross-section.  
To estimate the QCM-D mass sensitivity factor, four chips with known fibril length and 
density were incubated in the QCM-D with 0.5 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 
saline at 37 °C for 3.5, 8.5, 13.5, and 18.59 min. Frequency shifts were assessed by 
extrapolating the linear frequency slope during the last 3-18 min to respective times, because 
elongation during the 30 s adsorption phase was assumed to take place even though the signal 
was concealed by the adsorption signal. Fibril length was assessed by AFM after the 
experiment by measuring 400 fibrils per sensor. The mass sensitivity factor was estimated 
according to equation ( 5-1 ) for each sensor. Measured and calculated values are summarized 
in Table 6-1. 
The average mass sensitivity factor is 17.7±3.4 Hz min-1, which is in exact accordance with 
the theoretical mass sensitivity of a rigid layer formation. This is a striking result, because 
fibrils only cover a part of the chip surface and are in equilibrium with an adsorbed peptide 
 
9 The unconventional times are due to 90 s lag time in the equipment caused by dead volume.  
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layer. The mass sensitivity result indicates that no additional dissipation is caused by the fibril 
elongation, and any dissipation increase during the experiment is a result of nonspecific 
adsorption with little contribution to overall mass in the elongation phase. In fact, the 
measured dissipation signal only increased little during the elongation phase, compared to the 
adsorption phase (not shown). The rigidity of fibrils is given by the generally stiff nature of 
mature amyloid-like fibrils [91]. Exclusive elongation does not necessarily change the water 
content of the system, because the incorporation of water within fibrillar material is included 
in the assumed crystal density, and the expected increase of water adsorption due to increased 
surface roughness replaces water bound to the presumably unstructured peptide layer. 
Therefore, within small elongation and in the absence of fibril loss, Oxyntomodulin fibril 
elongation can be modelled like a rigid monolayer, and frequency slopes are in good 
approximation proportional to mass changes in the fibrillar material.   
As fibril numbers are proportional to elongation rate, even small differences between 
experiments would prevent quantitation of elongation rates. Use of a direct mass correlation 
requires the measurement of fibril density on each sensor before and after each experiment, 
because deviations in amounts of deposition are caused by the pipetting of small amounts of 
viscous fibril stocks, the sonication step and the drying on sensor surfaces. Imaging and 
counting of each sensor before and after experiment was however not practicable.  
  
Table 5-1: Direct measurement of QCM-D mass sensitivity during Oxyntomodulin 
fibril elongation 
Γ, fibril density on QCM-D sensor; Δl, elongation during QCM-D experiment; Δf, 
frequency change during elongation extrapolated from f3/3 slope; n, calculated mass 
sensitivity; ρ, average protein crystal density, 1.2 g cm-3; As, sensing surface, 1 cm2.   
Elongation 
time Δt, min Γ, fibrils µm
-2 Δl, nm Δf, Hz n, µg Hz-1 
(method) 
AFM, fibrils in 
32 µm
2 
AFM, 400 
fibril lengths QCM-D 
𝛥f ∗ ρ ∗ (
𝑑
2
)
2
∗ 𝜋
∗ ∆𝑙 ∗ Γ ∗ 𝐴𝑠 
3.5 40.75 9 -1.50 -18.07 
8.5 34.84 35 -3.90 -23.1 
13.5 38.66 26 -4.10 -15.1 
18.5 26.77 75 -8.55 -14.54 
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As seen in Table 6-1, fibril numbers per frame were not constant for deposition of the same 
seed stock. To standardize liquid coverage on the surface during the drying of a seed 
dispersion, sensor deposition was performed using a deposition device for following 
measurements. Sensors were centrally aligned in a water-tight, sealed PTFE chamber that 
only exposed the active surface, and immobilized with springs. A 40 µL drop per chip was 
contained by the PTFE walls during drying, enabling even drying on the whole surface, as 
opposed to direct drop deposition with preferential fibril accumulation in the middle of the 
drop.  
Fibril number differences due to pipetting and sonication could not be standardized. 
Therefore, an internal standard condition was inserted in all experimental setups. This 
condition was chosen as a 15 min, 100 µL min-1 injection of 0.5 mg mL-1 Oxyntomodulin in 
0.9 mg mL-1 saline at 37 °C, due to the observed moderate frequency shifts and elongations at 
these parameters. Using the proportionality of fibril mass and frequency decrease at equal 
fibril numbers, the elongation slopes in each experiment can be shown as a relative elongation 
rate in proportion to the slope of the standard condition. Experimental repeats are then 
independent of the number of fibril ends, and deviations are only due to the nature of external 
conditions tested in the respective experiment. Repeatability within 3 sensors of one 
experiment is shown in (Figure 6-4), where f3 frequency slopes were -1.25 Hz min
-1 at a 
standard deviation of 0.05 Hz min-1.  
Figure 5-4: Repeatability of internal QCM-D standard  
QCM-D f3 signals of three sensors (orange, grey, blue) during incubation of a stream of 
0.5 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 saline with 0.4 µg fibril seeds adsorbed to the 
SiO2 sensing surface with a standardized deposition device. Measurements at 37 °C. Signals 
are taken 2 min after start of peptide flow to omit frequency changes by unspecific adsorption. 
Slopes after linear fitting are -1,25±0.05 Hz min-1, R2 ≥ 0.99. 
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5.3 Electrolytes accelerate Oxyntomodulin self-assembly and 
stabilize fibrils 
In chapter 3.3 and 3.4, it was observed that Oxyntomodulin’s nucleation and fibril elongation 
is promoted in presence of electrolytes. Moderate amounts of sodium chloride (< 20 mM) 
accelerated fibril formation without precipitation and shifted the equilibrium of soluble and 
assembled peptide to the fibril side. It is assumed that chloride anions stabilize associated 
Oxyntomodulin molecules by shielding positive surface charges. Here, fibril elongation and 
peptide release from fibrils is studied in more detail in presence or absence of sodium 
chloride. The impact of anion size on fibril stabilization is tested with different salts. 
A QCM-D seed elongation assay was performed at sodium chloride concentrations from 
0.09 mg mL-1 to 9 mg mL-1. This corresponds to a range of 1-100 % physiologic saline. All 
other experimental parameters correspond to the internal standard condition. Results are 
presented as the ratio of elongation slope to the elongation slope of the internal standard at 
0.9 mg mL-1 sodium chloride (10 % saline). 
As shown in the top panel of Figure 6-5, the frequency slopes steepened drastically with 
increasing saline concentration. Relative elongation rates were in good approximation linearly 
dependent on salt concentration. At 0.09 mg mL-1 sodium chloride, the frequency slope was 
not significantly steeper than the background signal caused by adsorption of soluble peptide 
to the sensor’s surface. AFM images showed fibril shortening compared to the fibril seeds 
before the elongation experiment (see Figure 6-6 A and B). From the internal standard 
elongation condition at 0.9 mg mL-1 to 4.5 mg mL-1 sodium chloride, the elongation rate 
increased by factor 6. Further increase to 9 mg mL-1 sodium chloride approximately doubled 
the relative elongation rate compared to 4.5 mg mL-1 sodium chloride. Variability between 
independent repeats increased with increasing salt concentration, which may be due to 
nonlinearity of the mass-to-frequency relationship when fibrils extend into the medium. As 
shown in Figure 6-6 C-E, fibril elongation at increasing sodium chloride concentration was 
observable by AFM-imaging.   
While 100 % saline has approximately the molarity of subcutaneous fluid, it needs to be 
stressed that subcutaneous fluid only contains trace amounts of sodium chloride and is mostly 
composed of carbonates and minor amounts of phosphates. In chapter 3, it was shown that 
monomer release occurs in PBS but not in 0.9 mg mL-1 saline. No fibril nucleation occurred 
in ThT screenings containing PBS. While not experimentally tested, it is assumed that 
carbonate-ions have a minor stabilizing effect on Oxyntomodulin self-assembly, due to the 
more delocalized negative charges compared to phosphate- and chloride-ions. Therefore, the 
results shown here do not contradict peptide release seen in vivo in [6]. 
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Figure 5-5: Oxyntomodulin fibril elongation rate dependence on NaCl concentration 
by QCM-D 
QCM-D elongation of Oxyntomodulin seeds in presence of 0.5 mg mL-1 soluble 
Oxyntomodulin at 37 °C and increasing concentration of saline (NaCl). Seeds: mature 
Oxyntomodulin fibrils sonicated for 15 min, 0.4 µg per sensor physically adsorbed per SiO2 
QCM-D sensors. Top: exemplary f3/3 slopes of one repeat, at 0.09 mg mL
-1 (blue), 
0.9 mg mL-1 (orange), 4.5 mg mL-1 (grey) and 9 mg mL-1 (green) saline, from 2-10 min of 
peptide injection. Bottom: slopes of linear approximation of each repeat’s f3/3 data divided 
by the internal standard slope at 0.9 mg mL-1 saline of each repeat (physiologic saline 
contains 9 mg mL-1 NaCl). 3 independent repeats presented as average ± standard deviation. 
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A 
B C 
D E 
Figure 5-6: AFM imaging of QCM-D sensors confirms elongation promotion by NaCl  
AFM imaging of the SiO2 QCM-D sensors matching the top panel in Figure 5-5, before (A) 
and after (B-E) a total exposure of 8 min to 0.5 mg mL-1 soluble Oxyntomodulin at 37 °C and 
increasing NaCl concentrations. After peptide exposure, sensors were rinsed in the respective 
peptide-free medium. B, 0.09 mg mL-1 NaCl; C, 0.9 mg mL-1 NaCl; D, 4.5 mg mL-1 NaCl; E, 
9 mg mL-1 NaCl. AFM images were processed in Gwyddion to remove imaging scars and 
background signal. Resolution: 512*512 pixel at 4*4 µm scanning size. Note that fibril length 
in B is shorter than before the experiment, and fibril length increases successively from C-E. 
>50 nm high spherical or edged features are artefacts stemming from salt crystallization 
during sensor drying.   
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Fibril degradation was tested by QCM-D in flow of water and 0.9 mg mL-1 saline. As shown 
in Figure 6-7, in presence of sodium chloride, only little frequency shift was seen over 5 h of 
flow. The frequency increase was linear in good approximation (R2=99.5 %) with a slope of 
7.36 Hz h-1. Assuming this slope stems from peptide release from a constant number of seeds 
and the mass correlation is analogous to fibril elongation (see chapter 5.2), this corresponds to 
a release of 0.65 µg (16.2 %) over 5 h. In water, frequency shifts were approximately linear 
(R2=96.3) with a slope of 320 Hz h-1 in the first 30 min, followed by a nonlinear increase to 
181 Hz by 5 h. This corresponds to 3.2 µg (80.2 %) release. The signal nonlinearity is 
consistent with fibril loss by dissolution. At the end of the experiment, only few fibrils were 
seen by AFM imaging of the sensor, while fibril density was markedly higher on in images of 
a sensor flushed with 0.9 mg mL-1 saline (see Figure 6-7 B-D).  
A 
B C D 
Figure 5-7: Fibril degradation in flow of peptide-free medium 
A, QCM-D frequency shift during 100 µL min-1 flow of water (orange) and 0.9 mg mL-1 
saline (blue) over sensors with 4 µg Oxyntomodulin fibrils physically adsorbed to the SiO2 
surface. B-D, QCM-D sensor imaging by AFM. B, before experiment; C, after incubation in 
water for 5 h, D, after incubation in 0.9 mg mL-1 saline for 5 h. AFM images were processed 
in Gwyddion to remove imaging scars and background signal. Resolution: 512*512 pixel at 
4*4 µm scanning size.   
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While these results indicate faster off-kinetics in water compared to 0.9 mg mL-1 saline, it is 
not possible to exclude an additional signal contribution from fibril detachment from the 
sensor’s surface. Fibril loss may be substantial because of higher fibril-fibril repulsion in 
absence of salt compared to presence of salt; increased adsorbed fibril mass per sensor 
compared to elongation experiments, and prolonged incubation under flow. Release kinetics 
derived from QCM-D may therefore represent an upper limit of fibril dissociation.   
In bulk release experiments without solvent replacement, no measurable free peptide was 
found in presence of 0.9 mg mL-1 saline. If the detection limit of NanoDrop 
spectrophotometry of 0.001 mg mL-1 (225 nM) is taken as the upper limit of equilibrium 
concentration in equations ( 1-10 ) and ( 1-11 ), the Gibbs’ free energy of Oxyntomodulin 
fibrillation at 37 °C in presence of 0.9 mg mL-1 saline is more negative than -38.2 kJ mol-1 (-
9.1 kcal mol-1). At otherwise constant conditions, bulk release in water reached an equilibrium 
of approximately 0.3 mg mL-1 (67 µM) after 4 h, as shown in Figure 6-8. This corresponds to 
a Gibbs’ free energy of -24.0 kJ mol-1. Similar values have been reported for amyloid-type 
fibrillation of other peptides [147][183][157]. 
Figure 5-8: Equilibrium of soluble peptide and fibrils in water 
Peptide release from Oxyntomodulin 0.5 mg mL-1 fibrils in water at 37 °C. Released peptide is 
measured form the A280 signal of fibrillar supernatant after centrifugation and filtration with 
50 kDa MWCO. Dotted line, total peptide. 
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To test if partially disaggregated fibrils can be re-stabilized, a fibril stock was diluted to 
0.5 mg mL-1 in water and incubated for 24 h, reaching a free peptide concentration of 
0.23 mg mL-1. Addition of 14.4 mM (the equivalent of 0.9 mg mL-1 NaCl) NaCl, LiCl, CsCl, 
or CsI to three samples each, and further incubation for 7 d at 37 °C shifted the equilibrium 
below 0.1 mg mL-1 free peptide, while control samples in water had 0.3 mg mL-1 soluble 
peptide at the same time (see Figure 6-9). Salts were selected for the hydrodynamic radius of 
cation and anion: NaCl and LiCl contain comparably small anions and cations, CsCl has a 
small anions paired with large cations, and CsI has large cations and anions. As all salts 
shifted the thermodynamic equilibrium of soluble and assembled Oxyntomodulin in a similar 
degree, it would be implausible to assume that ions structurally integrate in the fibril structure. 
Rather, the stabilization effect may be due to electrostatic shielding of charges on the fibril 
surface, or destabilization of the monomeric state compared to assembled states.  
In summary, salts not only accelerate the conversion of soluble Oxyntomodulin into fibrils, 
but also shift the equilibrium and therefore allow access of a different thermodynamic 
landscape. 
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Figure 5-9: Stabilization of destabilized fibrils by salt addition 
Oxyntomodulin fibrils partially disaggregated by incubation in water for 24 h (left column) 
and incubated for further 7 d in water and different salts at 37 °C. Released peptide is 
measured using the A280 signal of fibrillar supernatant after centrifugation and filtration with 
50 kDa MWCO. Salt concentration, 15.4 mM. Results are presented as average ± standard 
deviation, n=3. Dotted line, total peptide. 
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5.4 Oxyntomodulin elongation is a quasi first order reaction in 
absence of secondary nucleation 
It was seen in chapter 3.4 that the concentrations of soluble Oxyntomodulin and fibril seeds 
can affect the rate of conversion to fibrils. QCM-D elongation experiments analogous to 
Figure 6-7 were performed in presence of different soluble peptide concentrations to follow 
self-assembly at different peptide concentrations in quasi real time.  Figure 6-10 shows 
frequency shift of an exemplary repeat and average elongation rates in dependence of peptide 
concentration.  
Figure 5-10: Effect of soluble Oxyntomodulin concentration on fibril elongation 
QCM-D elongation of Oxyntomodulin seeds in presence of 0.9 mg mL-1 NaCl at 37 °C and 
increasing Oxyntomodulin concentration. Seeds: mature Oxyntomodulin fibrils sonicated for 
15 min, 0.4 µg physically adsorbed per SiO2 QCM-D sensors. Top: exemplary f3/3 slopes of 
one repeat, at 0.1 (blue), 0.25 (orange), 0.5 (grey) and 1 (green) mg mL-1 Oxyntomodulin, from 
2-10 min of peptide injection. Bottom: slopes of linear approximation of each repeat’s f3/3 data 
divided by the internal standard slope at 0.5 mg mL-1 Oxyntomodulin of each repeat. 3 
independent repeats presented as average ± standard deviation. 
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At 0.1 mg mL-1, signals were not significantly different from the background signals of 
peptide adsorption, and no elongation was seen in AFM images of sensors after the QCM-D 
experiment. AFM imaging after elongation in 0.25 mg mL-1 to 1 mg mL-1 showed increasing 
elongation in dependence of soluble Oxyntomodulin concentration. Frequency shifts were 
linear in good approximation during elongation, which is consistent with exclusive elongation 
at constant monomer concentration. Importantly, the relative elongation rate was directly 
A 
B C 
D E 
Figure 5-11: AFM imaging of QCM-D sensors confirms concentration dependency of 
Oxyntomodulin elongation 
AFM imaging of the SiO2 QCM-D sensors matching the top panel in Figure 5-10Figure 5-5, 
before (A) and after (B-E) exposure to increasing Oxyntomodulin concentrations in 
0.9 mg mL-1 NaCl at 37 °C. After peptide exposure, sensors were rinsed in 0.9 mg mL-1 
NaCl. B, 0.1 mg mL-1; C, 0.25 mg mL-1; D, 0.5 mg mL-1; E, 1.0 mg mL-1 Oxyntomodulin. 
AFM images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512*512 pixel at 4*4 µm scanning size. >50 nm high spherical or edged features 
are artefacts stemming from salt crystallization during sensor drying.   
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proportional to peptide concentration. This is in accordance with the concentration-dependent 
apparent elongation rate kapp in an elongation chain reaction (see equation ( 1-5 )) and the 
theoretical pseudo first-order reaction type of exclusive elongation shown in equation ( 1-6 ). 
The elongation rate of Oxyntomodulin fibrils at constant peptide concentration is therefore – 
among others – limited by diffusion, and within the concentrations tested here, growth 
competent fibril termini on the senor surface are not saturated.  
While not formally shown here, the fibril seed concentration also has an influence on the 
kinetics of elongation, trivially because of the multiplication of growth competent ends with 
the same elongation rate per end. It was seen in chapter 3.4 that low seed concentration 
decelerates elongation, but also favors polymorphism. Formation of a potentially more 
thermodynamically stable fibril species under conditions with slow elongation kinetics will be 
discussed in chapter 6. 
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5.5 Oxyntomodulin fibrillation has a unique temperature optimum 
at room temperature 
Temperature has an impact on folding and amyloid formation of many proteins and peptides. 
Native proteins are selected by evolution for structural stability and low aggregation tendency 
in their natural environment. At relatively low temperatures, the enthalpic gain of shielding 
hydrophobic residues from the aqueous environment is greater than the entropic cost of 
adopting an ordered structure, making the hydrophobic effect the main driving force for 
protein folding. Temperature increase – e.g. by fever – both alters the solubility of side chains 
and increases the entropic cost of folding, eventually resulting in thermal denaturation [156]. 
Every folded structure has an unfolding (“melting”) temperature range where the folded 
structure becomes thermodynamically destabilized compared to denatured states. Partial or 
complete unfolding is necessary to align molecules in an amyloid-like pattern. Therefore, the 
propensity to form self-assembled structures from naturally folded proteins generally rises 
with temperature increases, and temperature optima of amyloid formation are substantially 
higher than body temperature for most proteins and peptides (see also chapter 1.2.3).  
The thermal behavior of Oxyntomodulin self-assembly was investigated to determine optimal 
elongation temperatures for fast and monomorphic elongation, to assess the stability of fibrils 
in storage conditions, and to test the response to temperature changes in the context of 
subcutaneous injection. Conditions were considered up to 42 °C to prevent chemical 
denaturation of the peptide. Storage temperatures were assumed as 6-8 °C (fridge) and 25 °C 
(room temperature). 25 °C doubled as a lower limit of subcutaneous temperature for high 
dermal layers or in case of hypothermia. 32 °C represents the average subcutaneous 
temperature. 37 °C (physiological body temperature) was tested as an upper limit of 
subcutaneous temperatures and to determine thermal effects during transition of soluble 
peptide from subcutaneous space to the blood stream. 42 °C was chosen to investigate effects 
of hot climates or high fever on a subcutaneous depot.  
Oxyntomodulin fibril elongation was tested by a kinetic QCM-D assay analogous to the 
effects of salt- and monomer concentration. Every experiment tested four temperatures 
including the internal standard elongation condition at 37 °C, to account for differences in 
seed numbers per sensor batch. A separate triplicate experiment series with internal standard 
and an overlapping measurement at 25 °C was performed under external cooling for 
elongation measurement at 15 and 20 °C.  
As shown in (Figure 6-12), the QCM-D elongation assay suggests a temperature optimum of 
elongation between 25 and 32 °C. Elongation was fastest at 25 °C, with about threefold 
elongation rate compared to 37 °C. The elongation rate at 25 °C was insignificantly higher in 
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the measurement series at lower temperatures, and no effect of changing the sequence of 
measurement or the measurement chambers was seen. AFM imaging confirmed considerable 
elongation at 25 °C and 32 °C, while less elongation was seen at other temperatures (see 
exemplary images in Figure 6-13).  
Figure 5-12: QCM-D reveals Oxyntomodulin fibril elongation optimum at room 
temperature 
QCM-D measurement of Oxyntomodulin fibril elongation in presence of 0.9 mg mL-1 NaCl 
and 0.5 mg mL-1 Oxyntomodulin at different temperatures. Seeds: mature Oxyntomodulin 
fibrils sonicated for 15 min, 0.4 µg physically adsorbed per SiO2 QCM-D sensors. Top: 
exemplary f3/3 slopes of one repeat, at 25 (green), 32 (blue), 37 (cyan) and 42 (red) °C, 
measured from 2-10 min of peptide injection. Bottom: slopes of linear approximation of each 
repeat’s f3/3 data, divided by the internal standard slope at 0.5 mg mL-1 Oxyntomodulin of 
each repeat. Triangles: measurement at 25, 32, 37, 42 °C; squares: measurement at 15, 20, 25, 
37 °C with external cooling at 15 and 20 °C. 3 independent repeats presented as average ± 
standard deviation.  
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The thermal response of Oxyntomodulin fibril elongation seen in QCM-D elongation assays 
is highly unusual. No amyloid-type aggregation optimum below body temperature has been 
reported in the literature, neither for proteins nor for peptides. In a QCM-D fibril elongation 
assay with similar setup to the experiments shown here, A. Buell et al. showed increasing 
elongation with increasing temperature for nine amyloid-forming peptides and proteins in the 
temperature range from 25 to 45 °C [129]. One of the tested peptides was human glucagon, 
which corresponds to the 29 N-terminal amino acids of Oxyntomodulin. In other studies, it 
was shown that amyloid-like self-assembly of peptides and short proteins like amyloid β, 
bovine insulin, α-synuclein and β2-microglobulin do have a temperature optimum, but non-
Arrhenius behaviour or disaggregation only occur beyond 60 °C 
[184][156][133][147][185][153]. A similarly narrow optimum has been described for hen egg 
white lysozyme, which thermally unfolds at 55 °C followed by fibrillation maximum at 60 °C 
and amorphous aggregation at 65 °C [132]. 
Due to the independent reproducibility of the QCM-D results and the confirmation by AFM 
imaging, it is unlikely that the measured kinetics are an artefact of measurement at different 
A B 
C D E 
Figure 5-13: AFM imaging confirms maximum elongation rate at 25 and 32 °C 
AFM imaging of the SiO2 QCM-D sensors matching the top panel in Figure 5-12, before 
(A) and after (B-E) exposure to 0.5 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 NaCl at 
different temperatures. After peptide exposure, sensors were rinsed in 0.9 mg mL-1 NaCl. B, 
25 °C; C, 32 °C; D, 37 °C; E, 42 °C. AFM images were processed in Gwyddion to remove 
imaging scars and background signal. Resolution: 512*512 pixel at 4*4 µm scanning size. 
>50 nm high spherical or edged features are artefacts stemming from salt crystallization 
during sensor drying.   
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conditions. It was confirmed by the QCM-D manufacturer’s customer service that 
measurement at different temperatures does not interfere with absolute frequency changes or 
mass sensitivity after thermal equilibration. To exclude a surface-mediated effect, analogous 
QCM-D elongation experiments were performed on sensors with 50 % OH- and 50 % CH3-
terminated polyethyleneglycol self-assembled monolayers. Similar effects were observed, 
however the fibrils did not interact strongly enough with the surface to provide consistent 
fibril concentrations during the experiment, resulting in reduced signal-to-noise ratio and less 
linear frequency slopes (results not shown).  
To test if there is a thermal optimum in bulk and at longer incubation times, seeded kinetic 
assays were performed for 15 h at 25; 32; 37 and 42 h in presence of the fluorescent amyloid-
reporter dye ThT. Lower temperatures could not be measured because it was technically not 
possible to cool the fluorescence plate reader. The ThT elongation profiles shown in Figure 
6-14 are in accordance with results from QCM-D, showing a non-Arrhenius reaction type 
with more ThT binding and hence faster assembly kinetics for lower temperatures. Curves 
could be fitted with an exponential function analogous to equation ( 1-9 ) with R2 > 97 %, 
confirmed exclusive elongation of pre-formed seeds in absence of secondary nucleation.  
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Figure 5-14: ThT kinetics confirm inverse Arrhenius behaviour of Oxyntomodulin 
fibril elongation beyond room temperature 
ThT fluorescence in presence of 0.5 mg mL-1, 0.9 mg mL-1 saline and 50 µM ThT and 1 % 
Oxyntomodulin seeds at different temperatures, in Corning® 3881 microplates with non-
binding surface. Seeds were derived from 15 min sonication of a mature Oxyntomodulin 
stock. Green, 25 °C; blue, 32 °C, cyan, 37 °C, red, 42 °C. Results are presented as average 
± standard deviation, n=6. Dotted lines, exponential fitting with the ExpDec2 function in 
Origin; R2 > 97 %.  
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Fitted association rates decreased from 0.115 h-1 at 25 °C to 0.002 h-1 at 42 °C. At longer 
incubation times in ThT conditions at 37 and 42 °C, secondary nucleation occurred, and the 
twisted fibril type appeared in AFM images after three days (data not shown). It was thus not 
possible to derive information on the equilibrium concentrations by ThT assay.  
A seeded bulk elongation assay in dye-free conditions was performed to investigate the 
impact of temperature on the thermodynamic equilibrium of soluble and fibrillar peptide. 
Concentrations of soluble and assembled peptide were assessed after 1, 4, 7 and 14 days of 
incubation at 6 °C, 25 °C, 32 °C, 37 °C and 42 °C. AFM imaging confirmed the presence of 
fibrils and absence of unstructured aggregate at each end point. As displayed in Figure 6-15, 
the conversion of soluble peptide was fastest at 25 °C, with less than 20 % free peptide after 
24 h and no measurable soluble peptide after 7 d. At other temperatures, approximately 50 % 
fibril yield was reached after 24 h, but further assembly was slower and only reached full 
conversion at 6 °C after 14 d. Lowest conversion was seen at 37 °C, with only 78 % fibril 
yield after 14 d. Remarkably, AFM images after 7 and 14 d showed the presence of thin 
twisted fibrils in samples at 37 °C and 42 °C, while the fibrils at or below 32 °C exclusively 
represented the straight fibril type of seed fibrils (see Figure 6-16). In storage conditions at 
fridge or room temperature, the equilibrium is therefore far on the fibril side and kinetics are 
fast enough to prevent formation of alternative species. The fast and robust reproduction of 
mother fibrils is reassuring for storage stability of Oxyntomodulin fibrils in a fridge or at 
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Figure 5-15: Bulk elongation confirms temperature optimum at room temperature 
Soluble peptide after quiescent incubation of 1 % Oxyntomodulin fibril seeds in 0.5 mg mL-1 
Oxyntomodulin for 1, 4, 7 and 14 days. Remaining soluble peptide measured by NanoDrop 
absorption at 280 nm after 30 min sedimentation of fibrils at 13 000 rpm and 50 kDa 
MWCO filtration of supernatants. Red, 6 °C; green, 25 °C; blue, 32 °C; cyan, 37 °C; purple, 
42 °C. Results are presented as averages of independent triplicates ± standard deviation.  
 Kinetics and thermodynamics of Oxyntomodulin fibrils  95 
 
room temperature even after partial dissolution. This reflects the absence of changes in fibril 
samples over months of storage of fibril stocks. Kinetics at or above body temperature are not 
only slower, and equilibrium is not only shifted to the soluble peptide side, but prolonged 
incubation at these conditions also favours formation of a structure with an alternative 
minimum of the free energy landscape. This is in agreement with the observation of 
polymorphism after prolonged incubation in ThT conditions or in the elongation of longer 
fibrils in 5 mg mL-1 Oxyntomodulin at 37 °C. Metastability at body temperature may be a 
driving factor for the peptide release seen in vivo [6].  
While results from QCM-D, ThT kinetics and bulk elongation reproduce a unique 
temperature optimum of Oxyntomodulin fibril elongation at 25 °C, it is not clear why this low 
and narrow temperature optimum is adopted. To gain insights into the enthalpic driving 
Figure 5-16: AFM shows polymorphism after prolonged incubation at thermodynamically 
and kinetically unfavourable conditions 
AFM imaging before concentration measurement of 14 d samples shown in Figure 5-15. 
Elongation at 25 °C (A) and 32 °C (B) exclusively reproduced the seed fibril morphology. 
Elongation at 37 °C (C) and 42 °C (D) additionally caused growth of twisted fibril types (blue 
arrows). AFM images were processed in Gwyddion to remove imaging scars and background 
signal. Resolution: 512*512 pixel at 4*4 µm scanning size. 
A B 
C D 
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factors of Oxyntomodulin self-assembly, seed elongation was studied by isothermal 
calorimetry (ITC). ITC is classically used to measure heat effects of ligand binding and 
protein-protein association. One binding partner is equilibrated to measurement temperature 
in an insulated, stirred chamber, and heat flux is controlled and measured. Addition of a 
binding partner creates or consumes energy dependent on the type of interaction, causing 
negative or positive peaks of heat flux to maintain the set temperature. After subtraction of 
dilution heat and division by the molar amount of added ligands, the area under the heat flux 
curve is equivalent to the change of reaction enthalpy ΔH [cal mol-1]. The change of reaction 
enthalpy over temperature defines the change of heat capacity ΔCp [cal mol-1 K-1] [147]. 
Some publications describe heat effects of amyloid fibril extension by ITC. Pre-formed fibrils 
and soluble peptide or protein represent the binding partners, and heat flux is measured during 
monomer consumption [147][154][133].  
Heat capacity changes in amyloid fibrillation can be caused by several factors. The cross-beta 
backbone alignment and formation of steric zippers between sheets require the exclusion of 
side chains from an aquatic environment. Burial of hydrophobic residues is generally 
enthalpically favourable and becomes more favourable with an increase of temperature 
(negative ΔCp). Conversely, exclusion of polar or charged residues from bulk water is 
thermodynamically unfavourable and generally increases ΔCp [153][154]. A potentiating 
effect can be caused by surface burial during thermally driven association of fibrils. Large 
exothermic heat effects preceding thermal disaggregation have been attributed to the thermal 
effects of surface burial during fibril association at increased temperatures for several 
amyloid-forming peptides and proteins [147][153][186]. It is assumed that favourable 
enthalpic interactions saturate at higher temperatures [153]. 
In addition to side-chain and backbone interactions of fibrils, water within the fibril can have 
an impact on thermodynamics. If water molecules are excluded during fibril elongation or 
association, hydrophobic interactions and hydrogen bonding within the fibril or fibril bundle 
become enthalpically more favourable [155]. Inclusion of water in fibrils can create negative 
and positive heat capacity changes, depending on the hydrophilicity of the microenvironment 
and the degree of mobility within the fibril. For instance, hydration of polar or charged 
residues is enthalpically favourable, driving the thermodynamic potential of association at 
higher temperatures [153]. However, hydration of nonpolar residues is thermodynamically 
unfavourable and perturbs hydrophobic interactions. Restriction of water mobility 
additionally creates an entropic cost that scales with temperature, which may overall prevent 
association due to a positive free energy balance.  
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In this experiment, the reaction cell contained a 0.1 mg mL-1 seed solution with 15 min 
sonicated mature fibrils in 0.9 mg mL-1 saline. This condition was chosen because it provided 
sensitive enthalpy peaks while allowing completion of the assembly reaction (i.e. recovery of 
heat peaks to baseline), used an amount of fibrils that could be sonicated in one batch, and 
had a fibril concentration at least 100-fold higher than the equilibrium concentration in 
0.9 mg mL-1 saline. For the latter reason, fibril dissociation in the cell could be assumed 
negligible. The pipette contained a 1 mg mL-1 solution of Oxyntomodulin in 0.9 mg mL-1 
saline. For heat flux measurement, 12 µL were pipetted into 450 µL seed dispersion. With the 
seed dimensions estimated in chapter 5.2, the cell contained 8.0*1011 fibrils, and 2.7 nmol 
peptide (1.6*1015 molecules) were added per measurement, corresponding to a 2000-fold 
excess of monomer numbers to fibril numbers. Quantitative conversion to fibrils would create 
an average 26.7 % fibril elongation. It was technically not possible to recover samples after 
the reaction for AFM control of fibril elongation. A complete conversion to fibrils was 
assumed due to knowledge on equilibrium and kinetics of elongation in salt-containing 
condition, the low excess of monomer to fibril compared to QCM-D, ThT, and bulk 
elongation measurements, rigorous mixing in the reaction cell, and the recovery of thermal 
peaks to baseline within less than 10 min. Consecutive peptide injections into the same fibril 
dispersion created lower signals than the first elongation period, and signals did in some cases 
Figure 5-17: ITC reveals exothermic Oxyntomodulin fibril elongation with optimum 
below body temperature 
Oxyntomodulin fibril elongation enthalpies measured by isothermal titration calorimetry at 
8 °C, 15 °C, 20 °C, 25 °C, 32 °C, 37 °C, 42 °C. Enthalpies derived from integration of heat 
flux per monomer, after injection of 12 µL 1 mg mL-1 Oxyntomodulin into 450 µL 
0.1 mg mL-1 seeds derived from 15 min sonication of mature Oxyntomodulin fibrils, both in 
0.9 mg mL-1 NaCl. Heat flux is corrected for heat flux of peptide dilution in 0.9 mg mL-1 
NaCl. Points represent averages of three independent measurements ± standard deviation. 
 
10 20 30 40
-5000
-4000
-3000
-2000
-1000
0
E
n
th
a
lp
y
, 
c
a
l 
m
o
l-1
Temperature, oC
 
 
 Kinetics and thermodynamics of Oxyntomodulin fibrils  98 
 
not return to baseline within 10 min. This may be due to fibril association resulting in lower 
availability of growth-competent fibril termini, and hence reduced elongation kinetics [147]. 
Only first injections were used for the following analysis. 
As shown in Figure 6-17, Oxyntomodulin fibril elongation was enthalpically favourable 
(exothermic) in the measurement range from 8 °C to 42 °C. At 6 °C, 15 °C, 37 °C and 42 °C, 
the reaction was only moderately exothermic, whereas large enthalpy changes 
from -3 kcal mol-1 to -5 kcal mol-1 were measured from 20 to 32 °C. The experimental 
optimum was at 32 °C, however the true optimum may be between 25 and 32 °C. By 
definition, an optimum in enthalpy corresponds to a change of sign in heat capacity. 
It is not possible to explain the heat effects during Oxyntomodulin fibril elongation without 
an atomic-resolution fibril model. However, knowledge of the enthalpy, rate and equilibrium 
changes allows some reasoned assumptions on influence factors:  
Firstly, comparison of the elongation rates measured by QCM-D, temperature dependence of 
bulk elongation kinetics and equilibrium concentrations, and temperature dependence of 
reaction enthalpy show a striking similarity of kinetic, free energy, and enthalpic changes 
with alteration of temperature. Oxyntomodulin fibril elongation is therefore at least partially 
driven by enthalpy.  
Secondly, the strongly exothermic reaction at 25 °C and 32 °C cannot exclusively be 
explained by single binding events. Heat effects caused by association of fibrils are not 
impossible, but as fibril seeds are incubated at the reaction temperature before the event, the 
reaction is rigorously stirred, and elongation is small even after total consumption of free 
peptide, thermodynamic effects of fibril association during elongation cannot be large. 
However, a small effect of fibril association could explain the more exothermic reaction at 
32 °C than at 25 °C, while a kinetic optimum at 25 °C was seen at comparable reaction times 
in QCM-D. A potentially favourable thermodynamic effect of association at higher 
temperatures has no impact in QCM-D experiments due to the immobilization of fibrils.  
Thirdly, the sign change in heat capacity and drastic reduction of reaction enthalpy over a 
relatively small temperature range suggests a mechanistic change in elongation at enhanced 
temperatures. One explanation may be that the reaction is not quantitative above skin 
temperature due to the enhanced entropic cost of self-assembly at increased temperatures. As 
the magnitude of Gibbs’ free energy is greater than -9.1 kcal mol-1 for Oxyntomodulin 
fibrillation at 37 °C (see 5.3), there must be an entropic compensation. Consequently, 
entropically unfavourable events directly affect the equilibrium. Mechanistic or statistical 
changes in e.g. water exclusion from the fibril influence heat capacity and entropy changes 
during fibrillation, which feeds back to experimentally measured enthalpy and elongation rate 
due to an overall incomplete, slower reaction. A different explanation for anti-Arrhenius 
kinetics and thermodynamics may be that Oxyntomodulin’s net charge (or the screening of 
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charged residues) changes as a function of temperature. This can be mediated by subtle 
changes of the fibril structure that enhances charge-charge repulsion, such as reduced 
screening by anions in a dry environment. Changes of the medium, e.g. the increased 
dissociation of water at enhanced temperatures, can have an impact on fibril compactness and 
the structure of soluble peptide. Negative, zero, and positive heat capacity changes have been 
reported for elongation of glucagon fibrils derived from different environments. Importantly, 
it was shown that glucagon fibrils can lose or maintain positive charges during elongation 
[154]. Due to Oxyntomodulin’s structural similarity to glucagon, a change in charge patterns 
as a function of temperature is not unlikely. An experimental setup analogous to [154] was 
however not possible with Oxyntomodulin fibrils due to Oxyntomodulin’s fibrillation 
sensitivity to ions.  
Fourthly, temperature may have an influence on the architecture of soluble peptide 
monomers, making the soluble species more or less prone to self-assembly depending on 
environmental conditions. For instance, the 1-40 peptide fragment of amyloid β transforms 
from random to beta sheet when heated from 0 to 37 °C, accompanied by an increase in 
amyloid formation tendency [187][137]. As Oxyntomodulin is a human and rodent hormone, 
low tendency for aggregation at core body temperatures may be evolutionarily selected for. 
The helical molecular structure reported in literature has been confirmed with synthetic 
Oxyntomodulin at 37 °C in chapter 4.3 [48]. Generally, helical structures are sensitive to 
temperature increase [134][188].  
To test the influence of temperature on the structure of soluble Oxyntomodulin, the change of 
secondary structure was measured by circular dichroism at increasing temperatures. 
Measurement was performed analogously to structural measurement described in 4.1.3 with 
an additional 5 min of thermal incubation before measurement. As shown in Figure 6-18, the 
helical content of Oxyntomodulin decreased gradually with increasing temperature from 45 % 
at 8 °C to 32 % at 47 °C. Reduced helicity may be a driving factor for increasing fibril 
elongation rate and enthalpy with temperature increase at sub-physiologic temperatures. No 
significant alteration in other secondary structural elements was seen, indicating that the 
formation of unfavourable conformations of soluble peptide is not involved in the non-
Arrhenius kinetics and thermodynamics of Oxyntomodulin fibril elongation at elevated 
temperatures. As results from FTIR, CD, X-Ray diffraction and Cryo-EM imply, 
Oxyntomodulin likely adopts a β-arch fold in fibrils. The adoption of the folded conformation 
required for fibril elongation is likely to be disadvantaged at higher temperatures, as 
secondary structure formation is generally favourable at lower temperatures 
[135][134][158][164]. Fibril elongation is then limited by the native structure at low 
temperatures and by the thermodynamics of folding at high temperature.   
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If the folding thermodynamics of Oxyntomodulin are a major limiting factor in fibril 
elongation at higher temperatures, peptide release from fibrils must become more favourable 
with increasing temperatures, as any structured state would become destabilized. Because 
fibril release in elongation conditions was below the detection limit of conventional 
quantification methods, release was measured after dilution of essentially salt-free fibrils in 
water. Analogous to elongation experiments in bulk, soluble peptide was quantified in the 
filtered supernatant, and dissociation was controlled by AFM.   
Figure 6-19 shows that peptide release becomes faster with increasing temperatures, and 
higher soluble peptide concentrations are reached after 7 d. At 6 °C, only approximately 10 % 
released peptide is measured after 7 d, implying a kinetic and/or thermodynamic conservation 
of the fibril state at storage conditions. At 25 °C, release is markedly higher and faster. 
Highest release is reached at physiologic temperatures, where between 50 and 60 % soluble 
peptide were measured after one week of incubation. 
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Figure 5-18: Helicity of soluble Oxyntomodulin decreases with increasing temperature 
Secondary structure of Oxyntomodulin by circular dichroism spectroscopy from 260 to 
180 nm. Data deconvoluted with the online tool Dichroweb using the algorithms CONTIN-
LL, SELCON 3 and CDSSTR for each sample. Shown are averages of 3 independent sample 
runs ± standard deviation. Transparent, dotted: helix; light grey, striped: sheet; dark grey, 
solid: turns. 
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Figure 5-19: Oxyntomodulin fibril dissociation is favoured at increased temperatures 
A, Soluble peptide after quiescent incubation of 0.5 mg mL-1 essentially salt-free, mature 
Oxyntomodulin fibrils in water for 1 and 7 days, measured by NanoDrop spectrophotometric 
absorption at 280 nm, after 30 min sedimentation of fibrils at 13 000 rpm and 50 kDa MWCO 
filtration of supernatants. Red, 6 °C; green, 25 °C; blue, 32 °C; cyan, 37 °C; purple, 42 °C. 
Results are presented as averages of independent triplicates ± standard deviation. B-F, AFM 
imaging after 1 d shows preferential peptide release at increased temperatures, judged by the 
shortening and number reduction of fibrils and the increasingly blurry appearance of fibrils in 
enhanced soluble peptide concentrations. B, 6 °C; C, 25°C; D, 32°C; E, 37 °C; F, 42 °C. 
AFM images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 1024*1024 pixel at 4*4 µm scanning size. 
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Figure 5-20: Oxyntomodulin fibril reversibility and fibril polymorphism depends on 
incubation temperature 
(continued on following page) 
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Figure 6-20 (continued): AFM imaging after 7 d incubation of 0.5 mg mL-1 essentially salt-
free, mature Oxyntomodulin fibrils in water. Incubation temperature A-C, 6 °C; D-F, 25°C; 
G-I, 32°C; J-L, 37 °C; M-O, 42 °C. Images show preferential peptide release with increasing 
temperature, judged by the shortening and number reduction of fibrils and the blurry 
appearance of fibrils in enhanced soluble peptide concentrations. Blue arrows, formation of 
twisted fibril species at 37 °C. AFM images were processed in Gwyddion to remove imaging 
scars and background signal. Resolution: A, D, G, J, M, 512*512 pixel at 9*9 µm scanning 
size; B, E, H, K, N, 1024*1024 pixel at 4*4 µm scanning size; C, F, I, L, O, 1024*1024 pixel 
at 2*2 µm scanning size. 
 
Importantly, soluble peptide concentration decreased from day 1 to day 7 at 37 °C, along with 
the appearance of twisted fibrils by day 7. This structural rearrangement is analogous to the 
formation of an alternative fibril species after several days of ThT- or bulk elongation 
experiments at similar conditions. At other temperatures, only the straight, partially associated 
fibril type was seen. As shown in Figure 6-19 B-F and Figure 6-20, the increasing shrinking 
of fibrils from low to high temperatures could be followed by AFM imaging. Blurring of 
images implies successive release of soluble peptide without formation of microscopic non-
fibrillar aggregates. All fibrils appeared less bundled after incubation in water compared to 
stocks containing trace amounts of salt, and more single fibrillar structures with the 
morphology of protofibrils appeared. This supports the theory that mature fibrils are 
reversible assemblies of protofibrils, and that the electrolytes contained in mature fibril 
samples – among other effects – shift the equilibrium to the fibril side by enabling 
thermodynamically favourable lateral association. 
To quantify the dissociation rate, ThT kinetics were measured as a function of temperature 
under conditions where Oxyntomodulin fibrils completely dissolved. Complete dissolution 
was defined as a condition where the ThT fluorescence after release was not higher than the 
ThT fluorescence of release in 10 mM HCl after 1 h (not shown). It was found that 0.1 
mg mL-1 mature fibrils completely dissolved in water within 3 h in a ThT assay. It is 
noteworthy that ThT is a chloride salt; the assay thus contained 50 µM chloride anions. As 
shown in Figure 6-21, the initial ThT signal at different concentrations was not the same for 
different temperatures. ThT fluorescence is mildly sensitive to temperature, however the 
difference seen here is several orders of magnitude higher than differences in ThT sensitivity 
[132]. Rather, different fluorescence at the beginning of incubation is a result of preparation 
and measurement of independent dilutions from a concentrated fibril stock. ThT 
measurements at different temperatures had to be performed at different days because the 
equipment can only incubate at one temperature. Although care was taken to keep the times 
between sample preparation and the start of fluorescence reading minimal and constant, it is 
probable that the first few time points at rapidly dissociating conditions have been missed due 
to the instrumental lag time before measurement.   
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An exponential decay function was fitted to the average signals to quantify release. The 
exponential coefficient corresponds to the release constant of the fibril continuum λ (i.e. the 
time for signal reduction, in h-1) rather than a molecular koff parameter (i.e. the time for 
release of one ligand from one binding partner, in s-1). The insert in Figure 6-21 shows the 
relative dissociation rate defined by the quotient of dissociation constants by the dissociation 
constant at 37 °C. Dissociation is 1.5 times faster at 42 °C than at 37 °C, while release rate is 
reduced to 41 % and 72 % at 25 and 32 °C, respectively.  
Results and possible explanations of thermal response in Oxyntomodulin structure and 
Oxyntomodulin fibril elongation and dissociation are summarized in Figure 6-22. The 
unusually low and narrow thermal optimum of Oxyntomodulin fibril elongation has been 
shown by four orthogonal techniques: QCM-D, monomer depletion in bulk, ThT elongation 
assay, and ITC heat flux measurement. The optimum is measurable in elongation time frames 
from minutes to weeks, by bulk- and surface-bound techniques, and by measurements of mass 
change, concentration change, amyloid-reporter dye binding, and enthalpy measurement. 
Elongation kinetics, thermodynamic equilibrium and enthalpy loss show comparable thermal 
responses. It was shown that temperature increase destabilizes the native secondary structure 
of Oxyntomodulin, but also favors peptide release in undersaturated conditions.  
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Figure 5-21: Peptide release from Oxyntomodulin fibrils by ThT kinetics 
ThT fluorescence during incubation of 0.1 mg mL-1 essentially salt-free, mature 
Oxyntomodulin fibrils in water with 50 µM ThT at different temperatures. Shown are 
averages ± standard deviations of 6 repetitions per condition. Solid lines, exponential decay 
functions fitted to the average data points in Origin. Conditions and fitting parameters: green, 
25 °C, λ = 0.953 h-1, R2 = 97.4 %; blue, 32 °C, λ = 1.698 h-1, R2 = 98.9 %; cyan, 37 °C, λ = 
2.362 h-1, R2 = 99.3 %; purple, 42 °C, λ = 3.502 h-1, R2 = 98.7 %. Insert, plot of average decay 
constants derived from each repeat, normalized by the 37 °C decay constant, ± standard 
deviation.  
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Figure 5-22: Tentative energy landscape of Oxyntomodulin self-assembly 
Thermodynamically favoured states depending on temperature; reaction arrow length 
indicates kinetics and equilibrium. 1, the native helical monomer (black) is the favoured 
species at low temperatures; 2, heating disfavours the helical state and promotes formation of 
random species (grey); 3, arch formation (blue and orange) is presumably an energetically 
unfavourable intermediate step which is kinetically driven by 4, fast conversion to fibrils; 5, 
further temperature increase promotes enthalpically favourable fibril association; 6, after 
saturation of enthalpically favourable events, further temperature increase is disadvantageous 
for the assembled state due to entropic cost, and the system’s equilibrium shifts to unordered 
soluble state; 7 and 8, formation of folded species is generally disfavoured at high 
temperatures. 9, Polymorphism is presumably favoured after prolonged incubation at step 3.  
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While no definite explanation can be given for the temperature-dependent kinetics and 
thermodynamics of Oxyntomodulin self-assembly, a comprehensive model of the free energy 
landscape can be drawn from structural, kinetic and thermodynamic results. Structural 
reorganization events shown in Figure 6-22 are reasoned in the following list: 
• Reactions 1 and 2: As shown by CD spectroscopy of soluble Oxyntomodulin, the native 
helical fold is favored at low temperatures, but destabilized at increasing temperatures.  
• Reaction 3: It is assumed that destabilization of the native helix conformation allows the 
formation of a thermodynamically disfavored (hence not observed) intermediate species 
that resembles the arch structure of monomers in the fibril. This may not be a soluble 
species but a structural reorganization catalyzed at the fibril terminus. Possibly, the rate-
limiting step is the formation of a turn, as known from beta hairpin formation [135].   
• Reaction 4: Above room temperature, fibril elongation is kinetically and 
thermodynamically favored over monomeric species. Enthalpy measurement by ITC 
implies that the exclusion of hydrophobic residues from the aquatic environment is a 
driving factor. Elongation is presumably additionally driven by the entropically 
favorable exclusion of water [82], as a dry interface was shown by X-ray diffraction and 
Gibbs’ free energy of Oxyntomodulin fibrils cannot be exclusively explained by the 
measured enthalpic contribution. Elongation is accelerated and thermodynamically more 
favorable in presence of salts, indicating that electrostatic repulsion is a limiting factor 
in self-assembly. Partial loss of charges like for Oxyntomodulin’s sister peptide 
Glucagon is a possible further driving factor for self-assembly.  
• Reaction 5: Strongly exothermic fibril association has been reported to be preferred at 
increased temperatures and may contribute to the strongly exothermic fibrillation 
reaction at 32 °C. Enthalpy loss by close association can be accompanied by entropy 
loss due to release of surface-bound water molecules. Looser packing can however 
increase the system’s entropy by immobilization of water molecules.  
• Reaction 6: After saturation of enthalpically favorable interactions, the entropic cost of 
temperature increase cannot be counteracted by enthalpy loss. The peptide release 
reaction is then favored, as shown by ThT and bulk dissociation studies.  
• Reactions 7 and 8: Folding is thermally prevented at high temperatures, slowing the 
elongation reaction. As the dissociation reaction is faster at increased temperatures, a net 
dissociation of fibrils is observed.  
• Reaction 9: Enhanced incubation at semi-stable conditions enables access to alternative 
minima of the thermodynamic landscape in form of polymorphism. The observed 
twisted Oxyntomodulin fibrils will be characterized in the following chapter.  
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6 An alternative Oxyntomodulin fibril structure 
In chapter 3.4, it was observed that low seed- and peptide concentration can favor the 
formation of morphologically different fibrils with a twisted appearance at long incubation 
times. This species was not seen at high (10 mg mL-1) peptide concentration both in presence 
or absence of seeds. Twisted fibrils were also observed in chapter 5.5 after extended fibril 
incubation in ThT- and bulk elongation assays and in a release assay in water. This was seen 
after several days of incubation in water or 0.9 mg mL-1 saline at 37 and 42 °C, but not at or 
below 32 °C. The appearance of twisted fibrils in addition to originally straight fibrils also 
shifted the equilibrium to the assembled side. It was suspected that conditions with generally 
slow kinetics, or extended incubation with low seed amounts allow the formation of an 
alternative fibril species by secondary nucleation in bulk or on the surface of fibrils. 
Formation of the twisted species may be kinetically suppressed in conditions with fast 
elongation rates of the straight fibril type, but twisted fibrils may represent a generally more 
thermodynamically stable structure. In this chapter, the following questions shall be 
addressed: 
• Under which conditions can the twisted type be produced for analysis?  
• Is the fibril type more stable towards disaggregation than the straight type?     
• Is the fibril type structurally different from the straight type? 
To test the influence of seed concentration on (straight) Oxyntomodulin fibril elongation and 
formation of polymorphic species, elongation was studied in presence of different seed 
amounts. Triplicates of 0.5 mg mL-1 Oxyntomodulin samples were incubated in 
polypropylene centrifugation tubes with 0.5, 1.0 and 5.0 % fibril seeds for 7 d. This was 
performed at 37 °C, in quiescent conditions or with agitation at 300 rpm and 1.9 cm orbit. 
Analogous samples were incubated at 25 °C as a positive control for the growth competence 
of seeds. Fibril morphology was assessed by AFM imaging after 7 d, and conversion yield 
was measured from the peptide concentration in the 50 kDa MWCO filtered supernatant of 
sedimented samples. 
At 25 °C and at 37 °C with shaking, the conversion yield was approximately 97 % after 7 d, 
and no twisted fibrils were seen in AFM images irrespective of the seed concentration (see 
Figure 7-1). At 37 °C, conversion yield was approximately 60 % for 0.5 and 1 % seeding, 
and 81 % for 5 % seeding. Polymorphism was observed at 37 °C in quiescent conditions. 
Twisted fibrils were the predominant species at lower seeding strengths and appeared 
scattered at 5 % seeding. Similar behavior was observed in a three-day ThT elongation assay 
at different seed strengths.  
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Figure 6-1: Alternative Oxyntomodulin fibril formation is preferred at slow elongation 
conditions 
(details see next page) 
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To analyze the structure of twisted fibrils, parameters for exclusive growth of the twisted 
species had to be found. Despite extensive screening, no condition without co-occurrence of 
the straight species was found. Therefore, the twisted type was selected for by repetitive 
seeding: A first generation of fibrils was grown from seeding 0.5 or 1 mg mL-1 
Oxyntomodulin aliquots with 0.5 or 1 % seeds derived from 15 min sonication of (straight) 
mature Oxyntomodulin fibrils. The sample containing the highest prevalence of twisted 
species after two weeks was a 1 mg mL-1 aliquot with 0.5 % seeds. This sample was used to 
seed freshly prepared Oxyntomodulin solutions at the same conditions. After two further 
analogous rounds of seeding, elongation and selection, more than 80 % twisted fibrils were 
found by AFM imaging in one sample (see Figure 7-2). The conversion yield was 50 %. 
Fibrils could not be separated from soluble peptide because pellets after centrifugation did not 
resuspend readily. The third-generation sample was used for Cryo electron microscopy, FTIR, 
CD, ThT and Tryptophan fluorescence, and for seeding further generations. After three more 
generations, a similar sample was chosen for a release experiment in salt-free conditions. 
Generally, high contents of twisted fibrils were not found reproducibly. Even after six 
generations, most seeded samples contained predominantly straight fibrils, and only single 
samples inherited the twisted morphology. Mixed fibril samples did not convert to either type 
of fibrils within several months of incubation.  
As shown in Figure 7-2, twisted species adopted at least two morphologies. One type was 
tightly twisted with inter-twist differences (pitch) of approximately 55 nm and height 
differences of ~1.2 nm along the fibril length. The other type had a wider twist with 
approximately 80 nm pitch and ~2.5 nm height difference.   
Twisted fibrils were analyzed by CD, FTIR, ThT- and Tryptophan fluorescence analogous to 
mature fibrils and protofibrils. Results are summarized in Figure 7-3. As raw spectra were an 
overlay of 50 % fibrils and 50 % nonfibrillar peptide in the samples, background-corrected 
spectra corresponding to half the total peptide concentration were deducted from background-
corrected raw spectra of twisted fibrils. Resulting spectra were doubled before analysis to 
reflect the same fibril amount as free peptide and protofibrils. Error bars therefore contain 
uncertainty of fibril- and free peptide measurement. Potential differences in the signals of 
(continued from Figure 6-1) Oxyntomodulin seed elongation at different conditions with 
increasing seeding strength. Seeds were derived from 15 min sonication of a mature 
Oxyntomodulin fibril stock. A, conversion yields of 0.5 mg mL-1 initial soluble 
Oxyntomodulin in 0.9 mg mL-1 saline after 7 d incubation with seeds at 25 °C, 37 °C, and 
37 °C with 200 rpm shaking. Dotted, 0.5 % seeding strength; striped, 1% seeding strength; 
solid, 5 % seeding strength. B-J, Representative AFM images after 7 d incubation. B-D, 
25 °C; E-G, 37 °C, H-J, 37 °C 200 rpm. B, E, H, 0.5 % seeding; D, F, I, 1 % seeding; C, G, J, 
5 % seeding. Blue arrows, twisted fibrils. AFM images were processed in Gwyddion to 
remove imaging scars and background signal. Resolution: 1024*1024 pixel at 2*2 µm 
scanning size. 
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freshly dissolved peptide and soluble peptide in twisted fibril samples (e.g. oligomerization) 
could not be reflected due to limitations in fibril amounts. Therefore, results presented here 
can only be seen as an estimation of fibril structure.  
Structural determination by ThT- and Tryptophan fluorescence revealed an amyloid-specific 
ThT fluorescence increase and Tryptophan fluorescence blue shift comparable to mature 
Oxyntomodulin fibrils. Decreased blue-shift and signal broadening in Tryptophan 
fluorescence implies a higher degree of polymorphism in the twisted fibril sample. 
Quantification of secondary structure elements by CD does not reveal a significant difference 
of straight and twisted fibrils. FTIR signals were generally higher for twisted fibrils, but the 
peak locations were not distinguishable from signals of mature Oxyntomodulin fibrils.  
Figure 6-2: AFM images of Oxyntomodulin fibrils after repeated seeding and 
selection for twisted species 
Fibrils after 3 generations of seeding 1 mg mL-1 Oxyntomodulin in 0.9 mg mL-1 saline with 
0.5 % seeds at 37 °C and selection for the sample with the highest twisted fibril occurrence 
for further seeding. White arrows, tight twisting; red arrows, less tight twisting; green 
arrows, straight fibril type. AFM images were processed in Gwyddion to remove imaging 
scars and background signal. Resolution: 1024*1024 pixel at 4*4 µm (A) and 2*2 µm (B) 
scanning size. C, height profiles along fibrils marked in A; tightly twisted fibrils have a 
pitch of 55 nm and height difference of 1.2 nm along the fibril; less tightly twisted fibrils 
have a pitch of 80 nm and height difference of 2.5 nm along the fibril.  
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As twisted fibrils only appeared under unfavorable conditions for the elongation of straight 
fibrils, it is obvious to assume that twisted fibrils populate an alternative minimum of the free 
energy. Absence of changes in morphology over enhanced incubation periods indicate that the 
twisted species is not an on-pathway intermediate structure for formation of straight fibrils. 
The reorganization of straight fibrils to twisted fibrils after partial fibril dissolution implies 
that twisted fibrils form from – or catalyzed by – straight fibrils. Fibril species are 
consequently separated by high energy barriers that prevent rearrangement to the more 
thermodynamically stable species. It is however not known which species populates the lower 
accessible free energy minimum.  
Figure 6-3: Biophysical characterization of twisted fibrils 
Comparison of A, Circular dichroism spectroscopy; B, FTIR spectroscopy; C, ThT end-point 
fluorescence; D, intrinsic Tryptophan fluorescence of soluble peptide (open circles), 
protofibrils (light grey), mature fibrils (black) and twisted fibrils (orange). All data are 
presented as averages of triplicate measurements ± standard deviation. Data were acquired 
and analysed analogous to description in 4.1 and 4.2. Twisted fibril signals were corrected for 
50 % free peptide.  
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The dissolution and equilibrium concentration of twisted fibrils was assessed in salt-free 
conditions and at different temperatures. Before incubation, twisted fibrils were separated 
from soluble species and salt by centrifugation, and the pellet was re-dispersed in water and 
pelleted again. Fibril concentration was assessed photometrically after dissolution in 10 mM 
HCl, and aliquots were incubated in water at 0.5 mg mL-1 initial fibril concentration. Soluble 
peptide concentrations were measured after 1 h, 1 d and 7 d.  
As shown in Figure 7-4, the twisted fibrils sample generally dissolved more with increasing 
temperature, but release was substantially lower than in straight fibril samples (compared to 
Figure 6-19). Considering the presence of some straight fibrils in the twisted fibril sample, it 
is possible that the majority of released peptide stems from straight fibrils, and the 
thermodynamic equilibrium of soluble and twisted fibrils is far on the fibrillar side. This is 
not in contrast to the 50 % elongation yield measured above, as elongation may be hindered 
sterically or by formation of growth-incompetent, submicroscopic oligomers.  
Twisted fibrils were imaged by Cryo EM to gain insights into the structural differences to the 
straight species. Cryo EM confirmed that twisted fibril samples contained several different 
species, with a minority of straight fibrils and laminated twisted sheets and at least two types 
of helically twisted fibrils.   
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Figure 6-4: Twisted fibrils are more thermodynamically stable than straight fibrils 
Soluble peptide concentration after quiescent incubation of 0.5 mg mL-1 essentially salt-free, 
twisted Oxyntomodulin fibrils in water for 1 h (0 days), 1 and 7 days, measured by NanoDrop 
spectrophotometric absorption at 280 nm, after 30 min sedimentation of fibrils at 13 000 rpm 
and 50 kDa MWCO filtration of supernatants. Red, 6 °C; green, 25 °C; blue, 32 °C; cyan, 
37 °C; purple, 42 °C. Results are presented as averages of independent triplicates ± standard 
deviation. 
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Figure 6-5: Overview of polymorphic structures in a twisted fibril sample 
Cryo electron micrographs of the same sample as imaged by AFM in Figure 6-2. Images are 
taken on a Titan KriosTM G3i with a Falcon 3 detector with motion correction. Whole images 
were corrected for brightness and contrast in Fiji. Scale bars, 500 Å. Green arrows: there are 
few straight fibrils corresponding to the protofibrils shown in Figure 4-7. Red arrow: very 
few fibrils have several laterally aligned sub-fibrils that form a twisted sheet. White arrows: 
obviously helically twisted fibril type with two sub-fibrils (type 1). Blue arrows, seemingly 
parallelly twisting pairs of fibrils (type 2). Note that fragmented fibrils in image C maintain 
the twist, that the distance between fibril ends and cross-over points is random, and that fibrils 
do not contain overhanging fibril ends.  
 
 
 
 
 An alternative Oxyntomodulin fibril structure  114 
 
The few straight fibrils were indistinguishable from protofibrils described in chapter 4.4, and 
the very rarely occurring twisted sheet type correspond to laterally aligned protofibrils that 
occasionally occurred in protofibril and mature fibril samples. Both twisted types were 
approximately equally populated. The formation of twisted sheets implies that the alignment 
of individual peptides differs from the triangular alignment in protofibrils and fibrils, however 
a potential parallel alignment could not be formally proved. All fibril types had a 4.6-4.7 Å 
diffraction pattern. In some cases, the inter-strand spacing was directly visible from magnified 
images.  
The twisted fibril type with the longer pitch-to-pitch distance was called type A, and the type 
with the shorter distance type B. For comparison, both are shown in Figure 7-6. Type A had 
an obviously helical morphology with two thin sheets twisting around a common axis. Type B 
intuitively appeared as two thin sheets twisting next to each other but around separate axes. 
This will be discussed later. Measurement of critical distances in 150 type A and B fibrils 
revealed a clear difference in distances between the thin areas of high electron density. The 
distance was 794±74 Å in type A (n=94), and 664±57 Å in type B (n=56). The widths at the 
same locations differed with 50±7 and 80±12 Å for type A and B, respectively. Between the 
high-density areas, widths were indistinguishable with 124±13 and 126±8 Å, respectively. 
Fibril ends were randomly located in respect to high density areas. In none of over 180 
images, fibrils with overhanging ends of more than a few nanometers were found. As shown 
in Figure 7-5 C and Figure 7-6 B, the twists were conserved in short fragments of fibrils.   
Figure 6-6: Comparison of the two predominant fibril types in twisted fibril samples 
Cryo electron micrographs of the same sample as imaged by AFM in Figure 6-2. Images are 
taken on a Titan KriosTM G3i with a Falcon 3 detector with motion correction. Whole images 
were corrected for brightness and contrast in Fiji. Scale bars, 500 Å. White, type 1 fibrils; 
blue, type 2 fibrils. Note the different widths and distances between high density areas of type 
1 and 2 fibrils.  
A B 
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Closer examination of the density patterns in type A fibrils revealed that the most consistent 
structural model is a double helix consisting of two sheets that are approximately two 
protofibril distances (or two half peptide lengths) wide. As shown in Figure 7-7 A-D, a fibril 
structure could be reconstructed from electron dense areas indicating sheet edges, cross-over 
points and side views of sheets, and the striations from the 4.7 Å inter-strand spaces. In the 
double helical model, two sheets face each other and twist around a common axis. The 
electron dense, narrower “pitches” alternated slightly in their appearance and in the grey scale 
A 
B 
C 
D 
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Figure 6-7: Tentative structure of type A twisted fibrils reconstructed from Cryo EM 
Cryo electron micrographs of the same sample as imaged by AFM in Figure 6-2. Images are 
taken on a Titan KriosTM G3i with a Falcon 3 detector with motion correction. Whole images 
were corrected for brightness and contrast in Fiji. Visualization of patterns performed in 
Microsoft Paint. A, Cryo EM image of a type 1 fibril, image height 160 Å; B, highlighting of 
areas of high electron density that imply sheet edges, sheet overlaps, and sheet side-views; C, 
highlighting of the visible 4.7 Å striation pattern; D, double helical fibril model with inner 
sheet faces drawn in red and dark blue, outer sheet faces drawn in orange and light blue. E, F: 
Similar reconstruction in a fibril without visible diffraction pattern and a morphology more 
similar to type 2. There is less certainty in the dimensions of the sheets due to an offset of 
pitches in opposing sheets.   
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in the electron lucent space between the highest densities. This further implies a double 
helical twist where one high density area corresponds to the crossing-over of sheets, and the 
next high-density area shows sheets sideways separated by an electron lucent area. The 
“pitches” then correspond to a 90 ° turn of the fibril. A similar structure was reported in [176]. 
As shown in Figure 7-7 E and F, classification is not unambiguous. The fibril highlighted 
clearly has a double helical structure, but sheets are more separated than in the fibril shown 
above. This indicates that several alignments are possible.  
A double helical structure contradicts the height patterns observed in AFM. According to 
AFM, every ~800 Å spaced “pitch” corresponds to a 180 ° turn due to height differences, and 
the only structure consistent with this pitch would be a double-pleated sheet twisting around 
its centre. An aligned double-pleated sheet would explain strong diffraction patterns in some 
type 1 fibrils due to reinforcement by several peptide layers. However, the density patterns in 
Cryo EM images are not consistent with this structure: there are theoretically dense areas 
missing in Cryo EM images if a double-pleated sheet is assumed, and additional dense 
structures seen that are not explained by a double-pleated sheet. As only type 1 “pitch” 
matches in Cryo EM and AFM, and the type 2 pitch is different, it is probable that the 
observed pitch differs in flash-frozen and dried samples. The Cryo EM images taken here 
were not numerous enough to enable computational helical reconstruction of the different 
fibril classes. 
Type B fibrils intuitively seem to twist parallel to each other and interact in a side-by-side 
manner. While this structure is the visually most obvious possibility, no physicochemical 
explanation for this behaviour could be found. If there were an attractive force leading to the 
side-by-side alignment of twisted fibrils, there would be occasional fibril splitting and 
merging visible in the case of a weak interaction, and raft-like alignments of more than two 
(proto)fibrils in the case of a strong interaction. No such structures were seen in 180 images 
with approximately 10 type B fibrils per image. Moreover, the absence of overhanging fibril 
ends strongly implies that elongation occurs parallel or alternating on each sheet, but not 
independent from each other as in a fibril with longer-range interactions to another fibril. 
Therefore, a fibril as sketched in Figure 7-8 B lacks a physical explanation. A densely twisted 
structure as shown in Figure 7-8 C is more consistent with pitches seen by AFM, but not 
consistent with the density patterns seen in Cryo EM. Moreover, such a structure would 
require a more tilted angle of cross-beta patterns that was not observed in images. From 
density patterns and dimensions of spaces between the denser areas, it is probable that type B 
also represents a double helical structure. Where and how exactly sheets cross over each other 
cannot be reconstructed from transmission Cryo EM images, as depicted in Figure 7-8 C-E. 
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In summary, there is evidence that twisted Oxyntomodulin fibril species represent an 
alternative thermodynamic minimum to the straight fibril species. Due to the comparably 
slow nucleation and elongation of twisted species but high stability under diluted conditions, 
it is probable that the twisted species represents a deeper minimum on the thermodynamic 
landscape. The fast-forming straight species is presumably a metastable kinetic trap with a 
high thermodynamic barrier to formation of the more stable, twisted species. A comparably 
low stability of straight fibrils also explains the reversibility of straight species upon dilution 
or incubation at physiological conditions. Twisted fibrils only form in conditions that 
destabilize straight species and cause co-incubation of peptide and fibrils for several days. It 
is not sure if such conditions could occur in vivo. Subcutaneously applied concentrations of 
straight fibrils are several times higher than the concentrations where twisted fibrils occur, 
and released peptide is likely to be removed from the fibril depot by the flow of interstitial 
fluid. However, straight fibrils have been found to be destabilized by phosphates and at 
A B C D E F 
Figure 6-8: Tentative structure of a type 2 twisted fibril by Cryo EM 
Cryo electron micrographs of the same sample as imaged by AFM in Figure 6-2. Images are 
taken on a Titan KriosTM G3i with a Falcon 3 detector with motion correction. Whole images 
were corrected for brightness and contrast in Fiji. Visualization of patterns performed in 
Microsoft Paint; lighter areas face the observer; darker areas face the inside of a fibril. A, Cryo 
EM image of a type 2 fibril; B, visually tentative but not physicochemically explicable side-
by-side alignment of twisted sheets; C, double helical model with every electron dense area 
corresponding to a side view of sheets. This model is not consistent with observed electron 
density patterns. D, E, F: double helical structures consistent with all features seen by Cryo 
EM. Handedness (D, E) and the location of cross-over (F) are not distinguishable.  
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physiological temperatures, and it is not sure how fast released peptide is removed from the 
fibrils in vivo. Because formation of insoluble species in vivo is not desired for 
pharmacokinetics, and can potentially cause toxic or immunogenic side-effects, the long-term 
morphology of fibrils should be tested in vivo or in a biomimetic perfusion model. 
Interestingly, glucagon shows a very similar condition-dependent polymorphism. A twisted 
morphology was reported at low peptide concentrations and could only be inherited in 
seeding experiments at low concentrations. At high concentrations, a straight fibril type 
prevailed and was conserved in seeded daughter generations [94][111]. 
Evidence of twisted sheets in twisted Oxyntomodulin fibrils further implies that the peptide 
alignment in twisted fibrils is markedly different to straight fibrils. As no difference in 
fluorescence or spectroscopic measurements was seen, the different morphology and stability 
is most certainly caused by the alignment of peptide monomers to each other, rather than the 
conformation of monomers. Possibly, but admittedly speculative, monomers in twisted sheets 
are aligned parallel to each other rather than in a triangular shape. Surface catalysis of 
twisted-type nucleation is consistent with the frequent observation of twisted fibril nucleation 
in presence of straight fibrils, as sketched in Figure 6-22. Results from Cryo EM strongly 
indicate an overall double helical morphology of fibrils, but the exact alignment of sheets and 
monomers within sheets could not be determined from the Cryo EM data. According to FEI 
technicians, high-resolution helical reconstruction of both identified helical fibril classes may 
be possible with a substantially higher number of images and fibril type classification 
according to pitch-to-pitch distances. 
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7 Cross-seeding of Oxyntomodulin and -fibrils  
One concern for the in vivo use of Oxyntomodulin fibrils was if they can serve as a template 
for fibril formation by other peptides. Subcutaneous tissue is deprived of peptides and 
proteins, and fibril interaction with cells is limited to cell membrane molecules or – in the 
case of occasional cellular fibril fragment uptake – sequestered inside phagosomes and thus 
separated from the intracellular environment. However, it is possible that fibrils reach the 
bloodstream after an injury. Due to glucagon’s sequence similarity to Oxyntomodulin, 
prevalence in the bloodstream, and known ability to form fibrils in a range of conditions, it 
was important to test if glucagon can be seeded by Oxyntomodulin fibrils.  
QCM-D fibril elongation assays were performed with Oxyntomodulin fibril seeds on the 
sensor surface and Glucagon in the peptide stream. Glucagon was dissolved at an approximate 
concentration of 10 mg mL-1 in 10 mM HCl, filtered with a 0.22 µm centrifuge filter to 
remove potential aggregates, and pH-neutralized with 10 mM NaOH. The concentration was 
measured photometrically by NanoDrop with a theoretical 1 % extinction coefficient of 
glucagon, as computed using the online ProtParam tool of Expasy. Glucagon was then diluted 
to 0.5 mg mL-1 in 0.9 mg mL-1 saline and used within one hour to prevent spontaneous 
aggregation in bulk.  
QCM-D sensors with or without Oxyntomodulin fibril seeds were prepared and thermally 
equilibrated as described in 5.1.2. Glucagon was flown over an empty chip as a negative 
control, and Oxyntomodulin was flown over Oxyntomodulin seeds as a positive control. 
Glucagon was incubated with Oxyntomodulin seeds to test the cross-seeding ability of 
Oxyntomodulin fibrils.  
Glucagon’s adsorption to an empty sensor was slower than for Oxyntomodulin. As described 
in chapter 5.2, Oxyntomodulin adsorption was complete after two minutes before a constant 
frequency slope of -0.11 Hz min-1 was reached. Glucagon adsorption went on for three more 
minutes before adopting a comparable approximately linear frequency change with a slope of 
-0.10 Hz min-1. On sensors with Oxyntomodulin fibrils and soluble Glucagon, even less 
overall frequency change was measured, indicating that glucagon does not or only minorly 
bind to fibrils, but to the sensor surface between fibrils. No fibril elongation was seen by 
AFM after cross-seeding of Oxyntomodulin fibrils with glucagon. Results are shown in 
Figure 8-1. If Oxyntomodulin was flushed over QCM-D chips after incubation of 
Oxyntomodulin fibrils with glucagon, approximately half of the frequency change and 
elongation than without previous glucagon application was found compared to direct 
application of Oxyntomodulin on Oxyntomodulin fibrils. Therefore, the peptide layer formed 
by glucagon reduced the growth competence of Oxyntomodulin fibrils (results not shown).   
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Figure 7-1: Oxyntomodulin fibrils do not elongate in presence of Glucagon 
QCM-D fibril elongation assay with Oxyntomodulin seeds in presence of Oxyntomodulin and 
Glucagon. Both hormones were applied at 0.5 mg mL-1 at pH 6.5 in 0.9 mg mL-1 saline and at 
37 °C. A, QCM-D frequency shifts from 2-18 min after start of peptide flushing; green, 
Oxyntomodulin fibril seeds incubated with Oxyntomodulin (positive control); navy and royal 
blue, glucagon incubated with Oxyntomodulin seeds; red, glucagon incubated with a fibril-
free sensor (negative control). B, sensor with Oxyntomodulin fibril seeds before incubation; 
C, positive control after experiment; D, sensor after Oxyntomodulin fibril incubation with 
glucagon; E, negative control after experiment. AFM images were processed in Gwyddion to 
remove imaging scars and background signal. Resolution: 1024*1024 pixel at 4*4 µm size. 
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Self-assembly of the Oxyntomodulin analogue Aib-2-Oxyntomodulin was investigated by 
postdoctoral researcher Myriam Ouberaï parallel to the Oxyntomodulin fibril project 
described in this thesis. Aib-2-Oxyntomodulin has reduced affinity to GCGR and enhanced 
affinity to GLP-1R compared to human Oxyntomodulin, making it a potential drug candidate 
with higher expected activity in blood sugar regulation, but less activity in regulation of 
appetite and energy expenditure. Due to substitution of serine in position 2 with the non-
coding amino acid aminoisobutyric acid (Aib), Aib-2-Oxyntomodulin is not degraded by the 
enzyme DPP4 in the bloodstream. Aib-2-Oxyntomodulin was found to self-assemble in 
similar conditions as Oxyntomodulin, however fibrillation was generally slower and fibrils 
dissolved more readily. Fibrils were formed using the three-step method described in 3.4, with 
a 1.8 mg mL-1 saline instead of a 0.9 mg mL-1 in salt-containing conditions, and an incubation 
temperature of 25 °C instead of 37 °C. Fibrils were provided by Myriam Ouberaï.  
Sonicated Oxyntomodulin- and Aib-2-Oxyntomodulin fibril seeds were adsorbed on SiO2 
QCM-D sensors and thermally equilibrated as described in chapter 5.1.2. Oxyntomodulin or 
Aib-2-Oxyntomodulin in 0.9 mg mL-1 saline were flown over the sensor surface. All 
experiments were carried out at 25 °C at a flow rate of 0.1 mg mL-1. Incubation of 
Oxyntomodulin fibril seeds with 0.5 mg mL-1 Oxyntomodulin caused a frequency slope 
of -1.19 Hz min-1. Equivalent conditions with Aib-2-Oxyntomodulin and Aib-2-
Oxyntomodulin fibril seeds did not cause a frequency decrease distinguishable from the slope 
of peptide adsorption to an empty sensor. Upon increase of the soluble peptide concentration 
to 2 mg mL-1, a frequency slope of -1.09 Hz min-1 indicated moderate elongation, and 
elongation was visible by AFM imaging. Oxyntomodulin fibril elongation at 2 mg mL-1 
caused frequency shifts as high as -4.97 Hz min-1 and drastic elongation visible by AFM 
imaging.  
AFM furthermore showed that sonicated Aib-2-Oxyntomodulin fibril seeds were more 
numerous than Oxyntomodulin fibril seeds on QCM-D sensors. Therefore, the measured four- 
to five-fold difference in elongation rate is an overestimation of Aib-2-Oxyntomodulin fibril 
seeds elongation rate.  
Figure 8-2 shows triplicate measurements of fibril incubation with the respective peptide at 
2 mg mL-1 peptide concentration. Figure 8-2 B demonstrates incubation of Oxyntomodulin 
fibrils with 0.5 mg mL-1 for comparison; a control experiment for peptide adsorption on an 
empty sensor; incubation of Aib-2-Oxyntomodulin fibril seeds in a stream of 0.9 mg mL-1 
saline; and cross-seeding of Aib-2-Oxyntomodulin fibril seeds with 0.5 mg mL-1 soluble 
Oxyntomodulin. Cross-seeding caused only marginally higher frequency shifts than control 
experiments, and no elongation was measured by AFM imaging. While minor cross-seeding 
is possible, it is probable that the increased surface area on seed-containing QCM-D sensors 
caused slightly higher peptide adsorption and/or water immobilization during adsorption.  
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Figure 7-2: Aib-2-Oxyntomodulin fibril elongation is slower than Oxyntomodulin fibril 
elongation and does not cross-seed Oxyntomodulin 
QCM-D fibril elongation assay with Oxyntomodulin fibril seeds and Aib-2-Oxyntomodulin 
fibril seeds, in 0.9 mg mL-1 saline at 25 °C. A, elongation of: blue, Aib-2-Oxyntomodulin 
fibrils; red, Oxyntomodulin fibrils with 2 mg mL-1 Aib-2-Oxyntomodulin or Oxyntomodulin, 
respectively. Shown is the average frequency slope ± standard deviation of three experiments 
(grey), R2>0.99. B, frequency shifts of control experiments: black, Aib-2-Oxyntomodulin 
fibrils incubated with 0.9 % NaCl; green, empty SiO2 sensor incubated with 0.5 mg mL
-1 
Oxyntomodulin at 25 °C; purple, Aib-2-Oxyntomodulin fibrils incubated with 0.5 mg mL-1 
Oxyntomodulin; red, Oxyntomodulin fibrils incubated with 0.5 mg mL-1 Oxyntomodulin. C, 
Aib-2-Oxyntomodulin fibrils before and D, after incubation with 2 mg mL-1 of Aib-2-
Oxyntomodulin. E, Oxyntomodulin fibrils before and F, after incubation with 2 mg mL-1 
Oxyntomodulin. AFM images were processed in Gwyddion to remove imaging scars and 
background signal. Resolution: 1024*1024 pixel at 4*4 µm size. 
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Although the results presented here only show seeding in the context of fibril elongation, and 
cross-seeding was only tested with two similar peptides, the absence of measured elongation 
in both setups is a strong indication for the specificity of fibril elongation for one sequence. 
As glucagon is known to be prone to fibril formation and is part of the Oxyntomodulin 
primary sequence, fibril elongation by glucagon was indeed expected before the experiments. 
Similarly, the discrete modification in Oxyntomodulin’s and Aib-2-Oxyntomodulin sequence 
brought about different kinetics and prevented Aib-2-Oxyntomodulin from cross-seeding 
Oxyntomodulin. As these peptide analogues cannot be cross-seeded by Oxyntomodulin 
fibrils, or cross-seed Oxyntomodulin, it is unlikely – but not excluded – that less related 
peptides are able to elongate Oxyntomodulin fibrils.   
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8 Future work 
This work was designed to provide proof of concept for the use of self-assembled, amyloid-
like peptides as a self-delivery system for enhanced exposure with pharmaceutical peptides 
released from a subcutaneous depot. Oxyntomodulin was chosen as a model peptide because 
of the potential use in T2DM and obesity, short plasma half-life, and the sensitivity of the 
mechanism of action towards structural changes that would allow a longer plasma half-life.   
Oxyntomodulin readily formed self-assembled, fibrillar structures in a range of conditions. 
Presence of sodium chloride and agitation promoted nucleation, while nucleation in absence 
of salts only occurred after weeks of incubation of concentrated peptide solutions. However, 
only short fibrils grew in conditions with fast nucleation. Formation of long fibrils with high 
conversion yield was achieved by nucleation in presence of sodium chloride, fibril elongation 
in salt-deprived conditions, and subsequent addition of sodium chloride. This method allowed 
reproducible formation of indistinguishable fibril batches within two weeks. It is 
acknowledged that a one-step fibrillation method would be favorable regarding time and 
scalability.  
While it cannot be excluded that there are conditions for a single-step formation of fibrils that 
meet requirements for production time, quality and quantity, previous results suggest that 
effective nucleation and elongation require different environments. It is however suspected 
that initial seed formation and elongation conditions can be optimized to allow a two-step 
method. Considering results from this work, sensible optimization parameters include pH, salt 
concentration, seed concentration and temperature. pH optimization could allow reduced 
concentration of salt by neutralization of side chains, which potentially accelerates nucleation 
and elongation while reducing lateral association. Sodium chloride was found to allow 
efficient nucleation and stabilize the formulation, but the range of concentration is limited by 
unspecific aggregation and clumping at higher saline concentrations, and slow kinetics at low 
concentrations. As other salts were not found to induce fibrillation but stabilize partially 
dissolved fibrils, seeding into solutions containing different salts could allow efficient 
elongation without further nucleation. Increasing seed number concentration was found to 
generally accelerate fibrillation and decrease risk of polymorphism. A simple way to achieve 
faster conversion into fibrils would therefore be extended seed sonication or application of 
higher seed mass concentrations. De novo fibrillation was almost exclusively screened at 
37 °C because increased temperature was initially expected to accelerate fibrillation. 
However, results from chapters 5 and 6 prove a fibrillation temperature optimum at ~25 °C 
that prevented polymorphism in otherwise destabilizing conditions like low peptide-, salt- and 
seed concentrations. Elongation at 25 °C could therefore not only accelerate fibrillation but 
also increase the robustness of the fibrillation process.   
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Presence of a narrow thermal optimum of fibril elongation kinetics below body temperature 
was shown by kinetic elongation assays in bulk, QCM-D, ITC elongation and ThT. These 
methods comprise orthogonal measurement typed with different microenvironments, sample 
sizes and agitation. A similarly low temperature optimum of fibrillation has so far not been 
reported in the literature.  Stabilization of fibrils and native α-helical soluble peptide was 
inversely correlated with temperature increase. It is assumed that the unique temperature 
optimum of Oxyntomodulin fibril elongation is a result of several temperature-dependent 
stabilizing and destabilizing factors. 
The found thermal effects have implications on the handling of peptide- and fibril samples 
and possible effects in vivo. Temperatures at or below room temperature are beneficial for 
storage of fibrillar samples, while physiological temperatures are presumably a driving factor 
for peptide release from the s.c. fibril depot. These effects are desired, however it needs to be 
investigated how sensitive fibrils are to repeated changes in temperature. For example, s.c. 
temperatures depend on ambient temperature, contact with hot or cold objects, and alterations 
in core body temperature such as thermal changes during female menstrual cycle, 
hypothermia or fever. The repeated temperature shifts experienced in vivo could be mimicked 
in a thermocycler or in a kinetic ThT assay, and thermal effects on morphology and peptide 
release can be measured by taking aliquots at critical time points. Changes in secondary 
structure of fibril samples could be quantified CD spectroscopy as a function of temperature 
changes. In addition to elongation studies, ITC could be used to gain insights to fibril 
dissolution at different temperatures by dilution of mature fibril sample with peptide-free 
medium in the measurement cell. Similarly, differential scanning calorimetry (DSC) could 
provide valuable information on the melting temperature of fibril samples. Because of the 
high sensitivity of ITC and DSC, it may be possible to study effects of different solution 
conditions in addition to thermal effects.  
Three fibril types were found and characterized in this work. The mature fibril type formed in 
presence of sodium chloride is with high certainty a lateral alignment of the protofibril fibril 
type in water. This hypothesis is justified by the very similar fibrillation conditions, 
dimensions by AFM and Cryo EM, dissociation of mature fibrils into fibrils with protofibril 
morphology in water, and very similar FTIR and CD spectroscopic results. The most obvious 
differences of mature fibrils compared to protofibrils are the enhanced binding of ThT, drastic 
reduction of free peptide concentration and lateral association of individual fibrils. By 
combination of fluorescence, spectroscopy, imaging and limited peptidolysis, a potential 
coarse-grain structure could be suggested. It needs to be stressed that the proposed alignment 
of arch-shaped peptides in a triangular cross-section was partially derived from single 
methods and exclusion of possibilities that would contradict measured parameters. A definite 
structure will require further work.  
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While 3D reconstruction of straight fibril types by Cryo EM is not possible due to the absence 
of a clear twist, more information on spacings within the fibril could be derived from 
additional diffraction data by Cryo EM or fibril X-Ray diffraction with synchrotron radiation. 
It was concluded from enzymatic degradation studies with trypsin that the fibril structure does 
not contain long sequences of unstructured peptide. Because trypsin only cleaves after Lysine, 
Arginine and Cysteine and requires several amino acids surrounding the cleavage position, a 
potentially unstructured region can still exist in Oxyntomodulin fibrils. Similar studies with 
other enzymes could provide further information. Especially, cleavage by the human enzyme 
DPP-4 could determine the protection or location of the N-terminus within fibrils. Enzymatic 
degradation could be analyzed on-line with an LC-MS peptide mapping approach in order to 
assign peaks to peptide fragment masses.  
Twisted fibrils formed under different conditions as straight fibril types, displayed a different 
morphology and showed higher stability upon dilution. Stability was only assessed by bulk 
release in water and should be confirmed with other methods such as a kinetic ThT assay to 
solidify the assumption of a quasi-irreversible fibril type. Because an alternative fibril type is 
not desired for in vivo use, the conditions under which the twisted type forms and potentially 
dissolved should be closely examined. Due to the regular structure, determination of a high-
resolution 3D structure will be attempted by Cryo EM. Fibrils will be sorted into classes 
dependent on the pitch-to-pitch distance, and fibrils in these classes will be computationally 
devided into single particles and realigned with single particle reconstitution software. 
Preparation for further Cryo EM experiments is currently ongoing, and fibril structure 
determination will be a central part of a recently started research project at the Nanoscience 
Centre, University of Cambridge.   
Proof of fibril reversibility has been given in vitro and in vivo. Upon incubation with peptide-
free medium in presence or absence of salts, fibrils released active peptide [6]. However, it is 
not yet understood if fibrils dissolve completely in a stream of peptide-free medium, 
especially in presence of salts such as in s.c. fluid. A possible setup could be incubation of 
fibrils separated from surrounding medium by a dialysis membrane, with frequent 
replacement of the medium outside of the fibril depot and concentration measurement in the 
medium. Because the presence of salts decreases released concentrations below the detection 
limit of photometry, a concentrating step or a more sensitive quantification method would be 
required. This could be achieved by peptide concentration in e.g. ion exchange 
chromatography followed by photometric measurement, by mass spectroscopy, or ideally by 
receptor activation quantification as described in [6]. Subcutaneous fluid could be mimicked 
by physiological salt composition in a CO2 incubator.  
Significantly increased Oxyntomodulin concentrations were found in the bloodstream of  
rodents after up to 5 d after s.c. injection of Oxyntomodulin fibrils [6]. Extended in vivo 
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studies will be required to assess the maximum time of Oxyntomodulin release from a s.c. 
fibril depot. Although no acute cytotoxicity was found, potential local tissue alterations or 
immunologic responses should be assessed in vivo. As receptors will be chronically 
challenged with unphysiological concentrations of an endogenous peptide, food uptake 
studies and glycemic control studies should be performed after repeated dosing of 
Oxyntomodulin fibrils to investigate potential habituation effects. Ideally, pharmacologic 
effects should be tested in a rodent model of T2DM and obesity.  
Due to the general propensity of peptides and proteins to form amyloid-like fibrils, concepts 
and methods shown in this study could potentially be applied to other pharmaceutically active 
substances. Initial data on fibrillation and in vivo effects of the fibrillated DPP-4 resistant 
Oxyntomodulin analogue Aib-2-Oxyntomodulin are currently being published. It needs to be 
investigated if Aib-2-Oxyntomodulin shows similar thermal behavior and polymorphic 
alternative fibrils as Oxyntomodulin. Finally, reversible fibrillation can be investigated as a 
formulation strategy for other molecules such as lipidated GLP-1 analogues, structurally 
unrelated peptides, and therapeutically active proteins.    
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9 Appendix 
9.1 Pre-screening of self-assembly conditions with Oxm2-37 
For reasons of peptide availability, ThT screening for nucleation conditions was mainly 
performed with Oxm2-37. Some of the results are shown here, as the most promising 
conditions were then tested with (native) Oxyntomodulin. The lag time of the ThT-positive 
conditions was not consistent, and in some positive conditions, not all wells showed increased 
ThT fluorescence. Therefore, the screening could only be used for detection of amyloid 
formation conditions, but not for kinetic analysis.  
An initial screening comprised Oxm2-37 concentrations ranging from 0.1 to 5.0 mg mL
-1 in 
water and in 25 mM phosphate buffer pH 7.4. At fixed peptide concentration of 0.5 mg mL-1, 
ThT fluorescence was measured in PBS, 50/100/150 mM NaCl, and 25 mM buffers 
pH 2/5/6.5/8. This screening was performed at the maximum agitation frequency (5 min 
shaking followed by 5 min reading) for 3 days to avoid false-negative results.  
The results are summarized in Table 9-1, and ThT raw results are shown in Figure 10-2, 
Figure 10-3 and Figure 10-4. In water and at pH 7.4, no ThT increase was detected at any 
concentration over three days. AFM images of these conditions showed a not-assembled 
peptide layer similar to the AFM images of freshly prepared peptide solutions (see Figure 
10-1 A and B). Although the concentrations used for salt- and pH-screening were 10-fold 
lower than the highest concentration in water or pH 7.4, Oxm2-37 self-assembled
 in some 
conditions. Buffering at pH 5 induced ThT increase and the formation of short fibrils with 
diameters between 10 and 20 nm. The scarce appearance of fibrils in the AFM images C and 
D of Figure 10-1 is due to detachment of fibrils during the rinsing process of AFM chips. 
Rinsing was necessary to avoid imaging mistakes and cantilever damage by salt 
crystallization on the surface. In presence of 50-100 mM NaCl, nearly all samples bound ThT. 
AFM images of these samples show large amounts of aggregate consisting of very short 
fibrils (see Figure 10-1 E). The grainy appearance could be explained by fibril fragmentation 
during the experiment. Imaging of a well at the onset of ThT signal increase (F) revealed 
long, spiraled fibrils without unstructured aggregate.  
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Table 9-1: Oxm2-37 self-assembly screening by ThT fluorescence assay  
Incubation of Oxm2-37 at 37 °C in different solvent conditions containing 50 µM of the 
amyloidophilic fluorescent dye ThT. 6 fluorescence measurements per hour (λex=440 nm, 
λem=480 nm) in bottom reading mode for 88 h. 5 min shaking at 600 rpm with 2 mm orbit 
before each measurement. Incubation of triplicates with 100 µL sample volume per well in 
low-binding polystyrene 92 well microplates (Corning® 3881). Selected conditions were 
imaged by AFM after the incubation.  
condition pH ThT binding AFM imaging 
concentration screening in water 
0.1 mg mL-1  6.6 no n.a. 
0.5 mg mL-1 6.6 no no fibrils 
1.0 mg mL-1 6.6 no n.a. 
5.0 mg mL-1 6.6 no no fibrils 
concentration screening in 25 mM phosphate buffer pH 7.4 
0.1 mg mL-1  7.4 no n.a. 
0.5 mg mL-1 7.4 no n.a. 
1.0 mg mL-1 7.3 no n.a. 
5.0 mg mL-1 7.4 no no fibrils 
pH screening in 25 mM buffers 
0.5 mg mL-1 in pH 2 HCl/NaCl 3.7 no n.a. 
0.5 mg mL-1 in pH 5 acetate 5.3 yes (2/3 wells) short fibrils + precipitate 
0.5 mg mL-1 in pH 5 citrate 5.0 yes n.a. 
0.5 mg mL-1 in pH 8 phosphate 8.1 yes (1/3 wells) precipitate 
salt screening 
0.5 mg mL-1 in PBS 7.3 no n.a. 
0.5 mg mL-1 in 50 mM NaCl 6.3 yes (2/3 wells) short fibrils + precipitate 
0.5 mg mL-1 in 100 mM NaCl 6.4 yes very short fibrils 
0.5 mg mL-1 in 150 mM NaCl 6.0 yes very short + long fibrils 
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Figure 9-1: Representative AFM images of Oxm2-37 samples after ThT screening (1) 
A, 0.5 mg mL-1 Oxm2-37 in water before incubation. B, 0.5 mg mL
-1 Oxm2-37 in water after 
incubation. C, 0.5 mg mL-1 Oxm2-37 incubated in HCl buffer pH 2; D, 0.5 mg mL
-1 Oxm2-37 
incubated in acetate buffer pH 5. E, 0.5 mg mL-1 Oxm2-37 incubated in 100 mM NaCl. F, 
0.5 mg mL-1 Oxm2-37 in 100 mM NaCl, beginning logarithmic phase of ThT kinetic curve. 
All AFM samples were produced by drying a 5 µL sample aliquot on freshly cleaved mica. 
Chips C-F were rinsed with 100 µL HPLC grade water before imaging to avoid imaging of 
salt crystals. All images were processed in Gwyddion to remove imaging scars and 
background signal. Resolution: 512x512 pixel; scanning size 4x4 µm.  
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Figure 9-2: Oxm2-37 concentration ThT screening 
Incubation of 0.1-5 mg mL-1 Oxm2-37 with 50 mM ThT in water or 25 mM phosphate buffer 
pH 7.4. Cycles of 5 min shaking and 5 min reading for 3.5 days. Black, control (50 mM ThT 
in water); coloured, triplicates of a condition. 
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Figure 9-3: Oxm2-37 ThT screening in different pH buffers 
0.5 mg mL-1 Oxm2-37 in 25 mM buffers pH 2-8. Cycles of 5 min shaking and 5 min reading at 
37 °C for 3.5 days. Black, control (50 mM ThT in water); coloured, triplicates of a condition. 
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To reduce fragmentation, the agitation frequency was decreased to 3x5 min agitation per hour 
in the following experiments. At 3x5 min agitation per hour and Oxm2-37 concentrations of 0.5 
or 1 mg mL-1 in 100 mM NaCl, no ThT signal or fibrillation was observed (results not shown) 
over 3 d. In the same conditions, 10 mg mL-1 solutions of Oxm2-37 in water or 100 mM NaCl 
induced an increase in ThT within 24 h. The fibril morphology in presence of salt was 
markedly different from incubation in water (see Figure 10-5 A-D). In water, long and 
spiraled fibrils with diameters of 5-15 nm were seen at the end of 3-day incubation in ThT 
screening conditions. In saline, the bulk of fibrils was short and clumped. Longer fibrils were 
straight and < 10 nm in height, and mostly associated to parallel bundles. An analogous setup 
with 100 mM NaCl and 10 mg mL Oxm2-37 was stopped at the beginning of ThT increase 
(5 h) and incubated for further 24 h without shaking. Fibril seeds formed after 5 h elongated 
during quiescent elongation, showing that the fibrils in NaCl are prone to fragmentation 
caused by agitation. Fibrils produced in water did not associate laterally, and almost no 
unstructured aggregate was seen at the end of 3-day incubation in ThT screening conditions.  
  
Figure 9-4: Oxm2-37 ThT screening in different salt solutions 
0.5 mg mL-1 Oxm2-37 in 50-150 mM NaCl and PBS, with 50 mM ThT. Cycles of 5 min 
shaking and 5 min reading at 37 °C for 3.5 days. Black, control (50 mM ThT in water); 
coloured, triplicates of a condition. 
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Figure 9-5: Representative AFM images of Oxm2-37 samples after ThT screening at 
increased peptide concentration and reduced agitation 
A and B, 10 mg mL-1 Oxm2-37 incubated in water. C and D, 10 mg mL
-1 Oxm2-37 incubated in 
100 mM NaCl. E, 10 mg mL-1 Oxm2-37 incubated in 100 mM NaCl until the start of ThT 
fluorescence increase (5 h). F, condition E incubated without shaking for further 24 h. All 
AFM samples were produced by drying a 5 µL sample aliquot on freshly cleaved mica. 
Samples C and D were rinsed with 100 µL HPLC grade water before imaging to avoid 
imaging of salt crystals. All images were processed in Gwyddion to remove imaging scars 
and background signal. Resolution: 512x512 pixel; scanning size: 4x4 µm (A and C); 2x2 µm 
(B; D-F).  
E F 
D 
A B 
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10 mg mL-1 Oxm2-37 solutions were further screened for self-assembly at different pH values. 
Incubation in PBS was used as a salt containing control condition. Because the initial pH 
screening at low peptide concentration indicated a preferential self-assembly in neutral pH 
conditions, the pH influence was tested in a range of pH 6.0-8.0. All solvents except PBS 
were 25 mM phosphate buffers. After concentrated Oxm2-37 stocks, the pH dropped ~0.5 units 
due to the acetate formulation of Oxm2-37. ThT fluorescence was measured for 3.5 days, 
followed by AFM imaging of aliquots. 
ThT binding was seen in all conditions (results not shown). In pH 6.0, 6.5, 7.0 and PBS, the 
half-maximum fluorescence intensity was reached within 24 h. At pH 7.4 and pH 8.0, the 
signal started to increase within the last day of incubation and did not reach a plateau phase. 
Fibrils formed in all conditions. At pH 6.0, a mixture of twisted fibrils and small unstructured 
aggregates were found. Incubation at pH 6.5 or pH 7.0 led to the formation of dense fibril 
networks. Imaging of less populated frames revealed a twisted fibril species and small 
aggregates. Individual fibrils had diameters < 10 nm and were partly associated. In pH 8, the 
same morphology was seen, however in very few numbers (see Figure 10-6). A comparison 
of fibril formation at physiologic pH (7.4) without salt and with salt (PBS) in Figure 10-7 
shows the influence of salt on fibril morphology. While the fibrils formed in the absence of 
salt were similar to the structures at neutral pH, the incubation in PBS induced the formation 
of grainy aggregate and very short fibrils.   
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Figure 9-6: Oxm2-37 after ThT screening in phosphate buffer pH 6-8 
10 mg mL-1 Oxm2-37 in 25 mM phosphate buffers. Images were taken after ThT assay in low 
binding Corning® 3881 microplates. Incubation with 50 µM ThT, 50 µL per well, triplicate, 
incubation at 37 °C with 3x5 min shaking at 600 rpm per hour for 3.5 days. A and B, pH 6.0; 
C and D, pH 6.5; E and F, pH 7.0; G and H, pH 8.0. AFM chips were rinsed with 100 µL 
water prior to imaging. All images were processed in Gwyddion to remove imaging scars and 
background signal. Resolution: 512x512 pixel; scanning size: 4x4 µm (left side) and 2x2 µm 
(right side). 
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Figure 9-7: Oxm2-37 after ThT screening in phosphate buffer pH 7.4 and PBS 
10 mg mL-1 Oxm2-37 in 25 mM phosphate buffer pH 7.4 (A-C) and in PBS (D-F). Images 
were taken after ThT assay in low binding Corning® 3881 microplates (50 µM ThT, 50 µL 
per well, triplicate, incubation at 37 °C with 3x5 min shaking at 600 rpm per hour for 3.5 
days). AFM chips were rinsed with 100 µL water prior to imaging. All images were 
processed in Gwyddion to remove imaging scars and background signal. Resolution: 
512x512 pixel; scanning size: 4x4 µm (A, B, D), 2x2 µm (C, E) and 1x1 µm (F). 
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9.2  ThT fluorescence is not well-suited to screen Oxyntomodulin 
self-assembly conditions 
The following images show false-positive and false-negative ThT fluorescence increase in 
salt-, pH- and concentration-screenings of Oxyntomodulin. For description and interpretation 
see chapter 3.2.6.  
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Figure 9-8: Representative AFM images of Oxyntomodulin ThT screening for different 
salt solutions 
Images taken after 48 h of incubation in ThT conditions. 1 mg mL-1 Oxyntomodulin in 
25 mM salts with increasing chaotropicity, with 50 mM ThT. 50 μL per well, triplicate. 
Cycles of 5 min shaking at 600 rpm and 15 min quiescent incubation at 37 °C for 5 days. A 
and B, Na2SO4; C and D, NaCl; E and F, NH4Cl. Fibrils are only seen in NaCl even though all 
conditions showed amyloid-typical ThT fluorescence increase, as shown in Figure 9-9. All 
images were processed in Gwyddion to remove imaging scars and background signal. 
Resolution: 512x512 pixel at 9*9 µm scanning size (C) and 4*4 µm scanning size (E); 
1024*1024 pixel at scanning size 2*2 µm (A, D, E) and 1x1 µm (B). 
 Appendix  139 
 
 
Figure 9-9: ThT fluorescence screening of Oxyntomodulinm self-assembly in different 
salt solutions 
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(continued from figure 10-9) 1 mg mL-1 Oxyntomodulin in 25 mM salts with increasing 
chaotropicity, with 50 mM ThT. 50 μL per well, triplicate. Some wells dried during 
incubation (not shown). Cycles of 5 min shaking at 600 rpm and 15 min quiescent incubation 
at 37 °C for 5 days.  
A B 
D C 
E F 
Figure 9-10: Representative AFM images of ThT fluorescence screening at pH 6 to 8 
ThT conditions analogous to description in Figure 9-11, in 25 mM phosphate buffers at 
increasing pH. A, pH 6; B, pH 6.5; C, pH 7; D, pH 7.4; E, pH 8; F, pH 6 with additional 
25 mM NaCl. No fibril formation although all conditions showed amyloid-typical ThT 
increase in all conditions, as shown in Figure 9-11. All images were processed in Gwyddion 
to remove imaging scars and background signal. Resolution: 512x512 pixel at scanning size 
9*9 µm. 
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Figure 9-11: ThT fluorescence of Oxyntomodulin self-assembly at different pH 
1 mg mL-1 Oxyntomodulin in 25 mM phosphate buffer pH 6-8, with 50 mM ThT. 50 μL per 
well, triplicate. Some wells dried during incubation (no shown). Cycles of 5 min shaking at 
600 rpm and 15 min quiescent incubation at 37 °C for 5 days. 
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Figure 9-12: Representative AFM images of ThT fluorescence screening at increasing 
peptide concentrations 
Imaging analogous to Figure 9-8. A, B: 1 mg mL-1; C, D: 5 mg mL-1; E, F: 10 mg mL-1; G; H: 
10 mg mL-1 100x dilute in water before deposition on mica. Fibril formation despite very 
limited ThT fluorescence increase shown in Figure 9-13. All images were processed in 
Gwyddion to remove imaging scars and background signal. Resolution: 512x512 pixel at 
scanning size 9*9 µm (A, C, E, G), 1024*1024 pixel at scanning size 2x2 µm (B, D, F, H). 
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Figure 9-13: ThT fluorescence screening of Oxyntomodulin self-assembly in water 
Oxyntomodulin with 50 mM ThT at increasing concentration. 50 μL per well, triplicate. Some 
wells dried during incubation (no shown). Cycles of 5 min shaking at 600 rpm and 15 min 
quiescent incubation at 37 °C for 5 days. 
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[128] K. Škerget, A. Vilfan, M. Pompe-Novak, V. Turk, J. P. Waltho, D. Turk, and E. 
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